CV Dr. Pinedo

C U R R I C U L U M V I T A E

HERBERT MICHAEL (BOB) PINEDO

1

T a b l e o f c o n t e n t s

PAGE

- Medical education................................................................................................................3

- Positions held...................................................................................................................... 3

- Summary of main research interests and related activities...................................................4

- Administrative functions....................................................................................................5-6

- Functions in European organizations...................................................................................6

- Functions in Amercian societies...........................................................................................7

- International cancer societies/institutes/foundations..........................................................7-8

- Honorary memberships of societies award committees........................................................8

- Membership of boards of foundations..................................................................................9

- Membership of societies......................................................................................................9

- Awards and scientific grants..............................................................................................10

- Editorial responsibilities of Scientific Journals...............................................................10-11

- Editorships of books and supplements...............................................................................11

- Postgraduate teaching responsibilities...............................................................................12

- Supervisor academic theses………………..………………………………………………..…12-14

- Presidency / Board member international symposia, workshops and conferences...........................................................................................................14-17

- Invited chairmanship at international symposia/conferences..........................................17-22

- Invited lectures (international symposia/courses/conferences).......................................22-34

- Chapters / Invited papers / Proceedings........................................................................34-41

- Publications (Peer reviewed, excluding national articles)……………………………….......41-72

2

Name Herbert Michael (Bob) Pinedo, IJ-Prijs Amsterdam Silver Medal of Amsterdam

Knight of the Order of the Netherlands Lion Commander in the Order of Orange-Nassau

Present position Consultant to the Board of the VUmc Cancer Center Amsterdam Professor-emeritus VU University Medical Center, Amsterdam, The Netherlands Visiting Professor Johns Hopkins University, Baltimore, USA Visiting Professor Technical University Twente, The NetherlandsDate of birth August 25, 1943 Place of birth Willemstad, Curaçao Sex MaleHome address Villapark Zuurzak, Kaya Macabeo 8 Willemstad, Curacao Telephone +31 (20) 6648083 (home)E-mail [email protected] Married to Rita M. HarveyChildren Danielle, Sabine, Marsha, David, Shoshana (5)Languages Fluent in English, Spanish and Dutch

MEDICAL EDUCATION1960 Admitted to the Medical School of the University of Leiden, the Netherlands. 1965 Masters' Degree. 1967 M.D. examination. 1967 Specialization in Internal Medicine, University Hospital, Leiden,The Netherlands1969 Certificate Educational Council Foreign Medical Graduates. 1972 Certificate Internal Medicine, University Hospital, Leiden. 1972 Ph.D. in Medical Sciences

POSITIONS HELD1972 Chief Registrar, Department of Internal Medicine University Hospital, Utrecht, The

Netherlands.1972-1976 Assistant Professor of Internal Medicine University Hospital, Utrecht, the Netherlands.1972-1979 Head of the Division of Medical Oncology, Department of Internal Medicine,

University Hospital, Utrecht, the Netherlands.1974-1976 Visiting scientist at the Laboratory of Biochemical Pharmacology (head: Dr.

B.A. Chabner), Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

1976-1978 Assistant Professor of Medical Oncology, Chief of Department of Medical Oncology, University of Utrecht, the Netherlands.

1978-1979 Associate Professor of Medical Oncology, University of Utrecht, Netherlands. 1979-present Professor of Medical Oncology, Free University (VUMC) Amsterdam, the

Netherlands.1979-2003 Head Department of Oncology, Free Univeristy MC, Amsterdam, Netherlands. 1979-1983 Head Pharmacology Laboratory, Netherlands Cancer Institute, Amsterdam,

Netherlands.1989-1993 Clinical Research Director, Netherlands Cancer Institute, Amsterdam (1989-

1993).2003-2005 President and Chairman of the Board of the Free University (VUmc) Cancer

Center Amsterdam (CCA), the Netherlands. 2004-2008 Vice-Chairman of the Board of the Netherlands Organisation for Health

Research and Development (ZonMw).2006-present Honorary Chair of the VUmc-CCA, practicing medical oncologist of the VU University

Cancer Center, Amsterdam, the Netherlands.2008-present Visiting Professor of Oncology, Johns Hopkins University, School of Medicine,

Baltimore, Maryland. 2008-present Visiting Professor at the Technical University of Twente, Enschede,

Netherlands

3

SUMMARY OF MAIN RESEARCH INTERESTS AND RELATED ACTIVITIES

Over the years my main interest has focussed on early clinical research: translational research/bench-to-bed research. For this reason my laboratory was integrated in my department, with close interaction between basic scientists and clinicians.1974-1976 (NCI)As a NCI visiting associate of the Pharmacology Branch ( mentor Dr. Bruce A. Chabner), I mainly focussed my research on the pharmacology of methotrexate. The antipurine effect of this antimetabolite on the bone marrow stem cell became evident. Pharmacology studies on bone marrow stem cell rescue provided useful information for the development of new clinical strategies of rescue.1976-1979 (Utrecht)During the final years in Utrecht the work on methotrexate initiated at the NCI was pursued with laboratory based research studies on clinical pharmacology of the anti-metabolite, and methods of rescue (such as thymidine). Besides, the Dutch randomized studies with platinum combination in ovarian cancer and testicular cancer were initiated. Also, the large EORTC randomized adjuvant study in soft tissue sarcomas was initiated and coordinated.1979-1988 (Amsterdam)During this period the first phase I studies in medical oncology in the Netherlands were initiated. All studies were pharmacokinetically guided. The phase I study on daily cisplatin plus radiotherapy formed the basis for the EORTC trial in lung cancer which has led to thepublication in the New England Journal of Medicine. During these years laboratory activities were extended from the work on methotrexate to the pharmacology of fluoropyrimidines. The work in this area contributed to understanding the mechanism of action of the 5-fluorouracil-leucovorin combination. Mechanistic studies on new drugs, including VP-16, were initiated. Knowledge on mechanistics of drug action became the basis for clinical trials on drug resistance.Last but not least the first Phase 1 study of the hypomethylating drug 5-Azacytidine was performed in our department!In 1983 I set up the EORTC New Drug Development Office which was initially located at the Free University Hospital. This office coordinated for many years studies of the EORTC Early Clinical Trials Group. 1988-1997 (Amsterdam)This period was marked by the work on multidrug resistance (MDR). The main interest was the evaluation of functional studies in MDR. In collaboration with the hematology department clinical MDR studies were started in acute myeloid leukemia. A close interaction with the group of Piet Borst, which was involved with the genetics of MDR, developed. In those days the Bristol Myers Institutional grant on MDR was approved, apparently with an exceptionally high score. More recently the PgP work was extended to non-PgP related MDR for which a grant of the Netherlands Cancer Society was provided. The functional studies were further developed, and proved to be valuable tools in non-PgP MDR as well. The biochemical pharmacology of anti-purines and anti-pyrimidines was pursued and included tumor thymidylate synthase assays and correlations to response in colorectal cancer patients. During all these years Drug Development remained a key stone.1997-2008 (Amsterdam)The Spinoza grant was both a recognition of the past research and a stimulus for the development of new research lines in my department. The grant has enabled the Division two stimulate two important research programs. The Angiogenesis program included several projects studying the role of vascularization for prognosis and chemosensitivity of solid tumors. Also, the role of intratumoral body fluids, and the contribution of platelets to angiogenesis and the place of angiogenic inhibitors in the cancer treatment. In conjunction with these studies I initiated a series of phase 1 studies with inhibitors of the VEGF receptor.A second research program which has been stimulated by the Spinoza grant is my immunotherapy program that has focused for years on active specific immunotherapy in resected colon cancer,neoadjuvant chemo-immunotherapy with GM-CSF and chemotherapy in locally advanced breast cancer.Finally tumor specific chemotherapy is been developed at the department through investigating genedirected enzyme prodrug therapy in the Gene Therapy Unit. The results of this approach in prostate cancer has recently been published in Lancet Oncology. This work was performed in close collaboration with the Johns Hopkins Oncology Center.2009-presentDuring the past three years I have been mainly been working with the Twente Group to develop an oral

4

diagnostic pill, which detects hypermethylation by using Nanotechnology. The first results are very promising.In the past four years I have established a Prevention Center in close collaboration with the VUmc in the Caribbean island of Curacao. Also, the Johns Hopkins University has shown interst in this Caribbean activity.

ADMINISTRATIVE FUNCTIONS

VRIJE UNIVERSITEIT (VU UNIVERSITY)- Chairman of Department of Medical Oncology, VU University Medical Center Hospital (1979-2002).- Head Laboratory of Oncology, Department of Medical Oncology, VU Medical Center Hospital (1979-

2005).- Administrative Board of the Medical Faculty (1983-1985). - Administrative Board of the VU University Medical Center Oncology Research Institute (1994-2002).- President and Chairman of the Board of the VUmc Cancer Center Amsterdam (2003-2008).- Honorary Chair of the Vumc Cancer Center Amsterdam (2005-present)- Advisor to the Board of the VUmc (2008-present)- Chairman of the International Advisory Board at the VU Medical Center- Visiting Professor at Johns Hopkins University

OTHER UNIVERSITIES IN THE NETHERLANDS- Advisor nomination committee Medical Oncology and Immunotherapy, University of Nijmegen (1999)- Advisor nomination committee Medical Oncology, University of Limburg (2003)- Visiting Professsor at Technical University of Twente

THE NETHERLANDS CANCER INSTITUTE- Head of Laboratory of Pharmacology (1979-1983)- Clinical Research Director (1989-1993)

COMPREHENSIVE CANCER CENTER AMSTERDAM (IKA)- Administrative Board: Past-Chairman (1980-1992)

DUTCH CANCER SOCIETY (NKB/KWF)- Scientific Advisory Board: member (1979-1988)- Scientific Advisory Board: chairman (1984-1988) - Administrative Board: member (1984-2005)- Administrative Board: vice chairman (1989-1991)- Committee advising on priority issues in oncology: chairman (1999-2005) - Committee supporting the Development of the Department of Oncology SEHOS, Curacao: member

(2002-2005)

MINISTRY OF SCIENCE AND MINISTRY OF HEALTH- Netherlands Organisation for Health Research and Development (ZonMw)

The Dutch Medical Research Council:. Acting Chair of the Board (2007). Vice-Chairman of the Board (2004-2009)

- National Committee on Animal Research (1997-1999)- Council for Health Research (RGO): member- Dutch Organisation for Scientific Research (NWO): member of the chairman’s committee- Council for Medical Science (RMW): member

CENTER FOR TRANSLATIONAL MOLUCULAR MEDICINE- member of the founding fathers (2006)- member of the supervisory board (2006-2014)

THE AEGON ASSOCIATION (Life insurance company)

5

- Member of the Board Vereniging Aegon 2009-2013

FOUNDATION NEW DRUG DEVELOPMENT OFFICE – ONCOLOGY (NDDO-,acquired by INC)- Administrative Board: member (1998-2010)- Consultant to NDDO-Oncology (2005-2010)

OTHER DUTCH COMMITTEES- KennisKring Amsterdam (1992-present)- Amsterdamse Kring (1997-present)- Oncology Founding Task Force Meeting, Amsterdam, The Netherlands (1998)- Evening on Science and Society, The Hague, The Netherlands (2000)- Public Debates “Rode Hoed”, Amsterdam, The Netherlands (2000,2007)

FUNCTIONS IN EUROPEAN ORGANIZATIONS

EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC)- Administrative Board and Council: past member (1977-1994) - New Drug Development and Coordinating Committee: member (1979-1998)- Pharmacology and Molecular Mechanisms Group (PAMM), (1982-2008)- New Drug Development Office (NDDO): founder, past-director (1984-1991)- Foundation of the New Drug Development Office: member of the Board (1984-1998)- Pharmacokinetics and Metabolism Group: founder, past-secretary (1977-1982)- Soft Tissue and Bone Sarcoma Group: founder, past-secretary (1976-1981) - Early Clinical Trials Group (ECTG): past-chairman (1982-1985)- NCI-EORTC-CRC Committee for Joint Development of New Drugs: member (1986-1998)- EORTC Independent Data Monitoring Committee (IDMC): member (2003-2005)

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)- Past-president (1987-1989),first president after Dr. Mathe (France)

- founder of the ESMO-fellowship program- initiator of the Committee of National Representatives- initiator of the European Board Examination for Medical Oncology- co-founder of the Annals of Oncology

FED OF EUROPEAN CANCER SOCIETIES (FECS) and European Cancer Organization (ECCO)- First president of both (1982-1984) - Member of the Board (1982-1992)

EUROPEAN UNION- Representative of the Netherlands Organisation for Scientific Research - Advisory Board for Cancer Research of the Commissioner for Research and Health (2000-2004).- European Strategy Forum for Research Infrastructures (ESFRI), member (2004-present)- European Cancer Research Initiave (ECRI), board (2000)- European Medical Research Councils (EMRC), member (2007)- European Advanced Translational Research Infrastructure in Medicine (EATRIS), member (2007)

EUROPEAN SCIENCE FOUNDATION (ESF)- Member of European Medical Research Councils (EMRC) 2004-2007- Member of the ESFRI (2005-2006)

EUROPEAN SCHOOL OF ONCOLOGY (ESO)- Scientific Committee: member (1982-1984) - Postgraduate Courses in Medical Oncology: director (1982-1992) - Master Courses Oncology : director (2003-present)- Advisory Board Member (2005-present)

EUROPEAN CANCER CONCORD (ECC)-Co-founder and member of the steering committee

6

-Launch of Bill of Patient’s Rights at EU

OTHER EUROPEAN ORGANIZATIONS- Academia Europaea, member- Di Bella Committee, Rome, Italy (1998)- World Summit against Cancer, Paris, France (2000), an initiative of Prof.Khayat- Inserm Units and Teams (2001)- European Cancer Research Managers Forum, member (2004-2009)

FUNCTIONS IN AMERICAN SOCIETIES

AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR)- Associate editor Clinical Cancer Research (1995-1997)- Member of the Editorial Board of Clinical Cancer Research (1995-2005)- Program Committee (1996-2000)- Clinical Research Committee (1996-2000)- Development Committee (1996-2000)- Public Forum (2001)- Editorial Board of Molecular Cancer Therapeutics (2001-present) - Bruce F.Cain Memorial Award (2005-2006)- Burchenal Award Committee (2005-2006)- Hindenthal Award Committee (2005-2006)

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)- Program Committee, Subcommittee Clinical Pharmacology (1997-2000)- Editorial Board Journal of Clinical Oncology (2002-2006)- Cancer Research Committee (2006-2008)- International Advisory Committee (2006-2010)- International Committee Trials Workshop (ICTW) (2010-2015) -Post-ASCO courses, The Netherlands, director and initiator, first of it’s kind worldwide

INTERNATIONAL CANCER SOCIETIES/INSTITUTES/FOUNDATIONS

SCIENTIFIC ADVISORY BOARD CANCER CENTERS/UNIVERSITIES- Netherlands Cancer Institute- Imperial Cancer Research Fund (ICRF), International Scientific Advisory Board, UK- The University of York, UK - Institute of Research Hospital Vall d’Hebron (2003) - Lucy Curci Cancer Center, USA - KHCC (King Hussein Cancer Center) Jordan- Cancerpole Toulouse, Toulouse, France- Instituto Toscano Tumori, Florence, Italy (ITT)- Deutsche Krebshilfe, Scientific Advisory Board, Bonn, Germany- Queen Mary University London, UK (2004)- Charite Cancer Centre , Berlin (2010-2014)

ICRF SITE VISIT COMMITTEES - ICRF unit, Edinburgh, Scotland (1993)- MRC unit, London, U.K. (1998)- ICRF unit, Edinburgh, Scotland (1998)- St James’s University Hospital, external assessor of the review committee, U.K. (1998)- Centre Pluridisciplinaire d’Oncologie (CPO), Lausanne, Switzerland, June 228-29, (1999)- ICRF Unit, Cambridge, U.K. (2000)

7

VISITING PROFESSORSHIPS- Emory University Atlanta, 1985- Venezuelan Society of Oncology, 1988- Mexican Society of Oncology, 1989- MD Anderson Cancer Center, University of Texas, Division of Medicine, Department of Clinical

Investigation, Houston, 1993- Hadassa University Hospital, Jerusalem, 1996- South African Society of Medical Oncology, Cape Town, 1998- Johns Hopkins Oncology Center, Baltimore, 1999- University of Alabama, Birmingham, 2001- Emory University, Winship Cancer Institute, Alabama, 2002

INTERNATIONAL RESEARCH ORGANIZATION (HIRO)Member (2006-2009) Heads of International Research Organizations

HONORARY MEMBERSHIPS OF SOCIETY AWARD COMMITTEES

BOB PINEDO PRIZE FOR FOR CONTRIBUTIONS TO IMPROVEMENT IN THE CARE OF CANCER PATIENTS (Society of Tranlational Oncology)- The Bob Pinedo Prize was established 2006

DUTCH ROYAL ACADAMY OF SCIENCE - Committee for Animal Experiments, Transgenesis and Biotechnology (1997-2002)- Membership Committee (1994-2002)- Travel and Congress Committee (1994-2002)- Nominating Committee for the Dr. A.H. Heineken Prize for Medicine (1994-1998)- Committee for the Evaluation of the quality of High School Books (1999-2002)- China Committee (2000-2001)- Secretary of the Section of Medicine (2000-2001)- Chairman Membership Committee of the Section of Medicine (2000-2001)- Chairman Section of Medicine (2002-2004)- Evaluation Committee Masters (2004-2008)- Council for Medical Science (RMW)

CANCER SOCIETIES, memberships- American Society of Clinical Oncology (1976-present)- American Association of Cancer Research- European Society for Therapeutic Radiology and Oncology (ESTRO)- Royal Society of Medicine, U.K.- Spanish Society of Oncology- Asociación Española de Investigación sobre el Cáncer (ASEICA), Scientific Advisory Committee - Asociación Argentina de Oncología Clínica - European Society for Medical Oncology (ESMO)- Society for Translational Oncology (STO)

AWARD NOMINATING COMMITTEES- Bristol-Myers Squibb Award Selection Committee (1991-1996).- General Motors Kettering Award Selection Committee, U.S. (1991-1995)- Pharmacia Research Grant Selection Committee (1994-1998)- Albert and Mary Lasker Foundation: Albert Lasker Medical Research Awards (1993-1997)- Vera Bonte Foundation (1998-2004)- American Association For Cancer Research-Pezcoller International Award (2000)- Josephine Nefkens Award (2001)- American Association For Cancer Research – Bruce F.Cain Memorial Award (2005)

8

- American Association For Cancer Research – Burchenal Award Committee (2005-2006)- American Association For Cancer Research – Hindenthal Award Committee (2005-2006)- Dutch Cancer Society-the Muntendam Award (1990-1998)- Dutch Scientific Research (NWO) – Mozaiek Prize (2007)

MEMBERSHIP OF BOARDS OF FOUNDATIONS

- Foundation for the Support of Medical Oncology at the Free University (SBGO)- Margot Mattheijssen-van der Voort Foundation for Clinical Research in Breast Cancer- Dutch Cancer Society- New Drug Development Office Foundation- Max Geldens Foundation for the advancement of Dutch Society- Johan Baas Oncology Support Foundation- Benelux Foundation - Dr. Saal van Zwanenberg Foundation- Foundation Samah- Foundation "Vicki Brown" house- Hospice Amsterdam- De Vilder Foundation- Translational Research Foundation- Vanderes Foundation- ADAMAS Foundation- Alpe d’Huzes Foundation- Ingeborg Douwes Centrum- VUmc Cancer Center Amsterdam Foundation

MEMBERSHIPS OF SOCIETIES - European Society for Medical Oncology (ESMO, past president)- European Society of Clinical Investigation (ESCI) - American Association for Cancer Research (AACR)- American Society for Clinical Oncology (ASCO) (1976-present)- Anticancer Therapeutics and Oncology Society (ATOS)- Netherlands Society of Medicine - Netherlands Society of Internal Medicine - Netherlands Society for Oncology- Netherlands Society for Medical Oncology - Netherlands Federation and Biological Societies (past-board member)- American Association for the Advancement of Science- The American Society of Breast Disease - Society of Translational Oncology (STO), member of the board till 2015.

9

AWARDS AND SCIENTIFIC GRANTS

AWARDS- European Society for Medical Oncology - Award (1985) - European Society of Therapeutic and Radiation Oncology - Award (1986)- Award for Medicine of the Republic of San Marino (1991) - Bristol-Myers Squibb Foundation Cancer Grant Award (1992) - Bronzen Stier Award 1992 (National)- ESMO-Hamilton Fairly Award (1992)- International Chiron Award for Biomedical Research and Training (1993)- Dr. Josef Steiner Award (1995)- Spinoza Award (1997)- Cino del Duca Award (1999)- Michel Clavel Award, the EORTC-NCI-AACR (2000)- New Drug Development Organisation Award (2003)- IJ-Award, City of Amsterdam2006 (national)- Netherland-America Foundation-Dornbush Award (Washington DC, 2012)- ASCO David A. Karnofsky Memorial Award (Chicago, 2014)

SCIENTIFIC GRANTS- Netherlands Cancer Society - "In vivo metabolic modulation of the mode of action of 5 fluorouracil in

colorectal cancer in mice and in patients, with special regard to folates and uridine" (1988)- Netherlands Cancer Society - "Improving in vitro methods for anticancer drug screening for more

selective agents against solid tumors" (1988)- Bristol Myers Squibb Company, a competive grant programme - "Prospective studies in clinical

multidrug resistance, using multiparameter screening" (1988), highest score - Netherlands Cancer Society - "A prospective clinical and mechanistic study on P-glycoprotein related

multidrug resistance" (1989)- Netherlands Cancer Society - "Biochemical pharmacology of 2',2'-difluoro-deoxycytidine, a new cytidine

analog, in preclinical model systems and in patients: effects of biochemical modulation on toxicity and antitumor activity" (1990)

- Netherlands Cancer Society - "Optimalisation of intraperitoneal chemotherapy with regional hyperthermia" (1990)

- Netherlands Cancer Society - "Functional detection of P-glycoprotein and non-P-glycoprotein-mediated multidrug resistance in adult acute myeloid leukemia" (1993)

- Netherlands Cancer Society - "Analysis of the effects of (iso) flavonoids as modulators of Pgp/MDRand MRP related drug transport (1995)

- Netherlands Organization for Scientific Research (Spinoza Award 1997) - FOM project - Clinical application of photo acoustic holography. In cooperation with th University of

Twente (1999).

WORLD ONCOLOGY FORUM (Lugano, 2012)Invited participant

EDITORIAL RESPONSIBILITIES

MEMBERSHIPS OF EDITORIAL BOARDS OF JOURNALS- Cambridge Cancer Studies - Clinical Cancer Research (initially associate editor)- Drug Resistance Updates - Journal of Clinical Oncology (1995-1998, 2002-2006)- Oncology, International Journal of Cancer Research and Treatment- South-American Journal of Cancer- The Oncologist (founding member and associate editor) - Cancer Therapeutics- Current Opinion in Anticancer Drugs (co-editor)- Drug Resistance Updates: Cancer- Current Treatment Options in Oncology

10

- Lancet Oncology (2000-2002)- Current Oncology Reports (associate editor)- Revista de Oncologia (associate editor)- E-wise, Medical/Digital publisher (editor)- Molecular Cancer Therapeutics - Clinical Colorectal Cancer- Trends in Cancer Research- Current Cancer Therapy Reviews - Faculty of 1000 Medicine - Annals of Oncology (editor)

EDITORSHIPS OF BOOKS AND SUPPLEMENTS

-Clinical Pharmacology of Antineoplastic Drugs, Elsevier North-Holland, Amsterdam, 1978.- Cancer Chemotherapy Annual, Eds. H.M. Pinedo, D.L. Longo, B.A. Chabner since 1979 (17 books):

Excerpta Medica, Amsterdam-New York-Oxford, 1979. - The Structure Activity Relationship of Anticancer Agents, Eds. D.N. Reinhoudt, T.A. Connors, H.M.

Pinedo and K.W. van de Poll; Martinus Nijhoff Publishers, The Hague, 1982.- The Cancer Pharmacology Annual, Eds. H.M. Pinedo, B.A. Chabner: Excerpta Medica,

Amsterdam-Oxford, 1983, 1986.- Soft Tissue Sarcomas 4 editions Eds. J. Verwey, H.M. Pinedo, H.D. Suit: Martinus Nijhoff Publishers,

Boston.- Human Tumour Xenografts in Anticancer Drug Development, Eds. B. Winograd, M.J. Peckham, H.M.

Pinedo. Publisher: Springer Verlag, Heidelberg, 1988.- Progress and controversies in oncological urology II. Eds. F.H. Schroder, J.G.M. Klijn, K.H. Kurth, H.M.

Pinedo, T.A.W. Splinter, H.J. de Voogt; Alan R. Liss, Inc. New York, 1988. - Leucovorin Modulation of Fluoropyrimidines: a New Frontier in Cancer Chemotherapy, Eds. H.M.

Pinedo, Y.M. Rustum; Royal Society of Medicine Services, London/New York, 1989.- Forum Trends in experimental and Clinical Medicine, Eds. S. Aaronson, L. Frati, H.M. Pinedo, L. Santi,

Genoa, 1992.- Molecular Oncology and Clinical Applications, Eds. A. Cittadini, R. Baserga, H.M. Pinedo, T. Galeotti,

D. Corda, Birkhäuser Verlag, Basel, Boston, Berlin, 1993.- Annals of Oncology; Taxol supplement, Vol. 5, suppl. 6, 1994 (guest editor).- Eur. J. Cancer, Taxol supplement, 1994, (guest editor).- The Topoisomerase Inhibitors, Eds. M. Potmesil, H.M. Pinedo, (1995).- Oxford Textbook of Oncology, Eds. M. Peckham, H.M. Pinedo, U. Veronesi, Oxford Press,1995.- Supplement to Seminars in Oncology, vol.23, no. 5, supl. 11. Investigators' Workshop and Consensus

Conference on Paclitaxel. Part 1: Breast Cancer I. October, 1996. Guest editor.- Drug Resistance, illustration of the complexity of translational research, Steiner Award Lecture, Int. J. Cancer 1996; 65 (5), 561- 566. - Supplement to Seminars in Oncology. Ozols, R.F., Pinedo, H.M. The Fox Chase Cancer Center and Free University Hospital. Iinvestigators Workshop and Consensus Conference on Paclitaxel Part 1: Lung Cancer, 1997; 24. - Drug Resistance in the Treatment of Cancer. Eds. H.M. Pinedo and G.Giaccone, Cambridge Press,

1997.- Chemotherapy, The Lancet, 349 (suppl. II): 7-9, 1997. H.M. Pinedo and G. Giaccone.- Supplement to the Oncologist. Clinical Science in Practice, chapter on "Drug Resistance in the

Treatment of Cancer. Cambridge University Press, March 26, 1998.- Proceedings of the Symposium on The role of VEGF in Tumor Angiogenesis, H.M.Pinedo,

Washington DC, November 16, 1999.- Proceedings of the Symposium on The Role of VEGF in Tumor Angiogenesis, H.M.Pinedo.

Amsterdam, November 7, 2000.

- Targeting Treatment of Soft Tissue Sarcomas, J. Verweij, H.M.Pinedo Kluwer Academic Publishers, 2004

11

- Milestones in Drug Therapy, Volume; Drugs affecting Growth of Tumours, H.M.Pinedo, C.Smorenburg Birkhäuser Verlag, 2006

POSTGRADUATE TEACHING RESPONSIBILITIES

LECTURES AND COURSES IN THE NETHERLANDS - Post-ASCO courses, The Netherlands, director and initiator, first of it’s kind worldwide- Lectures in Medical Oncology, Medical curriculum of the Free University, Amsterdam.- Organizer of Biannual Postgraduate Courses in Medical Oncology for Medical Oncologists, Free

University Hospital, Amsterdam. - Postgraduate CME Course on Intensive Sequential Chemotherapy,Dose -Intensity,Noordwijkerhout

(1995). - Postgraduate Course Medical Oncology, Veldhoven, 26-27 September (1996) - Postgraduate Lectures, NAKSHO, Curaçao, Netherlands Antilles (1998).Masterclass in Clinical Oncology

EUROPEAN SCHOOL OF ONCOLOGY -Medical Oncology Courses (director, 1982-1992).- Medical Oncology Course of the European School of Hematology (director,1993). - Tenerife, Spain, January 20-25, 2003.- Nicosia, Cyprus, March 6-11, 2004.- Larnaca, Cyprus, March 5-11, 2005- St. Julians, Malta, February 11-17, 2006- St. Julians, Malta, February 24-March 2, 2007- Sophia< Bulgaria, March 1-6, 2008- WORLD ONCOLOGY FORUM, 2012 (ESO) Participant- European School of Oncology Strategic Meeting (2016) Scientific committee member

SUPERVISOR OF ACADEMIC THESES

1. J.G.S. Breed: "Studies on anthracycline induced cardiac toxicity". Free University, Amsterdam, January 16, 1981.

2. J.A.J.M. Taminiau: "Response of the small intestinal epithelium of the rat to methotrexate". State University, Utrecht, October 20,1981.

3. J.H. Schornagel: "Studies on the reversal of methotrexate toxicity by thymidine and on the role of thymidine as an anticancer drug". State University, Utrecht, June 8, 1982.

4. J.P. Neyt: "Combination chemotherapy for patients with advanced ovarian carcinoma". State University, Utrecht, September 6, 1983.

5. J.P.M. Holthuis: "Bioanalysis, electrochemistry and pharmacokinetics of etoposide, teniposide and metabolites". State University, Utrecht, June 26, 1985.

6. J. Verwey: "Studies on mitomycin C". Free University, Amsterdam, January 10, 1986. 7. E. Boven: "Human ovarian cancer xenografts in nude mice; application of a new model in the

selection of novel agents for ovarian cancer". Free University, Amsterdam, May 30, 1986. 8. J. den Hartigh: "Analysis, electrochemistry and pharmacokinetics of mitomycin C". State

University, Utrecht, September 16, 1986. 9. J.B. Vermorken: "Cisdiamminedichloroplatinum(II) (cisplatin) clinical pharmacologic studies". Free

University, Amsterdam, December 10, 1986.10. P. Lelieveld: "Preclinical screening and toxicology of platinum analogs". State University, Leiden,

September 2, 1987.

12

11. F. Elferink: "Analysis, electrochemistry and pharmacokinetics of second generation platinum compounds". Free University, Amsterdam, December 3, 1987.

12. J.M.S. van Maanen: "Metabolic activation of the antitumor agent VP-l6-2l3". Free University, Amsterdam, February 24, 1988.

13. G. Schwartsmann: "Biochemical and pharmacological approach to the clinical development of a new anticancer agent: Brequinar sodium (NSC 368390)". Free University, Amsterdam, June, 1988.

14. G. Stoter: "Chemotherapy in Testicular Cancer". Free University, Amsterdam, October 26, 1988.15. H.G. Keizer: "Doxorubicin: mechanisms of toxicity and resistance". Free University, Amsterdam,

November 20, 1989.16. G. Los: "Experimental basis of intraperitoneal chemotherapy". Free University, Amsterdam, March

28, 1990.17. C.J. van Groeningen: "Clinical pharmacology and biochemical modulation of 5-Fluorouracil. Effects

of leucovorin and uridine". Free University, Amsterdam, December 19, 1990.18. C.F.M. Molthof: "Therapeutic application of radiolabeled monoclonal antibodies in experimental

ovarian cancer". Free University, Amsterdam, April 1, 1992.19. J. Baars: "The use of interleukin-2 in medical oncology". Free University, Amsterdam, October 9,

1992.20. C.K. van Kalken: "Clinical and physiological aspects of p-glycoprotein mediated multidrug

resistance". Free University, Amsterdam, November 13, 1992.21. P. Pizao: "Multilayered postconfluent tumor cell cultures as a model for in vitro chemosensitivity

tests". Free University, Amsterdam, December 21, 1992.22. C.L. van der Wilt: "Metabolic Modulation of 5-Fluorouracil activity in colon cancer". Free University,

Amsterdam, February 2, 1994.23. C.H.M. Versantvoort: "Drug Transport in Multidrug Resistant Tumor Cells without P-Glycoprotein

Overexpression". Free University, Amsterdam, April 6, 1994.24. F.E. van Leeuwen: "Second malignancy as a sequel to cancer treatment; an assessment of risk".

Free University, Amsterdam, September 14, 1994.25. E.C. Spoelstra: "In vitro cellular pharmacokinetics of the anticancer drugs 5-fluorouracil and

daunorubicin". Free University, Amsterdam, October 7, 1994.26. V.W.T. Ruiz van Haperen: "Biochemical pharmacology of gemcitabine, (2',2'-difluoro-2'-

deoxycytidine)". Free University, Amsterdam, January 18, 1995.27. G. Giaccone: "Experimental and clinical research in lung cancer". Free University, Amsterdam,

March 29, 1995.28. M.W. Dercksen: "Homing of peripheral blood hematopoietic progenitor cells". Free University,

Amsterdam, October 13, 1995.29. G.R. Westerhof: "Folate and antifolate transport in tumour cells". Free University, Amsterdam

December 6, 1995.30. H.S. Mülder: "Kinetics of anthracycline transport in multidrug resistant cancer cells". Free

University, Amsterdam, December 13, 1995.31. J.A.M. van Laar: "Modulations of 5-fluorouracil and 5-fluoro-2'-deoxyuridine". Free University,

Amsterdam, March 8, 1996.32. W.E. Meijs: "The suitability of Zirconium-89 for the labelling of antibodies for positron emission

tomography". Free University, Amsterdam, May 31, 1996.33. E. Kievit: “Improvement of Radioimmunotherapy in Ovarian Cancer; An Experimental Approach”.

Free University, Amsterdam, May 7, 1997.34. A.H. Honkoop: “Dose-intensive chemotherapy in breast cancer”. Free University, Amsterdam,

November 6, 1997.35. S.C. Linn: “Clinical probing and reversal of multidrug resistance in solid tumors”. Free University,

Amsterdam, January 28, 1998.36. C.J.A. Van Moorsel: “Preclinical and clinical interactions between gemcitabine and cisplatin in

ovarian, non-small cell lung and head and neck cancer”. Free University, Amsterdam, December 10, 1999.

37. V. Krashnyk: “Genetic targeting of adenoviral vectors”. Free University, Amsterdam, December 22, 1999.

38. B. van Triest: “Prognostic value of thymidylate synthase in patients with colorectal cancer; implications for enzyme-directed therapy”. Free University, Amsterdam, June 7, 2000.

39. J.H. Hooijberg: “Transport proporties and ATPase activity of the multidrug resistance protein”. Free University, Amsterdam, June 14, 2000.

13

40. H.M.W. Verheul: “Concomitant Activation of Angiogenesis and Coagulation in Cancer. Free University, January 19, 2001.

41. H.H.J. Backus: “Downstream effects of Thymidylate Synthase inhibition. Free University, Amsterdam, June 27, 2001.

42. A.M.Bergman: “Resistance, cross-resistance and collateral sensitivity to gemcitabine”. Free University June 5, 2002.

43. G.M. Kolfschoten: “Cellular determinants for drug response in ovarian cancer”. Free University, September 13, 2002.

44. F. Croon-de Boer: “Parameters for graft quality in peripheral blood stem cell transplantation”. Free University, November 1, 2002.

45. D.T.Curiel: “Genetic Capsid Modification for Adenovirus Retargeting”. Rijks Universiteit Groningen, December 13, 2002.

46. J.R. Kroep:”Preclinical and Clinical Pharmacology of Gemcitabine & Combinations with Paclitaxel and Cisplatin”. Free University, Amsterdam, February 12, 2003.

47. A.H. van Hattum: ”Novel camptothecin derivatives:antitumor efficacy and mechanisms of resistance”. Free University, Amsterdam, May 2, 2003.

48. P.H.J. Houba: ”Selective Chemotherapy with Glucuronidated anthracyclines activateby monoclonal anti-ß-glucuronidase conjugates”. Free University, Amsterdam, May 7, 2003.

49. B.C. Kuenen: “Clinical experience with receptor tyrosine kinase inhibitors as anti-angiogenic treatment in cancer patients”. Free University, Amsterdam, September 10, 2003.

50. Y. van Hensbergen: “The role of Cd13/Aminopeptidase N in vascular and ovarian cancer biology”. Free University, Amsterdam, May 12, 2004.

51. M. de Graaff: “ Selective chemotherapy with glycosyl prodrugs of anthracyclines “. Free University, Amsterdam July 2, 2004

52. M. de Bruin: Role of Platelet derived endothelial cell growth factor/ thymidine phosphorylase in drug sensitivity and angiogenesis”. Free University, Amsterdam November 10, 2004

53. D. Oosterhoff: “Adenoviral gene therapy combined with (selective) chemotherapy for the treatment of cancer”. Free University, Amsterdam, June 17, 2005.

54. J. Grill: “Gene therapy and virotherapyof brain tumors with recombinant adenoviruses; targeting with capsid modifications and conditional oncolysis”. Amsterdam December 20, 2005.

55. A. Baars: “Active specific immunotherapy for solid tumors”. Amsterdam, October 12, 2007 56. R.Maurits: Determinants of antifolate and 5-fluorouracil efficacy, February 2011

BOARDS OF DIRECTORS, CONSULTANCIES, SCIENTIFIC ADVISORY BOARDS AND DATA MONITORING BOARDS

2004-2010 OSI Pharmaceuticals:Member of the Board of Directors 2004-2008 Jennerex Biotherapeutics: Member of the Board of Directors 2004-2008 Oncomethylome: Member of Directors 2006-present Spectrum Pharmaceuticals: Consultant and Member of the Scientific Advisory Board2006-present Gilde Health Investments: advisor to the Management2008-present Vitromics Health Services (VHS), consultant2008-present Pamgene,consultant2011-present EBI, consultant2008-present DMC Ipilumumab, BMS

PRESIDENCY/BOARD MEMBER INTERNATIONAL SYMPOSIA/WORKSHOPS/CONFERENCES

- Workshop on Clinical Pharmacology of Antineoplastic Agents, Lunteren, The Netherlands, 1978: President.

- Symposium on “Therapeutic Progress in Ovarian Cancer, Testicular Cancer and Sarcoma in Adults”, Noordwijkerhout, The Netherlands, 1979: Member of the Scientific Program Committee.

- First European Conference on Clinical Oncology, Lausanne, Switzerland, 1981: Member of the Scientific Program Committee.

- Workshop on Structure Activity Relantionship of Anticancer Agents, Noordwijkerhout, The Netherlands,

14

1982: Member of the Organizing Committee.- 2nd European Conference on Clinical Oncology, Amsterdam, The Netherlands, 1983: President.- Symposium on Management of soft tissue and bone sarcomas, Utrecht, The Netherlands, June 1984:

Member of the Organizing Committee, Member of the Scientific Program Committee.- International Worksop on Formulation on Antineoplastic agents, Amsterdam, The Netherlands, April 1984: Chairman of the Organizing Committee, Member of the Scientific Program Committee.- Symposium on Chemotherapy preceding surgery or irradation in cancer medicine, Valkenburg a/d

Geul, The Netherlands, January-February 1985: Member of the Scientific Committee.- 3rd European Conference on Clinicial Oncology, Stockholm, Sweden, 1985: Member of the Scientific

Committee.- 5th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, October

1986: President.- 1st Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Munich, Germany,

1987: Member of the Scientific Board.- 4th European Conference on Clinical Oncology, Madrid, Spain, November 1-4, 1987: Member of the

Scientific Committee.- Interleukin-2 International Symposium, Amsterdam, The Netherlands, November 1988: President.- Leucovorin modulation of Fluoropyrimidines, Amsterdam, The Netherlands, 1989: President.- 2nd Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Montreux,

Switzerland, March 5-8, 1989: Member of the Advisory Board.- 6th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, March

1989: President.- 16th International Congress on Chemotherapy, Jerusalem, Israel, June 11-16, 1989: Member of the

International Scientific Committee.- International Congress on Strategies for Care in Oncology, Baltimore, Maryland, USA, August 22-25,

1989: Member of the Advisory Committee.- XIth International Congress of Pharmacology, Amsterdam, The Netherlands, July 1990: Member of the

Scientific Program Committee.- 6th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer

Chemotherapy, San Diego, California, USA, January 23-26, 1991: Member of the International Scientific Committee.

- European Cancer Center, Inaugural Symposium, Amsterdam, The Netherlands, March 16, 1992: President.

- 7th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, March 17-20, 1992: President.

- 4th International Congress on Anti-Cancer Chemotherapy, Paris, France, February 2-5, 1993.- International workshop on Growth Factors and Medical Oncology, Rimini, Italy, June 14-16, 1993: Chairman on session “Clinical applications in solid tumors”.- 18th International Congress of Chemotherapy, Stockholm, Sweden, June 27-July 2, 1993: President.- 8th International NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The

Netherlands, March 1994: President.5th L April 1994.- Reunion Cientifica ASEICA, 10th anniversary, Madrid, Spain, April 1994.- 7th International Symposium on Platinum, Amsterdam, The Netherlands, March 1-4, 1995: President.- International Conference on DNA-Topoisomerases: from molecular aspects to clinical application,

Amsterdam, The Netherlands, September 6-8, 1995: President.- 9th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, March

12-15, 1996: President.- 9th Congress of European Society for Psychosocial Oncology, Amsterdam, The Netherlands, July 1996:

Member of the Advisory Board.- 7th Conference on DNA Topoisomerases in Therapy, New York, New York, USA, October 21-24, 1996:

Membr of the Organizing Committee.- 8th International Congress on Anti-Cancer Treatment, Paris, France, February 3-6, 1997: Member of the

Scientific Committee and International Advisory Board.- Telecongress “Future Development in Cancer Treatment”, Amsterdam-Baltimore, Amsterdam, The

Netherlands, March 27, 1997: Member of the Organizing Committee.- Biological Therapy of cancer, From Basic Research to Clinical Application, Munich, Germany, June 11-

14, 1997: Member of the Scientific Committee.

15

- 3rd Fox Chase Cancer Centre and Free University Hospital Investigators’ Workshop and Consensus Conference on Paclitaxel, St. Thomas, United Kingdom, March 25-26, 1998: Co-chairman.

- 10th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, June 16-19, 1998: President.

- 4th Acos International Conference, Jakarta, Indonesia, Augsuts 4-7, 1998: Member of the International Scientifica Advisory Board.

- 9th Conference on DNA Topoisomerases in Therapy, New York, New York, USA, October 5-7: 1998: Member of the Organizing Committee.

- 9th International Congress on Anti-Cancer Treatment, Paris, France, February 2-5, 1999: Member of the Scientific Committee and International Advisory Board.

- 2nd International Congress Biliopancreatic Malignancy: From Gene to Cure, Amsterdam, The Netherlands, February 4-6, 1999.

- Chemotherapeutic Strategies for Treatment of Colorectal Cancer, Present and Future Developments, Amsterdam, The Netherlands, Februari 10-12, 1999 (European Cancer Center): Member of the Scientific Committee.

- 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy ISPCC, Oxford, United Kingdom, March 28-31, 1999: Member of the Scientific Committee.

- 10th Conference on DNA Topoisomerases in Therapy, Amsterdam, The Netherlands, October 6-8, 1999: Member of the Organizing Committee.

- 1st International AACR/NCI/EORTC Conference on Molecular Targets and Cancer Therapeutics, Washington DC, USA, November 16-19, 1999: Member of the Scientific Committee.

- International Symposium on Cancer Chemotherapy, Tokyo, Japan, December 2-3, 1999: Member of the

Scientific Committee.- Mini Symposium on The role of VEGF in tumor angiogenesis, Washington DC, USA, November 16,

1999: Chairman.- 10th International Congress on Anti-Cancer Treatment, Paris, France, February 2, 2000: Member of the

Scientific Committee and the International Advisory Board.- World Summit Against Cancer, Paris, France, February 3-4, 2000: Member of the Scientific Committee.- 1st Interational Symposium on Genetic Anticancer Agents, Amsterdam, The Netherlands, March 7-9,

2000: Member of the International Scientific Committee.- 1st European Spring Oncology Conference, Marbella, Spain, April 28-May 1, 2000: Member of the

Organizing Committee.- 11th NCI/EORT Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands,

November 7-10, 2000: President.- Symposium on the Role of VEGF in tumor angiogenesis, Amsterdam, The Netherlands, November 7,

2000: President.-11th International Congress on Anti-Cancer Treatment, Paris, France, February 6-9, 2001: Member of the Scientific Committee and International Advisory Board.- 4th 4th International Symposium on Leukemia and Lymphoma – Molecular Pharmacology and new

treatment ACDR symposium on drug-related issues in neighbouring research schools, Leiden, The Netherlands,

- Modalities, Amsterdam, The Netherlands, March 7-10, 2001: Member of the Scientific Advisory Board.- 2nd European Spring Conference, Marbella, Spain, June 13-15, 2001: Member of the Scientific

Committee.- 6th International Symposium on Cancer Chemotherapy, Tokyo, Japan, November 13-14, 2001: Member

of the Scientific Committee.- 12th International Congress on Anti-Cancer Treatment, Paris, France, February 2002: Member of the

Scientific Committee and International Advisory Board.- 3rd International Symposium on Genetic Anticancer Agents, Amsterdam, The Netherlands, February 28-

March 2, 2002: Honorary President.- 1st International Symposium on Signal Transduction Modulators in Cancer Therapy, Amsterdam, The

Netherlands, September 23-25, 2002: President.- Oncology Update-1, Wassenaar, The Netherlands, October 11, 2002: Member of the Organizing and

Scientific Committee.- 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt,

Germany, November 19-22, 2002: Member of the Scientific Committee.

16

- 7th International Symposium on Cancer Chemotherapy, Tokyo, Japan, December 2-3, 2002: Member of the Scientific Committee.

- Winter Masterclass in Clinical Oncology European School of Oncology, Tenerife, Canary Islands, Spain, January 20-25, 2003: Chairman.

- 14th International Congress on Anti-Cancer Treatment, Paris, France, February 1-4, 2003: Member of the Scientific Committee.

- 7th joint congress on Biotherapy of Cancer – From Disease tot the Target, Munich, Germany, September 10-13,2003 Member of the Scientific Advisory Board.

- 9th ESACP / 16th ISDQP International Conference on Applied Genomics, Amsterdam, The Netherlands, October 1-4 2003: Member of the Scientific Advisory Board.

- 15th International Congress on Anti-Cancer Treatment, Paris, France, February 9-12, 2004: Member of the Scientific Committee and Advisory Board.

- 1st ISC International Conference on Cancer Therapeutics Molecular Targets, Pharmacology and Clinical Applications, February 19-21, 2004, Firenze, Italy: Member of the International Advisory Board.

- ESOC-3, “Latest Advances on Anticancer Drugs in Clinical Development”, Marbella, Spain, June 16-18, 2004: Member Scientific Advisory Board.

- 16th International Congress on Anti-Cancer Treatment, Paris, France, February 1-4, 2005: Member of the Scientific Committee and Advisory Board.

- 3rd International Conference on Targeted Anticancer Therapie (ICTAT) Amsterdam, The Netherlands, March 2005; member of scientific committee

- 3rd Bergamo Congres (Third edition of the International Conference on Thrombosis and Hemostasis Issues in Cancer), Bergamo, Italy, October 14-6, 2005 member of International advisory board.

- 9th International Symposium on Cancer Chemotherapy, Tokyo, Japan – January 26-27, 2006 – committee member

- 17th International Congress on Anti-Cancer Treatment, Paris, France, January 28-31, 2006: Member of the Scientific Committee and Advisory Board.

- 5th Masterclass in Clinical Oncology, St. Julians, Malta, February 11-17, 2006 - chair- 4th International Symposium on Targeted Anticancer Therapies – Amsterdam, March 16-18, 2006 –

member of the Scientific Advisory Board- 4th European Spring Oncology Conference Marbella, Spain, June 14-16,2006 – member of the

Scientific Advisory Board- 5th International Breast Cancer From Gene to Cure, Chairman, February 2-4, 2006- International Scientic Advisory Board of the Toulouse-Canceropole, February 2-3, 2006- Aspen Cancer Conferences, Aspen USA, -Advisory Committee July 16-21, 2006- Angiogenesis Symposium Maastricht Netherlands, - member of the Organizing Committee, September

15, 2006- 18th International Congress on Anti-Cancer Treatment, Paris, France, February 6-9, 2007: Member of

the Scientific Committee and Advisory Board.- 6th Masterclass in Clinical Oncology, St. Julians, Malta, February 24-March 2, 2007 – chair

- 5th International Conference on Targeted Anticancer Therapie (ICTAT) Amsterdam, The Netherlands, March 8-10 2007; member of scientific advisory board

- 7th Masterclass in Clinical Oncology, Sofia, Bulgaria, March 1-6, 2008 – chair- 19th International Congress on Anti-Cancer Treatment, Paris, France, February 5-8, 2008: Member of

the Scientific Committee and Advisory Board.

INVITED CHAIRMANSHIP AT INTERNATIONAL SYMPOSIA/CONFERENCES

1983 - 1990- UICC Postgraduate Course on Clinical Cancer Chemotherapy, Sao Paulo, Brasil, May 3, 1983.- UICC Advanced course on clinical chemotherapy, St. Gallen, Switzerland, February 27-March 1, 1984.- Organizing Committee of the international workshop on formulation of antineoplastic agents, Free

University, Amsterdam, the Netherlands, April 3-4, 1984.- Course on Medical Oncology, European School of Oncology, Pomerio, Italy, April 23, 1984.- Round Table Conference "The relative merits of epirubicin". International Symposium "Advances in

anthracycline chemotherapy: epirubicin", Milan, Italy, June 12, 1984.- Session on Chemotherapy. EORTC symposium "Management of soft tissue and bone sarcomas",

17

Utrecht, the Netherlands, June 18, 1984.- EORTC Symposium on Alpha-2 Interferon in Cancer Therapy, Brussels, Belgium, February 28, 1985.- Session on Clinical Pharmacology Phase I, ECCO-3, Stockholm, Sweden, June 16-20, 1985.- Course on Medical Oncology, European School of Oncology, Pomerio, Italy, July 8-14, 1985.- UICC Advanced course in Cancer Chemotherapy, St. Gallen, Switserland, February 24, 1986.- "Human tumour xenografts in anticancer drug development" seminar. European School of Oncology,

Pomerio, Italy, May 26-27, 1986.- "The role of clinical pharmacology in cancer research. 14th International Cancer Congress, Budapest,

Hungary, August 22, 1986.- Fifth NCI/EORTC Symposium on New Drug Development, Amsterdam, the Netherlands, October 1996. - EORTC Symposium on Recent Advances in Cancer Management, Hong Kong, September 21, 1987. - "Update Solid Tumors". XXVI World Congress of the International College of Surgeons, Milan, Italy,

July 3-9, 1988.- "Chemo-and hormonal therapy of cancer (I)". New approaches in cancer therapy, Ulm, Germany,

February 11-13, 1988.- "International Symposium on Hormonal Therapy in Oncology", Bologna, Italy, March 23-25, 1988.- Seminar on Medical Oncology, Orta, Italy, July, 1988.- Seminar on "Pharmacology of anti-cancer drugs", San Servolo Island, Venice, Italy, September 29-30,

1988.- "Conference on Drug Resistance", Swiss Cancer Conference and Joint Scientific Meeting with UICC

Lugano, Switzerland, October 29, 1988.- Session on "Pharmacology", 13th Congress of the European Society for Medical Oncology, Lugano,

Switzerland, October 30-November 1, 1988.- Symposium "Leucovorin Modulation of Fluoropyrimidines, a New Frontier in Cancer Chemotherapy",

Amsterdam, the Netherlands, April 12, 1989.- European School of Oncology, Advanced Course on Medical Oncology, Madrid, Spain, June 12-

16,1989.- Drug Resistance: Mechanisms and Reversal, Pezcoller Symposium, Buffalo, U.S., June 19-21, 1989.- Advanced Course on Medical Oncology, European School of Oncology, Orta, Italy, July 2-8, 1989.- ESMO Symposium "Growth Factors: Clinical significance and applications", 5th European Conference

on Clinical Oncology, London, U.K., September 3-7, 1989.- Session "Does chemotherapy fulfill its expectations in cancer therapy", 5th European Conference on

Clinical Oncology, London, U.K., September 3-7, 1989.- 6th NCI/EORTC Symposium on New Drug Development, Amsterdam, the Netherlands, March, 1990- Postgraduate Course on Medical Oncology, European School of Oncology, Amsterdam, the

Netherlands, April 22-28, 1990.- International Pharmacology Congress, Amsterdam, the Netherlands, July 1-6, 1990.- Session on Clinical Pharmacology of New Drugs, UICC 15th International Cancer Congress, Hamburg,

Germany, August 18, 1990.- Cilag Satellite Symposium, UICC 15th International Cancer Congress, Hamburg, Germany, August 18,

1990.

18

- Satellite Symposium on Correction of Anemia by Recombinant Human Erythropoietin: Potential for Improved Cancer Therapy Management. UICC 15th International Cancer Congress, Hamburg, Germany, August 18, 1990.

- XVth Congress of the European Society for Medical Oncology, Copenhagen, Denmark, Session Pharmacology and New Drugs, December 2-5, 1990.

1991- Session on Clinical Trials. VIth International Symposium on Platinum and other Metal Coordination

Compounds in Cancer Chemotherapy, San Diego, U.S., January 25, 1991.- Postgraduate Course on Medical Oncology, European School of Oncology, Amsterdam, the

Netherlands, April 21-27, 1991.- Bone Marrow Growth Factors and Cancer Therapy Symposium, Amsterdam, the Netherlands, June 7,

1991. - Postgraduate Course on Medical Oncology, European School of Oncology, Caracas, Venezuela,

August 1991. - Session on Experimental Aspects of Melanoma Therapy, 3rd Annual Meeting of the European Society

for Pigment Cell Research, Amsterdam, the Netherlands, September 8-11, 1991.- 4th International ARTAC Workshop on Therapeutic Trials in Cancer and Aids. Session: Chemo

resistance and therapeutic approaches to its circumvention, Paris, France, September 25-27, 1991.- 4th International ARTAC Workshop on Therapeutic Trials in Cancer and Aids, Paris, France,

September 25-27, 1991.- Session on Modulation of Drug Resistance, ECCO-6, Florence, Italy, October 30, 1991.

1992- 7th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, the Netherlands, March

17-20, 1992.- Session on Clinical studies of DNA Topoisomerase I inhibitors. The Fourth Conference on DNA

Topoisomerases in Therapy, New York, U.S., October 28, 1992.

1993- Session on New Drugs and Clinical Pharmacology, 4th International Congress on Anticancer

Chemotherapy, Paris, France, February 5, 1993.- European Society of Hematology: New Approaches to Anticancer Chemotherapy: from Basic Concepts

to Therapeutic Strategy, Session on Multidrug Resistance, Maffliers, France, April 23, 1993.- Jury member-International Consensus Conference on Intensive Chemotherapy plus Hematopoietic

Stem Cell Transplantation in Malignancies, Lyon, France, June 4-6, 1993.- Session on Clinical Applications in Solid Tumors, International Workshop Growth Factors and Medical

Oncology, Biological Acquisitions and Clinical Applications, Rimini, Italy, June 15, 1993.- Session on Chemotherapy Leukemias and Lymphomas. 18th International Congress of Chemotherapy,

Stockholm, Sweden, July 2, 1993.- Gordon Research Conference; Chemotherapy of Experimental and Clinical Cancer, Irsee, Germany,

October 3-8, 1993.- Session on Autocrine Growth Control. Second International Symposium on Cytokines and Growth

Factors in Cancer, Munich, Germany, October 27-30, 1993.- Session on Emerging concepts in clinical oncology, and a session on phase I studies. ECCO-7,

Jerusalem, Israel, November 14-19, 1993.

1994- 1st International Conference on Reversal of Multidrug Resistance in Cancer, Member of Scientific

Committee, Chairperson session MDR in Solid Tumors.St.Gallen, Switzerland, September 1-3, 1994. - 5th Conference on DNA Topoisomerases in Therapy; Chairperson session Camptothecins: Clinical

Studies. New York, U.S., October 3-5, 1994.

1995- 15th Anniversary International Congress Colorectal Cancer: From Gene to Cure, Member of the

Scientific Committee, Chairman session Current Therapeutic Modalities, Lecture: Current Chemotherapeutic Possibilities. Amsterdam, the Netherlands, February 9-11, 1995.

- 19th International Congress of Chemotherapy; Chairman Session Promising new chemotherapeutic agents for cancer, Montreal, Canada, July 16-21 1995.

19

- 19th International Congress of Chemotherapy; Chairman Taxanes - a critical review. Montreal, Canada, July 16-21, 1995.

- ECCO 8, The European Cancer Conference; Drug Design and Development, Paris, France, October 29 November 2, 1995.

1996- Management of Advanced Cancer: Patient Needs, Challenges and New Treatment Options, Co-

chairperson Session Designing Drugs to Make the Difference, Prague, Czech Republic, January 27, 1996.

- Seventh Conference on DNA Topoisomerases in Therapy, Co-chairperson Session Camptothecins in Clinical Research, New York, U.S., October 21-24, 1996.

1997- Minisymposium “From Biology to the Clinical Management of Breast Cancer”, Co-chairman, AACR,

San Diego, U.S., 12-16 April, 1997.- Post ASCO meeting: New therapies, Chairman, Zeist, June 26,1997.- UICC Symposium, First Cancer Management Meeting: Drug Resistance, Chairman, Nice, France, June

29, 1997.- ECCO 9. Novartis Symposium: New avenues in Cancer Therapeutics, Chairman. Hamburg, Germany,

September 16, 1997. - Breast and Ovarium Cancer Symposium. Co-Chairman session IV: Breast-cancer: the Relevance of

the Dose. Chairman session VI: New Perspectives Biological aspects of extended chemotherapy plus GM-CSF in Locally Advanced Breast Cancer, PISA, Italy, September 26, 1997.

1998- 3rd International Symposium on Drug Resistance in Leukemia and Lymphoma Abstracts, University

Hospital Amsterdam, Chairman on Session "Lung resistance protein (LRP) and mdr-1, Amsterdam, the Netherlands, March 7, 1998.

- The FoxChase Cancer Center and Free University Hospital Paclitaxel Investigators’Workshop and Consensus Conference. Co chairman on session: Lung. Amsterdam, the Netherlands, March 26, 1998.

- 89th Annual ASCO meeting, Chairman on session: Mechanisms of drug Action Section. New Orleans, U.S., March 31, 1998.

- 34th ASCO meeting. Chairman on Session: New Approaches in Drug Development. Los Angeles, U.S., May 16, 1998.

- Post-ASCO meeting. Chairman on Session: New Drug Development. Zeist, the Netherlands, June 10, 1998.

- Combined South African Societies of Medical and Radiation Oncology and South African Lymphoma Study Group congress,chairman on session about chemotherapy in advanced malignancies, Cape Town, South Africa, October 3, 1998.

- 9th Conference on DNA Topoisomerases in Therapy. Chairman on Session: Camptothecins Coming of Age. New York, U.S., October 6, 1998.

1999- 20th Anniversary winter meeting of the EORTC PAMM-SPG-PTMG Groups, PAMMsterdam 99:

Angiogenesis related factors relevant for response to chemotherapy, Amsterdam, the Netherlands, January 21, 1999.

- 9th International Congress of Anti-cancer Treatment: prolonged neoadjuvant treatment in locally advanced tumours: a novel concept based on biological considerations. Also a round table discussion about quality care & education in Europe: doctor’s issues. Paris, France, February 3-5, 1999.

- Chemotherapeutic Strategies for Treatment of Colorectal Cancer. Session New Drugs and Combinations – preclinical, Part I, Amsterdam, the Netherlands, February 10, 1999.

- 35th ASCO Annual Meeting: Pharmacology of Topoisomerase Inhibitors and Other New Agents. Atlanta, GA, US, May 16th, 1999.

- 10th Conference on DNA Topoisomerase in therapy: Topo-1 inhibitors in clinical trials, Amsterdam, theNetherlands, October 8, 1999.

- 4th International Symposium on Cancer Chemotherapy: Genetic Approaches and New AntitumorAgents under Development in the US, Europe and Japan, Tokyo, Japan, December 2nd, 1999.

20

2000- 1st International Symposium on Genetic Anticancer Agents: Replicative viruses as anticancer agents.

Amsterdam, the Netherlands,March 8-9, 2000.- International Meeting on Angiogenesis: Scientific Board: Anti-angiogenesis: the future. Vrije

/Universiteit, Amsterdam, The Netherlands. April 27-29, 2000.- Post ASCO Evaluation meeting, Zeist, The Netherlands, June 8, 2000.- 11th NCI-EORTC Symposium on new drugs in cancer therapy, Amsterdam, the Netherlands,

November7-10, 2000.

- Chemotherapy in the 21st Century; a Symposium on the Occasion of 5 years of Gemzar: Pancreascarcinoma, state of the art. Utrecht, The Netherlands, November 23, 2000.

2001- Post ASCO Evaluation Meeting. Zeist, The Netherlands,June 7, 2001,- 22nd International Congress of Chemotherapy, Amsterdam: Session on New Anticancer Treatments,

The Netherlands, June 30-July 3, 2001.- 4th UICC “Global Cancer Management: Towards a European model” , Paris, France, September 23-26,

2001.- 6th International Symposium on Cancer Chemotherapy: Session on Angiogenesis, Tokyo, Japan,

November 13-14, 2001

2002- Post ASCO Evaluation Meeting, Zeist, the Netherlands, June 6, 2002.- Workshop “Thromboprophylaxis in Medical Patients and Workshop : The Frontline Survey”, 9th

International Symposium on Thromboembolism, Seville, Spain, June 7-8, 2002.- Translational Research Symposium “Mechanisms of Drug Resistance: New Developments”, 17th

Meeting of the European Association for Cancer Research, Granada, Spain, June 8-11, 2002.- European Oncology First Steering Committee Meeting, June 27-28, Venice, Italy- 1st International Symposium on Syngal Transduction Modulators “Plenary Session 3: Antio-angiogenic

approaches”, Amsterdam, The Netherlands, September 23-25, 2002.- 1st International Symposium on Syngal Transduction Modulators “Plenary Session 5: SMTs: Clinical

and translational research (2)”, Amsterdam, The Netherlands, September 23-25, 2002.- Oncology Update-1, Wassenaar, The Netherlands, October 11, 2002.- 4th Major International Meeting “From Gene to Cure”- Cancer of Esophagus and gastric Cardia,

Amsterdam, The Netherlands, Dec. 13-15 2002. Plenary Session: Therapeutic advances.

2003- Second International Meeting on Angiogenesis, February 13-15, 2003 Leiden, The Netherlands- European Oncology Second Steering Committee Meeting, February 21-23, 2003 Mijas Coast,Spain- Post ASCO Evaluation Meeting, The Netherlands, June 19, 2003.- ECCO Satellite Symposium on Advances in Cancer Anemia Management, Copenhagen, Denmark,

September 21, 2003- 8th International Symposium on Cancer Chemotherpy, Tokyo, Japan, December 1-2, 2003

2004- 15th International Congress on Anti-Cancer Treatment, Paris, France, February 9-12, 2004- European School of Oncology, Master Course, Cyprus, March 6-11, 2004.- 11th International Symposium on Thromboembolism, Barcelona, Spain, September 10-11, 2004

2005- 3rd International Symposium on Targeted Anticancer Therapies, Amsterdam, the Netherlands, March 3-5, 2005

- European School of Oncology, Master Course, Larnaca, Cyprus, March 5-11, 2005- 12th International Symposium on Thromboembolism,”Plenary Session 2: The management of Cancer Associated Thrombosis”, Athens, Greece, September 23-24, 2005

21

2006- 17th International Congress on Anti-Cancer Treatment, “Urological Tumors”, Paris France, Jan 30–Feb 2, 2006- 5th Masterclass in Clinical Oncology, St. Julians, Malta, February 11-17, 2006- 21st Aspen Cancer Conference, “Session on Prostate Cancer “, Aspen, USA, July 16-21, 2006 - Angiogenesis Symposium Maastricht Netherlands, September 15, 2006

2007- 6th Masterclass in Clinical Oncology, St. Julians, Malta, February 24 – March 2, 2007- 5th International Symposium on Targeted Anticancer Therapies, Amsterdam, the Netherlands, March 8-10, 2007

2008- 7th Masterclass in Clinical Oncology, Sofia, Bulgaria, March 1-6, 2008- 19th International Congress on Anti-Cancer Treatment, Lung cancer, Paris France, February 5th,2008- 19th International Congress on Anti-Cancer Treatment, Targeted Therapy, in particular Signal

Transduction Inhibitors, Paris France, February 5th, 2008- American Association of Cancer Research, Chairman Educational Session on Drug Resistance, San

Diego,April 12th, 20082014- The 42nd David A. Karnofsky memorial award lecture: Understanding, Chicago, May 31, 20142015-

INVITED LECTURES (INTERNATIONAL SYMPOSIA, COURSES, CONFERENCES)

1. The role of cisplatin in the treatment of sarcomas. Platinum Symposium, Stockholm, Sweden, April 2, 1979.

2. Studies with BCNU in Europe. BCNU Symposium, Venice, Italy, May 26, 1979.3. Current problems in chemotherapy of gynecological cancer. Symposium on Oncological

Gynaecology, Groningen, the Netherlands, September 27, 1979.4. Ongoing European studies on testicular cancer. UICC Workshop on Testicular Carcinoma,

Lugano, Switzerland, September 28, 1979.5. The role of thymidine in oncology. NCI-EORTC Symposium on New Drugs in Cancer Therapy,

Brussels, Belgium, October 20, 1979.6. Treatment of advanced testicular tumors. NCI-EORTC Symposium on New Drugs in Cancer

Therapy, Brussels, Belgium, October 20, 1979.7. Rescue of methotrexate with leucovorin or thymidine. Methotrexate Symposium, London, U.K.,

November 3, 1979.8. Treatment of primary bone tumors. CEMO Symposium on Bone Diseases, Basel, Switzerland,

November 7, 1979.9. Treatment of advanced soft tissue sarcoma. Boerhaave Symposium: Recent advances in the

treatment of ovarian and testicular cancer and/or soft tissue and bone sarcomas, Noordwijker-hout, the Netherlands, December 8, 1979.

10. Quality control in multicenter clinical trials. 16th Annual Meeting of the American Society for Clinical Oncology, San Diego, U.S., May 27, 1980.

11. Indications and results of chemotherapy. XXI Postgraduate Course on Clinical Oncology, Milan, Italy, June 24, 1980.

12. Chemotherapy of adult soft tissue sarcomas. International Symposium on Cancer, New York, U.S., September 16, 1980.

13. Biochemical pharmacological and clinical studies of PALA. EORTC Symposium New Approaches in Cancer Therapy, Madrid, Spain, October 2, 1980.

14. Chemotherapy of advanced soft tissue sarcomas. EORTC Symposium New Approaches in Cancer Therapy, Madrid, Spain, October 3, 1980.

15. Clinical pharmacology. Jornadas Internationales de Oncologia, Buenos Aires, Argentina, October 30, 1980.

16. Soft tissue sarcomas. Jornadas Internationales de Oncologia, Buenos Aires, Argentina, October

22

31, 1980.17. Biochemical pharmacology of PALA. Enzymology Symposium, Academisch Ziekenhuis Utrecht,

Utrecht, the Netherlands, November 28, 1980.18. Pharmacology of cisplatin and mitomycin C. UICC Cancer Chemotherapy Seminar, Cairo, Egypt,

December 2, 1980.19. Pharmacology of podophyllotoxins. UICC Cancer Chemotherapy Seminar, Cairo, Egypt,

December 3, 1980.20. Tamoxifen chemotherapy in breast cancer. Symposium on Progress in the Endocrine Treatment

of Breast Cancer, Tokyo, Japan, June 27, 1981.21. Adjuvant chemotherapy in soft tissue sarcomas. VIIIth Course on Medical Oncology, Perugia,

Italy, October 6, 1981.22. Selective and sensitive assay of the antitumor agent mitomycin C and possible metabolites and

application in clinical practice. Third NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium, October 15, 1981.

23. Randomized phase II trial of carminomycin versus 4'- epiadriamycin in advanced breast cancer. Third NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium, October 17, 1981.

24. Establishment of anticancer drug safety and efficacy in clinical trials. Scientific and ethical considerations. International Symposium on the Management and Realization of Anticancer Drug Development, Granada, Spain, March 25, 1982.

25. Treatment of testicular cancer. Georgia Oncology Hematology Clinic, P.C., Atlanta, U.S., April 20, 1982.

26. Pharmacology of antineoplastic agents. Georgia Oncology Hematology Clinic, P.C., Atlanta, U.S., April 21, 1982.

27. Treatment of ovarian cancer. Georgia Oncology Hematology Clinic, P.C., Atlanta, U.S., April 23, 1982.

28. Phase I study and pharmacokinetics of cis-l,l-di(aminomethyl)-cyclohexane Pt II sulphate (TNO-6). 18th Annual Meeting of the American Society for Clinical Oncology, St. Louis, U.S., April 24, 1982.

29. Adjuvant chemotherapy in soft tissue sarcoma. International Conference on Advances in the Adjuvant Therapy of Cancer, Southampton, Great Britain, June 16, 1982.

30. Treatment of soft tissue and bone sarcoma. Sociedad Venezolana de Oncologia, Caracas, Venezuela, July 27, 1982.

31. New drug in the treatment of cancer. Sociedad Venezolana de Oncologia, Caracas, Venezuela, July 29, 1982.

32. Chemotherapy of ovarian and testicular cancer. Sociedad Venezolana de Oncologia, Caracas, Venezuela, July 30, 1982.

33. Potentials of pharmacokinetic studies in cancer chemotherapy. Symposium on Pharmacology of Antineoplastic Agents of the 13th International Cancer Congress, Seattle, U.S., September 13, 1982.

34. Chemotherapy of head and neck cancer. Postgraduate Course in Head and Neck Surgery and Oncology, Free University, Amsterdam, the Netherlands, November 24, 1982.

35. Pitfalls in clinical trials. UICC Postgraduate Course on Clinical Cancer Chemotherapy, Sao Paulo, Brasil, May 3, 1983.

36. Testicular cancer. UICC Postgraduate Course on Clinical Cancer Chemotherapy, Sao Paulo, Brasil, May 4, 1983.

37. Recent results in the chemotherapy of soft tissue sarcoma. UICC Postgraduate Course on Clinical Cancer Chemotherapy, Sao Paulo, Brasil, May 6, 1983.

38. Controversy on osteogenic sarcoma. UICC Postgraduate Course on Clinical Cancer Chemotherapy, Sao Paulo, Brasil, May 6, 1983.

39. Pharmacology of anticancer agents. Postgraduate Course on Medical Oncology of the European School of Oncology, Milan-Pomerio, Italy, June 13, 1983.

40. Soft tissue sarcomas. Postgraduate Course on Medical Oncology of the European School of Oncology, Milan-Pomerio, Italy, June 15, 1983.

41. Bone sarcomas. Postgraduate Course on Medical Oncology of the European School of Oncology, Milan-Pomerio, Italy, June 15, 1983.

42. Clinical experience with l,l-diaminomethylcyclohexane (sulphato)platinum(II)(TNO-6). 4th International Symposium on Platinum Coordination Complexes in Cancer, Burlington, U.S.A.,

23

June 23, 1983.43. Treatment of soft tissue sarcomas. International Symposium on Adriamycin, Hakone, Japan,

July 16, 1983.44. Chemotherapy of ovarian cancer. The Cancer Institute, Melbourne, Australia, July 19, 1983.45. Clinical activity of new anthracyclines - European Experience. The Cancer Institute, Melbourne,

Australia, July 20, 1983.46. Trials in Soft Tissue Sarcomas. Sixth Annual Bristol Myers Symposium on Cancer Research,

"Clinical Trials in Cancer Medicine: Past Achievements and Future Prospects, Venice, Italy, October 19-21, 1983.

47. Phase II trials of 4'-epidoxorubicin in colorectal cancer and 4'-deoxydoxorubicin in GI cancer. International Symposium on Advances in the Chemotherapy on Gastrointestinal Cancer, Cologne, Germany, October 28-29, 1983.

48. Experimental and clinical pharmacology of TNO-6. Fourth NCI-EORTC on New Drugs in Cancer Therapy, Brussels, Belgium, December 14, 1983.

49. Recent results in the chemotherapy of soft tissue sarcomas. UICC Advanced Course on Clinical Cancer Chemotherapy, St. Gallen, Switzerland, March 1, 1984.

50. Controversy in osteogenic sarcoma and chemotherapy of other "pediatric" tumors. UICC Advanced Course on Clinical Cancer Chemotherapy, St Gallen, Switzerland, March 1, 1984.

51. Pharmacology of anticancer agents. European School of Oncology, Milan-Pomerio, Italy, April 24, 1984.

52. Adult soft tissue sarcomas. European School of Oncology, Milan-Pomerio, Italy, April 26, 1984.53. Chemotherapy of soft tissue sarcoma in adults. Course on Bone and Soft Tissue Sarcoma of the

European School of Oncology, Milan-Pomerio, Italy, May 21, 1984.54. Assessment of new drugs. European School of Oncology, Milan-Pomerio, Italy, May 22, 1984.55. Problems in multicentric studies. European School of Oncology, Milan-Pomerio, Italy, May 22,

1984.56. Adjuvant chemotherapy. European School of Oncology, Milan-Pomerio, Italy, May 22, 1984.57. New directions in management of non-Hodgkin's lymphoma. International Seminar on Cancer

Management `Curable Cancer in Adults', Sydney, Australia, May 29, 1984.58. Combined cisplatin and radiation therapy. International Seminar on Cancer Management Curable

Cancer in Adults', Sydney, Australia, May 30, 1984.59. Drug Resistance. International Seminar on Cancer Management `Curable Cancer in Adults',

Sydney, Australia, May 30, 1984.60. Management of advanced ovarian cancer. International Seminar on Cancer Management

"Curable Cancer in Adults", Sydney, Australia, May 31, 1984.61. Epirubicin in soft tissue sarcomas. International Symposium "Advances in anthracycline

chemotherapy: epirubicin", Milan, Italy, June 11, 1984.62. EORTC soft tissue and bone sarcoma group. Reflection on the past 10 years. EORTC

Symposium "Management of soft tissue and bone sarcomas", Utrecht, the Netherlands, June 10, 1984.

63. Chemotherapy in advanced soft tissue sarcomas. Symposium "Management of soft tissue and bone sarcomas", Utrecht, the Netherlands, June 19, 1984.

64. Review of activities of the EORTC Early Clinical Trials Group. EORTC Joint Meeting of ECTG, PAMM and SPG, Sutton, Great Britain, June 22, 1984.

65. Pharmacology of new drugs. Instituto Nacional de Cancer, Rio de Janeiro, Brasil, July 30, 1985.66. Soft tissue sarcoma. The Annual Council Meeting of the Israel Cancer Association, Jerusalem,

Israel, October 29, 1984.67. Ovarian and testicular cancer. The Annual Council Meeting of the Israel Cancer Association,

Jerusalem, Israel, October 29, 1984.68. Review on the Soft Tissue Sarcoma Meeting Utrecht, 10th Congress of ESMO, Nice, France,

December 7, 1984.69. Review on Phase I and Pharmacological studies. 10th Congress of ESMO, Nice, France,

December 8, 1984.70. A randomized trial comparing the effect of epirubicin and adriamycin in soft tissue sarcomas.

Progress in Anthracycline Therapy, London, Great Britain, January 28-29, 1985.71. The ESMO Award Lecture "New Drug Development in Europe, ECCO 3, Stockholm, Sweden,

24

June 16-20, 1985.72. Phase I and II studies. European School of Oncology, Milan-Pomerio, Italy, July 9, 1985.73. Adult soft tissue sarcomas. European School of Oncology, Milan-Pomerio, Italy, July 11, 1985.74. Malignant melanoma. European School of Oncology, Milan-Pomerio, Italy, July 11, 1985.75. Pharmacology of anticancer drugs. European School of Oncology, Milan-Pomerio, Italy, July 14,

1985.76. Success in Medical Oncology. 7th Congress of the Argentinian Association of Clinical Oncology,

Buenos Aires, Argentina, September 3-6, 1985.77. Controversy in the gynecological tumors. 7th Congress of the Argentinian Association of Clinial

Oncology, Buenos Aires, Argentina, September 3-6, 1985.78. Advanced Breast Cancer. 7th Congress of the Argentinian Association of Clinical Oncology,

Buenos Aires, Argentina, September 3-6, 1985.79. Chemotherapy of soft tissue and bone tumors. Int. Meeting on Oncology, Coimbra, Portugal,

October 20-23, 1985 80. Controversies in oncological treatment. Symposium Intervention decisions in primary care,

Amsterdam, the Netherlands, October 26, 1985.81. Recent advances in medical oncology. Congreso Iberoamericano de Oncologia, UICC, Madrid,

Spain, November 3, 1985.82. Tumores Testiculares. Congreso Iberoamericano de Oncologia, UICC, Madrid, Spain, November

6, 1985.83. The role of pharmacology in clinical trials with new cytostatic agents. Westdeutsches

Tumorzentrum, Essen, Germany, January 27, 1986.84. New Drugs. UICC Advanced course in cancer chemotherapy, St. Gallen, Switzerland, February

24, 1986.85. Pharmacology of anticancer drugs. UICC Advanced course in cancer chemotherapy, St. Gallen,

Switzerland, February 24, 1986.86. Treatment of soft tissue sarcomas. UICC Advanced course in cancer chemotherapy, St. Gallen,

Switzerland, February 27, 1986.87. Developmental directions of chemotherapy. Oncology/Haematology Symposium, Galway,

Ireland, April 5, 1986.88. Future developments in oncology. Schweizerische Krebstagung Journees suisses du cancer,

Zurich, Switzerland, June 27, 1986.89. Preclinical screening and toxicology. European School of Oncology, Milan-Pomerio, Italy, July 1, 1986.90. Phase I and II studies. European School of Oncology, Milan-Pomerio, Italy, July 1, 1986.91. Pharmacology of anticancer drugs. European School of Oncology, Milan-Pomerio, Italy, July 1,

1986.92. Osteosarcomas. European School of Oncology, Milan-Pomerio, Italy, July 4, 1986.93. Soft tissue sarcomas. European School of Oncology, Milan-Pomerio, Italy, July 4, 1986.94. Malignant melanoma. European School of Oncology, Milan-Pomerio, Italy, July 4, 1986.95. New possibilities for chemotherapy, Groningen, the Netherlands, September 4, 1986.96. Soft tissue sarcomas. 5th Annual ESTRO meeting, BadenBaden, Germany, September 8, 1986.97. New drugs in treatment of solid tumors. Symposium on new developments in medical oncology,

Forli, Italy, October 3, 1986.98. Development of new-anticancer drugs. European School of Oncology, Visiting professor, Madrid,

Spain, October 14, 1986. 99. Recent results BRM in medical oncology. European School of Oncology, Visiting professor,

Madrid, Spain, October 15, 1986.100. Basis for therapeutic selectivity of 5-fluorouracil activity by uridine. Fifth NCI/EORTC

Symposium, Amsterdam, the Netherlands, October 24, 1986101. Mechanisms of antitumor drug resistance. Annual meeting of the Italian Society of Oncology,

Bari, Italy, December 16, 1986.102. Clinical pharmacology - current status and therapeutic guidelines. Symposium on Methotrexate,

Taby, Sweden, April 1, 1987.103. Rationale for use of rescue. Symposium on Methotrexate, Taby, Sweden, April 1, 1987.104. New developments in medical oncology. France academique d'hommage a Yvon Kenis,

Brussels, Belgium, June 29, 1987.105. Development of New Anticancer Agents, ECCO IV, Stockholm, Sweden, August 1987.

25

106. Clinical Pharmacology. The 8th Asia Pacific Conference, Seoul, South Korea, September 14-19, 1987.

107. Pharmacology of anti-cancer drugs", EORTC Symposium & Exhibition on Recent Advances in Cancer Management, Hong Kong, September, 1987.

108. Recent Advances in Breast Cancer Management, EORTC Symposium & Exhibition on Recent Advances in Cancer Management, Hong Kong, September, 1987.

109. Clinical Prospects with Biological Response Modifiers, EORTC Symposium & Exhibition on Recent Advances in Cancer Management, Hong Kong, September, 1987.

110. Characterization of human ovarian cancer lines with a panel of monoclonal antibodies (MoAbs)", Workshop Nude-Mice in Oncology, Essen, Germany, September 17-19, 1987.

111. A nude mouse-phase II model for human ovarian cancer. Workhop "Nude-Mice in Oncology", Essen, Germany, September 17-19, 1987.

112. Controlled clinical trials, Buenos Aires, Argentina, September 2-4, 1987.113. Drug resistance, Buenos Aires, Argentina, September 2-4, 1987.114. Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude

mice. Workshop "Nude-Mice in Oncology", Essen, Germany, September 17-19, 1987.115. Pharmacology of Anti-Cancer Drugs. EORTC Symposium on Recent Advances in Cancer

Management, Hong Kong, September 21, 1987.116. Recent Advances in Breast Cancer Management. EORTC Symposium on Recent Advances in

Cancer Management, Hong Kong, September 22, 1987.117. Clinical Prospects with Biological Response Modifiers. EORTC Symposium on Recent Advances

in Cancer Management, Hong Kong, September 23, 1987.118. Goals and Future of Cancer Chemotherapy. Spanish Ministry of Health, Spain, October 16,

1987.119. Phase I Studies and Pharmacology. 4th European Conference on Clinical Oncology and Cancer

Nursing, Madrid, Spain, November 1-4, 1987.120. Developments in the Medical Treatment of Cancer. Symposium Pharmacology and Cancer

Chemotherapy, Norwich, Great Britain, March 22, 1988.121. Biological response modifiers and brain tumours. Neuro-Oncology: Recent developments in

biology and practice, London, Great Britain, March 28-29, 1988.122. Pharmacology of anti cancer drugs. Postgraduate course on Paediatric Oncology, Amsterdam,

the Netherlands, April 11-15, 1988.123. Pharmacology and Cancer Chemotherapy, Ass. of Cancer Physicians meeting, Norwich, Great

Britain, March 22, 1988.124. New Drug Development in the EORTC. Lilly Cancer Research Symposium, Indianapolis, U.S.,

May 18-20, 1988.125. Perspective in Medical Oncology. XXVI World Congress of the International College of

Surgeons, Milan, Italy, July 3-9, 1988.126. Interleukin-2 (IL-2) in the treatment of metastatic renal cell carcinoma (RCC), meeting of the New

York Section of the American Urological Association, Amsterdam, the Netherlands, October 1, 1988.

127. Clinical Research in Medical Oncology; Biochemical and Pharmacological Aspects, 4th Nagoya International Symposium on Cancer Treatment, Nagoya, Japan, October 11-13, 1988.

128. Actualizaciones en el tratamiento de los sarcomas de partes blandas. Symposium Avances en Oncologia, Sevilla, Spain, November 18-19, 1988.

129. Actualizaciones en el tratamiento deI cancer con modificadores de la respuesta biologica. Symposium Avances en Oncologia, Sevilla, Spain, November 18-19, 1988.

130. New Drugs in the treatment of cancer. Symposium Recent development in cancer diagnosis and treatment, Rio de Janeiro, Brasil, November 27-30, 1988.

131. Tumors of unknown primary site. Symposium Recent development in cancer diagnosis and treatment, Rio de Janeiro, Brasil, November 27-30, 1988.

132. 5-FU and leucovorin (summary). Sixth NCI-EORTC symposium on New Drugs in Cancer Therapy, Amsterdam, the Netherlands, March 10, 1989.

133. Summary and future directions. Leucovorin Modulation of Fluoropyrimidines, a New Frontier in Cancer Chemotherapy, Amsterdam, the Netherlands, April 12, 1989.

134. Secondary tumors in patients treated for head and neck cancer. Ist International Symposium "Advances in the multidisciplinary treatment of head and neck cancers", Barcelona, Spain, April 29, 1989.

26

135. Hypercalcemia in the oncology patient. International Symposium on "Hypercalcemia in Malignancy", Zeist, the Netherlands, May 12, 1989.

136. Methodology in clinical trials. European School of Oncology, postgraduate course on medical oncology, Madrid, Spain, June 14, 1989.

137. Pharmacology I. European School of Oncology, postgraduate course on medical oncology, Madrid, Spain, June 13, 1989.

138. Pharmacology II. European School of Oncology, postgraduate course on medical oncology, Madrid, Spain, June 15, 1989.

139. Drug resistance: Implications for treatment strategies. Pezcoller Symposium "Drug resistance: Mechanisms and reversal", Trento, Italy, June 21, 1989.

140. Pharmacology of anti-cancer drugs & drug resistance. European School of Oncology, postgraduate course on medical oncology, Orta, Italy, July 3, 1989.

141. Preclinical screening and toxicilogy. European School of Oncology, postgraduate course on medical oncology, Orta, Italy, July 5, 1989.

142. Soft tissue sarcomas and malignant melanoma. European School of Oncology, postgraduate course on medical oncology, Orta, Italy, July 8, 1989.

143. Drug resistance in chemotherapy. Recent developments in the field of the combat against cancer. Symposium and workshop on the occasion of the 40th anniversary of "Stichting Prinses Wilhelmina Fonds", Curacao, August 12, 1989.

144. Growth-factors. Recent developments in the field of the combat against cancer. Symposium and workshop on the occasion of the 40th anniversary of "Stichting Prinses Wilhelmina Fonds", Curaçao, August 12, 1989.

145. Cellular pharmacology and drug resistance. Third IST International Symposium, Genua, Italy, September 25-27, 1989.

146. New drugs and innovative therapeutic principles in oncology. 34th Annual Meeting of the German Society for Hematology and Oncology, Hannover, Germany, October 1-4, 1989.

147. EORTC trials of chemotherapy. Royal Marsden Hospital and Institute of Cancer Research Londen, Great Britain, November 2, 1989.

148. Biological response modifiers. IXth Argentine Congress of Clinical Oncology, Buenos Aires, Argentina, November 5, 1989.

149. Multi drug resistance. IXth Argentine Congress of Clinical Oncology, Buenos Aires, Argentina, November 7, 1989.

150. The Constance Wood Memorial Lecture: Clinical studies in multidrug resistance. Royal Postgraduate Medical School, University of London, Great Britain, April 3, 1990.

151. Dorothy Snider Foundation Forum on Cancer Research "Cisplatinum as a Radio Enhancer in the Treatment of Non Small Cell Lung Cancer: Dose and Scheduling", Symposium on Molecular Targets for Cancer, Memphis, U.S., April 20, 1990.

152. Preclinical screening and toxicology. Postgraduate Course in Medical Oncology, European School of Oncology, Amsterdam, the Netherlands, April 25, 1990.

153. Soft tissue sarcomas and malignant melanoma. Postgraduate Course in Medical Oncology, European School of Oncology, Amsterdam, the Netherlands, April 28, 1990.

154. Progress to date: New drugs in development in the EORTC. CRC-EORTC-NCI Joint Meeting, Washington, U.S., May 17, 1990.

155. Functional studies on drug resistance. The Mount Sinai Medical Center, New York, U.S., June 15, 1990.

156. Chemotherapy of solid tumors: a review. Postgraduate Course in Medical Oncology, European School of Oncology, Moscow, Soviet Union, June 20, 1990.

157. Endocrine therapy of cancer. Postgraduate Course in Medical Oncology, European School of Oncology, Moscow, Soviet Union, June 22, 1990.

158. Functional tests to determine drug resistance. EORTC Joint Meeting, PAMM Symposium on Drug Resistance, Glasgow, Great Britain, June 28, 1990.

159. Functional screening for multidrug resistant cells in human malignancies. Gordon Conference, New Hampshire, U.S., July 20, 1990.

160. Correction of anaemia by recombinant human erythropoietin: potential for improved cancer therapy management. Eprex Satellite Symposium. 15th International Cancer Congress, Hamburg, Germany, August 18, 1990.

161. Preclinical phase II studies. 15th UICC Congress, Hamburg, Germany, August 22, 1990.

27

162. New frontiers in the therapy of tumors. International multidisciplinary meetings on development '90, Torino, Italy, October 19-20, 1990.

163. Soft tissue sarcomas and malignant melanoma. Postgraduate Course in Medical Oncology, European School of Oncology, Portugal, November 20, 1990.

164. Radiotherapy combined with daily or weekly cis-diammine dichloroplatinum (II) (CDDP) in inoperable non metastatic non-small cell lung cancer (NSCLC): A randomized three arm phase II study of the EORTC lung cancer and radiotherapy cooperative groups. Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, San Diego, U.S., January 23, 1991.

165. Cellular mechanisms of resistance to drugs. Workshop "Current Topics in Anticancer Chemotherapy", Cadiz, Spain, April 12, 1991.

166. Drug resistance. Postgraduate Course on Medical Oncology, European School of Oncology, Amsterdam, the Netherlands, April 17-21, 1991.

167. III Congresso Ibero-Americano de Oncologia, Exponor, Portugal, June 22, 1991.168. Mechanisms of resistance to platinum compounds. Postgraduate Course on Platinum

Derivatives European School of Oncology, Corfu, Greece, September 20, 1991.169. Platinum derivatives in ovarian cancer. Postgraduate Course on Platinum Derivatives, European

School of Oncology, Corfu, Greece, September 21, 1991.170. Chemoresistance reversion by modulating agents: evaluation of current clinical trials. 4th

International Workshop on Therapeutic Trials in Cancer and Aids, (ARTAC) Paris, France, September 25-27, 1991.

171. New frontiers in Clinical Oncology. 4th Conference Highlights in Medical Virology, Immunology and Oncology, San Marino, Italy, October 2-6, 1991.

172. Molecular approaches. 4th Charles Heidelberger Conference, Marina del Rey, U.S., December 7-10, 1991.

173. Detection of multidrug resistance in acute myeloid leukemia and human tumor response. Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, the Netherlands, March 17-21, 1992.

174. Is Europe lagging behind in the area of biotechnology? 1st International Congress on "Cancer and Aids", Paris, France, March 23-25, 1992.

175. Perspectives in reversal of anticancer drug resistance. Workshop "Chemotherapeutic Drug Resistance, Mechanisms and Reversal". 26th Annual Scientific Meeting for Clinical Investigation, Vienna, Austria, April 1-4, 1992.

176. Drug resistance. European School of Oncology Postgraduate Course on Medical Oncology, Amsterdam, the Netherlands, April 6, 1992.

177. Functional tests in multidrug resistance. Organization of European Cancer Institutes (OECI), Amsterdam, the Netherlands, May 11, 1992.

178. Clinical aspects of drug resistance. VIIth World Conference on Clinical Pharmacology and Therapeutics, Tokyo, Japan, July 27, 1992.

179. Developments in the management of patients with testicular cancer. 17th International Congress of Life Assurance Medicine, London, Great Britain, September 10, 1992.

180. Multidrug resistance and its circumvention in the clinic: Cutting Edge. Course on Medical Oncology. Memorial-Sloan Kettering Cancer Center, New York, U.S., October 22, 1992.

181. Dose intensity of chemotherapy in breast cancer. ISREC. Geneva, Switzerland, November 6, 1992.

182. High dose chemotherapy for cancer. European Society for Medical Oncology (Hamilton-Fairley Award Lecture), Lyon, France, November 9, 1992.

183. New chemotherapeutics. International conference on cancer: Biological mechanisms and clinical application, Rome, Italy, November 18, 1992.

184. What's the impact of dose in cancer chemotherapy in solid tumors. World Health Organization, Geneva, Switzerland, January 29, 1993.

185. New Drugs in Early Development; educational lecture. Fourth International Congress on Anti Cancer Chemotherapy, Paris, France, February 5, 1993.

186. Recent developments in the field of dose effect relationship in chemotherapy of breast cancer. Royal Academy of Sciences, Amsterdam, the Netherlands, February 22, 1993.

187. Biology of drug resistance. European School of Oncology, Amsterdam, the Netherlands, April 6, 1993.

188. Multidrug Resistance. European School of Hematology, Mafliers, France, April 23, 1993.

28

189. EORTC Cooperation in Drug Development. 86th Meeting of the National Cancer Advisory Board, National Cancer Institute, Washington, U.S., May 4-5, 1993.

190. Functional Detection of Multidrug Resistance (MDR) in Acute Myeloid Leukemias. General Motors Cancer Research Foundation, International Symposium on Resistance Against Anticancer Drugs: Molecular Mechanims and Clinical Opportunities, Toronto, Canada, May 6, 1993.

191. New therapeutic orientations in cancer treatment. IVth National Congress of the Spanish Society for Medical Oncology, Madrid, Spain, May 28, 1993.

192. The clinical role of hematopoietic growth factors. International Workshop on Growth Factors and Medical Oncology, Biological Acquisitions and Clinical Applications, Rimini, Italy, June 14, 1993.

193. Functional tests in multidrug resistance. 18th International congress of chemotherapy. Stockholm, Sweden, July 1, 1993.

194. New treatments in soft tissue sarcomas. Argentina Oncology Congress, Buenos Aires, Argentina, September 2, 1993.

195. Strategies in melanoma treatment (roundtable). Argentina Oncology Congress, Buenos Aires, Argentina, September 2, 1993.

196. Development in Drugs (roundtable). Argentina Oncology Congress, Buenos Aires, Argentina, September 3, 1993.

197. European Cancer Control and Relationship with Latin America (roundtable). Argentina Oncology Congress, Buenos Aires, Argentina, September 3, 1993.

198. European Cancer Centers and their relationship with Latin America (roundtable). Argentina Oncology Congress, Buenos Aires, August 31-September 3, 1993.

199. MD Anderson, Houston, U.S.A., Visiting Professorship, November 30-December 3, 1993.200. Latest developments in chemotherapy for solid tumors of the G.I. tract. European Postgraduate

gastro-surgical School, Amsterdam, the Netherlands, December 17, 1993.201. New Drug Development-a European perspective, Cancer Treatment. London, U.K., January 20,

1994.202. MDR-clinical trials with reverters. Eigth NCI-EORTC symposium, Amsterdam, the Netherlands,

May 16, 1994.203. Multidrug resistance. Royal Dutch Acadamy of Science, September 26, 1994.204. Postgraduate course for surgeons, Amsterdam, the Netherlands, December 15-17, 1994.205. Dose effect relationship and the treatment of breast cancer. Fifth International Congress on Anti-

Cancer Chemotherapy, Paris, France, January 31-February 3, 1995.206. Breast cancer treatment in elderly women. Fifth International Congress on Anti-Cancer

Chemotherapy, Paris, France, January 31-February 3, 1995.207. Colorectal cancer: From gene to cure, Amsterdam, the Netherlands, February 9-11, 1995.208. Clinical Indications for Taxanes. 19th International Congress of Chemotherapy, Montreal,

Canada, July 16-21, 1995209. Screening Models in Drug Development. ECCO, Paris, France, October 29-November 1, 1995.210. Clinical Approaches to Drug Resistance: a Critical Viewpoint, Workshop on Drug Resistance,

Bern, Switzerland, November 3, 1995.211. Bridging the Gap between Basic Science and Clinical Oncology, Dr. Josef Steiner Award lecture,

Bern, Switzerland, November 3, 1995.212. Drug resistance, illustration of the complexity of translational research. Steiner Award lecture,

Bern, Switzerland, November 3, 1995.213. Introducción al Tratamiento del Cáncer de Ovario, VI Curso Internacional "Avances 95 en

Gineco-Obstreticia y Reproduccion Humana" Barcelona, Spain, November 9, 1995.214. Taxol en el Tratamiento del Cáncer de Ovario, VI Curso Internacional "Avances 95 en Gineco-

Obstreticia y Reproduccion Humana" Barcelona, Spain, November 9, 1995.215. Cytostatica: een draak met meerdere koppen?, Milestone 1995: Van cel naar kanker, van model

naar behandeling. Nederlandse Vereniging voor Oncologie, Noordwijkerhout, the Netherlands, November 24, 1995.

216. The relevance of multidrug resistant proteins in clinical oncology. Sixth International Congress on Anti-cancer Treatments, Paris, France, February 7, 1996.

217. Topoisomerase 1 inhibitors: a new cytotoxic approach, Paris, France, February 7, 1996.218. Have preclinical models in studies of drug resistance provided accurate predictions for clinicians?

American Association for Cancer Research, Washington, U.S., April 21, 1996.219. Clinical Relevance of Drug Resistance Proteins, 2 Encuentro en Segovia sobre oncologia,

29

Segovia, Spain, April 27, 1996.220. High Dose Chemotherapy in Breast Cancer, Freiburg, June 20, 1996.221. Clinical Aspects of Drug Resistance, Anticancer Targets and Strategies for the Twenty-first

Century, Castres, France, October 9-11, 1996.222. Extended neoadjuvant high dose doxorubicin, cyclophosphamide plus GM-CSF in locally

advanced breast cancer (LABC), Seventh International Congress on Anti-cancer Treatments, Paris, France, February 3-6, 1997.

223. ¿Qué han aportado en el momento actual los conocimientos biológicos del cáncer?, Oncología Básica para Oncologos Médicos, Almagro, Spain, March 20-21, 1997.

224. Extended neo-adjuvant high dose chemo-immunotherapy followed by surgery and radiotherapy for locally advanced breast cancer: a general proposal for high-risk primary tumors, American Association for Cancer Research, minisymposium : From Biology to the Clinical Management of Breast Cancer, San Diego, U.S., April 12-16, 1997.

225. Functional Studies and MDR protein. Castres, France, October 10, 1997.226. 13th Bristol-Myers Squibb: European Drug Development and its impact on national activities:

The Dutch Example. Nagoya, Japan, October 18, 1997.227. European Institute of Oncology: Milanoncologia: Drug resistance in Oncology, Milan, Italy,

October 29, 1997.228. Chemotherapy Foundation Symposium XV: chemotherapy plus GM-CSF in locally advanced

breast cancer: locally advanced disease versus metastatic disease. New-York, U.S., November 12, 1997.

229. AMC Laboratory: Neoadjuvant chemotherapy. Amsterdam, the Netherlands, November 25, 1997.

230. Educational Lecture: Platelet transporters of growth factor. Paris, France, February 4, 1998.231. XV Reunión Nacional Médica del Instituto Nacional de Cancerologia, Tlalpan, Mexico D.F.,

Mexico, 16-20 February, 1998232. Lecture: Cancer de mama localmento avanzado, Mexico. February 16, 1998233. Lecture: Resistencia a drogas antineoplasicas del laboratoria a la clinica, Mexico. February 17,

1998. 234. Medical Students Research Conference: Clinical-Scientific Research in the medical oncology,

Maastricht, the Netherlands, March 11, 1998.235. MCA/VU connection. At the occasion of the opening of the new department of MCA, opening

speech. Alkmaar, the Netherlands, April, 1998.236. First Pasman Gene Therapy Symposium: New developments in Gene Therapy. Opening

speech. Amsterdam, the Netherlands, May 8, 1998.237. 10th NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam. Opening speech.

June 16, 1998.238. N.A.S.K.H.O. Post Graduate Course Hemato-Oncology. Clinical implications of drug resistance

and chemotherapy in gastrointestinal cancer, November 1-3, Curaçao, 1998.239. 20th Anniversary winter meeting of the EORTC PAMM-SPG-PTMG Groups, PAMMsterdam 99:

The potential role of platelets in angiogenesis, Amsterdam, the Netherlands, January 21, 1999.240. Ulster Medical Society Lecture: The role of platelets in angiogenesis. Belfast, Great Britain,

January 21, 1999.241. 2nd International Congress Biliopancreatic Malignancy: From Gene to Cure. Current

chemotherapeutic possibilities. February 5, 1999. Amsterdam, the Netherlands.242. 90th Annual Meeting AACR: Sunrise Session: Integration of Biological Agents into

Chemotherapy.Philadelphia, US, April, 14th, 1999.243. 4th International Conference of the Asian Clinical Oncology Society (ACOS): The Promise and

Challenge of the Combination of Chemotherapy and Biological Agents. Bali, Indonesia, August 6,1999.

244. European Cancer Conference ECCO 10. Mechanisms of Drug Resistance – clinical implications. Vienna, Austria, September 14, 1999

245. NCI-All Ireland Cancer Conference. Plenary Session: Cancer therapeutics and Clinical Trials, October 5, 1999, Belfast, Ireland.

246. Killing Cancer Cells. Symposium. The Combined use of Chemotherapy and Biologicals. Amsterdam, the Netherlands, November 19, 1999.

247. Annual lecture in memory of Professor Alexander Symeonides: Long term neoadjuvant chemotherapy plus biological agents (immuno stimulands and/or antiangiogenic agents) in high

30

risk primaries. Thessaloniki, Greece, November 24, 1999.248. International Congress on Anti-Cancer Treatment: Bio-chemo Therapies Entering Clinical

Oncology. Paris, France, February 2, 2000.249. World Summit Aainst Cancer: How Can We Ensure Appropriate Quality of Anti-cancer

Treatment at Every level of Health Care Provision. Paris, France, February 3, 2000.250. Patiënt en informatie; Visie op de 21ste eeuw: De vier toekomstige pijlers van de medische

oncologie. Noordwijk, the Netherlands, February 19, 2000.251. 1st International Symposium on Genetic Anticancer Agents. Presidential Address. Amsterdam.

The Netherlands, March 8, 2000.252. 1st International Symposium on Genetic Anticancer Agents: Replicative virusses as anticancer

agents. Amsterdam, The Netherlands, March 9, 2000.253. The First Pharmacia & Upjohn Pan European Investigator Forum: New Clinical Insights and

Future Challenges in Breast Cancer: The role of VEGF in tumor angiogenesis. Geneva, Switzerland, April 8, 2000.

254. Symposium in Tokio: Clinical drug resistance, Tokyo, Japan, April 15, 2000.255. China Cancer Forum: Drug resistance in Medical Oncology. Beijing, China, April 19, 2000.256. International Meeting on Angiogenesis: Clinical anti-angionetic treatment: a change of mind. Vrije

Universiteit, Amsterdam, The Netherlands. April 27-29, 2000.257. I European Spring Oncology Conference: VEGF receptor kinase inhibitors. Marbella, Spain, April

28- May 1, 2000.

258. Symposium: The diverse spectrum of liver surgery. Academisch Ziekenhuis Groningen, June 27, 2000.

259. Novartis Foundation Symposium No. 240: Causes and consequences of acidic pH in tomours. London, England, October 10-12, 2000.

260. Second Nordic Conference on Chemoresistance to Cancer Treatment: Jerzy Einhorn memorial Lecture: Translational Research in Drug Resistance. Oslo, Norway, October 26-27, 2000.

261. 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy: Michel Clavel Lecture:Hidden Treasures of the Primary Tumor.Extended Neoadjuvant chemotherapy plus GM-CSF in locally advanced cancer. Amsterdam, The Netherlands. November 7, 2000.

262. 5th International Symposium on Cancer Chemotherapy: The Spinoza Trial: Longterm neo-adjuvant chemo-immunotherapy including GM-CSF (Session III). Tokyo, Japan, November 30, 2000.

263. 11th International Congress on Anti-Cancer Treatment: Teaching Lecture “How the biology of the tumor, in particular (anti) angiogene and immunology,will impact our future practice?” February 7, 2001. Paris, France.

264. 11th International Congress on Anti-Cancer Treatment: Patient’s Rights and Advocacy: a personal viewpoint. February 8 2001. Paris, France.

265. Longterm Neoadjuvant Chemotherapy in Breast Cancer: translational Research. University of Alabama, Birmingam, March 21 2001, Birmingham, Alabama

266. 92nd AACR Annual Meeting, Session: Cancer drug discovery and development – Public Forum “Ask the experts” March 24, New Orleans.

267. David de Wied lecture: Primary Tumor:Friend or Enemy? April 20 2001,Utrecht, The Netherlands.

268. The ECRI Conference: Collaborative Translational Research In Europe. May 22-24, 2001, Brussels, Belgium.

269. 20th AOCC: Anti-Angiogenesis drugs, New Treatments for Cancer.June 22 2001,Buenos Aires, Argentina.

270. 20th AOCC: Dendritic cells and the Spinoza Trial, June 22 2001, Buenos Aires, Argentina.271. 22nd International Congress of Chemotherapy: Oral Antineoplastic Agents, July 3 2001,

Amsterdam, the Netherlands.272. Symposium on the occasion of the Retirement of Professor Theo Wagener: Developments in

Oncology: Looking Backwards and a view into the Future. September 14, 2001, Nijmegen.273. IBME Conference-Targeted Cancer Treatment, Papendael,The Netherlands,October 8 2001.274. Banbury Conference on Monometric Cancer Treatment: The Role of Blood Platelets in Anti-

Angiogenesis Therapy. November 6 2001, Coldspring Harbor,New York.275. 6th International Symposium on Cancer Chemotherapy: Gan no Harikiri. Tokyo, Japan,

November 13 2001

31

276. The 2nd Clingendael Conference on Health Care, a Conference organized by the Dutch Ministry of Health and the American Embassy: Professional Autonomy. November 28 2001. The Hague,The Netherlands.

277. Symposium on New Developments in Cancer Therapy: New Drugs. November 30 2001, Leeuwarden, The Netherlands.

278. 12th International Congress on Anti-Cancer Treatment: Scientific Symposium II New Targets in Cancer Therapy; VEGF/VGFR, Paris, France , February 4-7, 2002.

279. XIX Reunion Nacional del Instituto de Cancerologia de Mexico: Spinoza Trial, Villahermosa, Mexico, February 19-23, 2002.

280. Pharmacia Oncology 3rd Pan-European Investigator From “Current Concepts and New Strategies for Cancer Treatment and Prevention”, Session: Novel Tyrosine Kinase Inhibitors, VEGF as a Target, Valletta, Malta, February 28-March 3, 2002.

281. Meeting on Endostatin: Structure, Function and Applications, Presentation: Intrapatient Comparison of Pharmacokinetics following Subcutaneous and Intravenous Administration of Endostatin, Banbury, Cold Spring Harbour, USA, March 10-13, 2002

282. Satellites Symposium “New Paradigms in Cancer Therapy, ASCO, Orlando Florida, USA, May 12002.

283. Frontline Participants Meeting: presentatie “Survey design and Methodology, demographics participants”. Asco,Orlando Florida, USA May 18-21 2002.

284. II European Spring Oncology Conference, Session: Vascular Targeted Therapies& Antiangiogenesis, “Checkpoints in anti-angiogenic Clinical Trials”, Marbella, Spain, June 13-15, 2002.

285. 1st International Symposium on Signal Transduction Modulators in Cancer Therapy, Session: Anti-Angiogenic approaches,”Small Molecules”, Amsterdam, the Netherlands, September 23-25, 2002.

286. Reunión Avances en Biología Tumoral – Instituto Universitario de Oncología del Principadeo de Asturias – Oviedo, Spain, November 8 2002. “Investigación Puente”.

287. 5th European Institute of Health Care Meeting ‘Cytokines and Cancer’: “VEGF and VEGF Inhibitors, Barcelona, Spain, November 9 2002.

288. Masterclass in “New Targets in Cancer Therapies”, ISFEM, Paris, France, January 9, 2003289. Clinical Advisory Board Retreat MPM Capitol,”Novel clinical agents: Thalidomide analogues,

proteosome inhibitors, monoclonals, COX-2 inhibitors, HSP-inhibitors, epothilones, vaccines and beyond….’ “, Boston , USA, January 16, 2003

290. Winter Masterclass in Clinical Oncology European School of Oncology, 3 Clinical casesTenerife, Canary Islands, Spain, January 20-25, 2003

291. 14th International Congress on Anti-Cancer Treatment, “New Targets”, ICACT- Paris France, feb 1-5, 2003.

292. XX Reunión Nacional Médica, Mexico. Immunotherapy in Breast Cancer. February 18-22, 2003.293. Centro National de Investigaciones Oncológicas, “Translational Research: ‘… there can be no

method without a pre-existent idea …’ “Madrid, Spain, March 3, 2003294. 3rd Symposium of the Lilly Foundation: Cancer;Molecular Targets for Novel Therapies, Madrid,

Spain, April 25-26, 2003.295. 94th AACR Annual Meeting Session: Careers in Clinical and Translational Research, Washington

USA, July 11, 2003.296. 2nd International Conference on Trombosis and Hemostasis Issues;”The role of VEGF in

oncology:effects on hemostasis and thrombis” , Bergamo, Italy, September 20, 2003.297. 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy: “Platelets

and Neo-vascularization”, Amsterdam, The Netherlands, October 23, 2003298. ESO 20th Anniversary Course,”Biological Effects of VEGF”, “Oral Anti Neoplastic Agents”,

“Neoadjuvant Chemotherapy”, Rio de Janeiro, Brasil, November 7-8, 2003, 299. 8th Int. Symposium on Cancer Chemotherapy, “Anti-VEGF drugs” Tokyo, Japan, December 1

2003300. ISCORT, “A Comeback of Spinoza”, Eilat Israel, January 15-16, 2004301. Erasmus Course MR of the Breast, “Chemotherapy Treatment of Breast Cancer”, Amsterdam,

The Netherlands, February 6, 2004302. 15th International Congress on Anti-Cancer Treatment, “Where are we with anti-angiogenesis”,

Paris, France, February 9-12, 2004.303. “New Frontiers in Cancer Research and Therapy”, “New Treatments”, Stockholm, Sweden,

32

March 4, 2004304. EIHC Symposium, “Anti Angiogenic Agents”, Barcelona, Spain, March 6, 2004.305. III European Spring Oncology Conference (ESOC-3), Keynote lecture “Present situation and

future of antiangiogenic therapy”, Marbella, Malaga, Spain, June 16-18, 2004.306. III European Spring Oncology Conference (ESOC-3), “Oral taxanes”, Marbella, Malaga, Spain,

June 16-18, 2004.307. 11th International Symposium on Thromboembolism, Barcelona, Spain, September 1-11, 2004.308. XII International Symposium in Treatment of Gastrointestinal Tumors, “Angiogenesis Inhibitors”,

Valencia, Spain, November 27th, 2004.309. 16th International Congress on Anti-Cancer Treatment, Symposium New Targets, ‘VEGF and

VEGFR in Cancer’, ICACT- Paris France, February 1-4, 2005.310. European School of Oncology, Master Course ‘Angiogenesis’ – Larnaca, Cyprus, March 5-11,

2005.311. Cancer 2005, State of the Art Lecture ‘Translational Research, taking the important steps’,

Dublin, Ireland, March 31-April 1, 2005.312. 1st Symposium on Translational Oncology, “New Drugs – Old Targets”, Barcelona, Spain, April

22-23, 2005.313. VI Madrid Breast Cancer Conference ‘Optimizing Chemotherapy for Drug Resistance in Breast

Cancer Based on Translational Studies’, Madrid, Spain, June 1-3, 2005.314. 12st International Symposium on Thromboembolism – Meet the expert session ‘Targeted cancer

therapies and VTE’- Athens, Greece, September 23-24, 2005315. 17th International Congress on Anti-Cancer Treatment, Anti”-angionenic Agents”, Paris France,

Jan 30 – Feb 2, 2006.316. 1st Angiogenesis in Cancer Educational Meeting – ‘Clinical management of antiangiogenesis

agents’, Barcelona, Spain, April 28-29, 2006317. 5th Masterclass in Clinical Oncology, St. Julians, Malta, February 11-17, 2006

318. 52nd Annual Meeting ISTH, Discussion and opposer “LMWHs have a clear future in trombosis management”, Oslo, Norway, June 28 – July 1, 2006

319. 21st Aspen Cancer Conference, “Inhibitors of Angiogenesis”, Session on Prostate Cancer Aspen, USA, July 16-21, 2006

320. Angiogenesis Symposium Maastricht: “Fundamental and clinical perspective, angiogenesis in clinical practice”, Maastricht Netherlands, September 15, 2006

321. 1st Vumc CCA Symposium: Session: Innovative cancer research and patient management: “Drug development: “New applications for old Vumc drugs”, Amsterdam, Netherlands, October 12, 2006

322. 3rd All Ireland Cancer Conference 2006: Session From the bench to the clinic and to the public – is translational research the way to go? “Cancer Medicine, past, present and future”, Belfast Ireland, November 12-15, 2006

323. CNIO Cancer Translational Research Symposium: Difficulties, opportunities and challenges”, Madrid Spain, November 21, 2006

324. PGS Mol Med Course: Basic and translational oncology: Session Cancer and clinical practice: “Emerging new therapies of different cancer”, Rotterdam Netherlands, November 27-December 1, 2006

325. 18th International Congress on Anti-Cancer Treatment, educational lecture “Cancer and Coagulation” and Meet the Professor “Cancer Management and Anticoagulation”, Paris France, February 2-9, 2007.

326. 6th Masterclass in Clinical Oncology, St. Julians, Malta, February 24 – March 2, 2007327. 2nd Angiogenesis: A key Target in Oncology, “Clinical Management of Anti-Angiogenic Drugs”,

Barcelona, Spain, May 4-5, 2007328. 10th Post-ASCO meeting for Belgium and Luxembourg, “What have we learned the last 10

years”, Brussels, Belgium, June 23, 2007329. 19th International Congress on Anti-Cancer Treatment, educational lecture and Meet the

Professor “Targeted therapies in particular signal transduction inhibitors”, Paris France, February 5-8, 2008.

330. 7th Masterclass in Clinical Oncology, Antiangiogenesis, Sophia, Bulgaria, March 1-6, 2008331. 18th ECCO-40th ESMO European Cancer Congress,Vienna, Austria, September 25-29, 2015,

Chairperson The Highlights Session September 29th ,2015.

33

CHAPTERS / INVITED PAPERS / PROCEEDINGS

1. Pinedo, H.M., Voûte, P.A. Combination chemotherapy in soft tissue sarcomas. In: Recent Advances in Cancer Treatment. Ed. Tagnon, H.J., Staquet, M.J. EORTC Monograph Series, vol. 3. Raven Press, New York, p.301, (1977).

2. Leyva, A., Van der Grint, L.,Pinedo, H.M., Reversal of methotrexate toxicity to mouse bonemarrow and Ll2l0 leukemia cells grown in vitro. Clinical Pharmacology of Anti-neoplastic Drugs. Ed. Pinedo, H.M. Amsterdam, p.39 (1978).

3. Pinedo, H.M., Rosenberg, S., Nieuwenhuis, M.G.,Chabner, B.A., Soft tissue sarcoma in adults. Randomized Trials in Cancer: A Critical Review by Sites. Eds. Staquet, J. EORTC Monograph Series. vol. 4. Raven Press, New York, p.359 (1978).

4. Pinedo, H.M. Reversal of methotrexate toxicity to mouse bone marrow and Ll2l0 leukemia cells grown in vitro. High Dose Methotrexate International Workshop, Florence, 1978. Chemotherapia Oncologica 2: 123 (1978).

5. Schornagel, J.H., Leyva, A., Buesa, J.M., Pinedo, H.M. Thymidine prevention of methotrexate toxicity in head and neck cancer. Clinical Pharmacology of Anti-neoplastic Drugs. Ed. Pinedo, H.M. p.83 (1978).

6. Bramwell, V.H.C., Pinedo, H.M., Voûte, P.A., Rosenberg, S.A., Adjuvant treatment of soft tissue sarcoma in children and adults. Adjuvant Therapy and Markers. Ed. Bonadonna, G., Salmon, S., Mathé, G. Springer Verlag, Heidelberg, vol. 68, p.60 (1979).

7. Bramwell, V.H.C., Pinedo, H.M. Soft tissue and bone sarcomas. In: Cancer Chemotherapy, Annual 1, 1979. Ed. Pinedo, H.M. Excerpta Medica, Amsterdam, chapter 20, p.424 (1979).

8. Stoter, G., Rozencweig, M., Pinedo, H.M. Genito-urinary tumors. Cancer Chemotherapy, Annual 1, 1979. Ed. Pinedo, H.M. Excerpta Medica, Amsterdam, chapter 16, p.317 (1979).

9. Stoter, G., Pinedo, H.M. Cis-diammine-dichloro-platinum single drug and combination chemotherapy in the treatment of genitorinary cancer. Bladder Tumors and other Topics in Urological Oncology. Plenum Publishing Corporation, New York, p.31 (1979).

10. Bramwell, V.H.C., Pinedo, H.M. Bone and soft tissue sarcomas. Cancer Chemotherapy, Annual 2, 1980. Ed.Pinedo, H.M. Excerpta Medica, Amsterdam, p.393 (1980).

11. Pinedo, H.M., Van Oosterom, A.T. Treatment of advanced soft tissue sarcomas in adults: Past, present and future. Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas. Ed. Van Oosterom, A.T., Muggia, F.M., Cleton, F.J. Martinus Nijhoff Publ. The Hague, Boston, London, p.425 (1980).

12. Stoter, G., Vendrik, C.P.J., Struyvenberg, A., Brouwers, Th.M., Sleyfer, D.Th., Schraffordt Koops, H., Van Oosterom, A.T.,Pinedo, H.M. An update of the Dutch multicenter PVB-study in disseminated testicular non-seminomas. Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas. Eds. Van Oosterom, A.T., Muggia, F.M., Cleton, F.J. Martinus Nijhoff Publishers, The Hague, Boston, London, p.247 (1980).

13. Bramwell, V.H.C, Pinedo, H.M. The treatment of metastatic bone and soft tissue sarcomas. Principles of Cancer Treatment. Ed. Carter S.K., Gladstein K., Livingston, R.B. Graw-Hill Book Co., p.718 (1981).

14. Bramwell, V.H.C. Pinedo, H.M. Bone and soft tissue sarcomas. Cancer Chemotherapy, Annual 3, 1981. Ed. Pinedo, H.M. Excerpta Medica, Amsterdam, p.409 (1981).

15. Leyva, A., Appel, H., Smith, P., Lankelma, J., Pinedo, H.M. Inhibition of cell growth by N-(phosphonacetyl)-Laspartic acid (PALA) in human and murine cells in vitro. Cancer Letters, Elsevier North Holland Scient., Publ. p.169 (1981).

16. Pinedo, H.M., Bramwell, V.H.C. Chemotherapy of adult soft tissue sarcomas. Cancer, Achievements, Challenges and Prospects. Eds. Burchenal, J.H., Oettgen, H.F.: Grune & Stratton, New York, vol. 2, p.405 (1981).

17. Bramwell, V.H.C., Stoter, G., Pinedo, H.M. Chemotherapy of adult soft tissue sarcoma. New Approaches in Cancer Therapy. EORTC Monograph Series, vol. 9. Eds. Cortes Funes, H., Rozencweig, M. Raven Press, New York, p.147-157 (1982).

18. Holthuis, J.J.M., Sijstermans, A.W., Van Oort, W.J., Pinedo, H.M., McVie, J.G. Sensitive high performance liquid chromatography analysis of VM-26, VP-l6-2l3 and cis-hydroxy acid of VP-l6-2l3 using UV and electrochemical detection. First International Symposium on the Podophyllotixins in Cancer Therapy, July 8-9 1981, Southampton. Cancer Chemother Pharmacol 7: 237 (1982).

19. Van Maanen, J.M.S., Van Oort, W.J., Pinedo, H.M. Studies on the metabolism of VP-l6-2l3 in the

34

rat. Proc. 1st Intern. Symposium on the Podophyllotoxins in Cancer Chemotherapy. Cancer Chemother. Pharmacol. 7: 236 (1982).

20. Pinedo, H.M., Ten Bokkel Huinink, W.W., Leyva, A., Lankelma, J., McVie, J.G. Clinical pharmacology and biochemical studies of N-(phosphonacetyl)-L-aspartate (PALA). New Approaches in Cancer Therapy. EORTC Monograph Series, vol. 9. Eds. Cortes Funes, H., Rozencweig, M. Raven Press: 47-52 (1982).

21. Peters, G.J. Laurensse, E., Leyva, A. Pinedo, H.M. Pyrimidine and fluoropyrimidine metabolism in human and murine tumor cell lines. Proc. 24th Dutch Federation Meeting Leiden: 315 (1983).

22. Vermorken, J.B., Ten Bokkel Huinink, W.W., McVie, J.G. Van der Vijgh, W.J.F. Pinedo, H.M. Clinical pharmacology of Cisplatin and some new platinum analogs. Proc. 2nd World Conf. Pharmac., Washington (1983).

23. Van der Vijgh, W.J.F., Lelieveld, P., Van Putten, L.M., Pinedo, H.M. Pharmacokinetics of five platinum compounds in dogs. Proc. 4th Int. Symp. Platinum Coord. Compl. Cancer Chemo-ther., Burlington, Vermont, USA: 54 (1983).

24. Van Heeswijk, W.A.R., Stoffer, T., Eenink, M.J.D., Potman, W., Van der Vijgh, W.J.F., Van der Poort, J., Pinedo, H.M., Lelieveld, P., Feyen, J. Synthesis characterization and antitumor activity of macromolecular prodrugs of adriamycin. Recent Advances Drug Delivery. Eds. Kim & Andersen, Plenum Press, New York: 77-100 (1984).

25. Leyva, A., Kraal, I., Lankelma, J., Pinedo, H.M. High uridine catabolic activity in cultured human melanoma cells. Proc. International Symposium on Human Purine and Pyrimidine Metabolism in Man, Maastricht, June 1982. Ed. Debruyne et al. Vol. Adv. Exp. Med. Biol. Publ. Plenum Press, New York; l65B: 395-400 (1984).

26. Leyva, A., Appel, H., Pinedo, H.M. Thymidine sensitivity and deoxynucleotide ools of human lymphoid and melanoma cells in vitro. Pro International Symposium on Human Purine and Pyrimidine Metabolism in Man, Maastricht, June 13-l8, 1982. Vol. Adv. Exp. Med. Biol. Eds. Debruyne et al. Publ. Plenum Press, New York: 389-394 (1984).

27. Vermorken, J.B., Ten Bokkel Huinink, W.W., McVie, J.G., Van der Vijgh, W.J.F., Pinedo, H.M. Clinical experience with l,l-diamminomethyl-cyclohexane(sulphate)platinum (II) (TNO-6). Platinum Coordination Complexes in Cancer Chemotherapy. Eds. Hacker, M. et al. Martinus Nijhoff Publ. Boston: 330-343 (1984).

28. Vermorken, J.B., Ten Bokkel Huinink, W.W., McVie, J.G., Van der Vijgh, W.J.F., Pinedo, H.M. Clinical pharmacology of cisplatin and some new platinum analogues. Pharmacology and Therapeutics. Eds. Lemberger L., Reidenberg, M., Am. Soc. Pharmacol. & Therap., Bethesda: 967-983 (1984).

29. Verwey, J., Pinedo, H.M. Clinical trials in adult soft tissue sarcomas. Clinical Trials in Cancer Medicine. Vol. 6 Bristol Myers, Cancer Symp. Series, Ac ad. Press, New York: 317-334 (1984).

30. Den Hartigh, J., Verweij, J., Pinedo, H.M. Mitomycin C. Cancer Chemotherapy. Annual 7. Eds. Pinedo, H.M. and Chabner, B.A. Elsevier, Amsterdam-New York-Oxford publ.: 83-90 (1985).

31. Verwey, J., Van Oosterom, A.T., Pinedo, H.M. Melanomas, soft tissue and bone sarcomas. A review on the papers presented at the 2nd European Conference on Clinical Oncology and Cancer Nursing. Melanomas, soft tissue and bone sarcoma. Amsterdam, November 2-5, 1983. Eur J Cancer Clin Oncol (suppl) 4: 75-85 (1985).

32. Verwey, J., Pinedo, H.M. Clinical trials in adult soft tissue sarcomas. Clinical trials in cancer medicine; Eds. Bonadonna, G. and Veronesi, U., Academic Press, New York: 317-334 (1985).

33. Mouridsen, H.T., Bramwell, V.H.C., Somers, R., Vendrik, C.P.J., Santoro, A., Buesa, J., Wagener, T., Van Oosterom, A.T., Van Unnik, J.A.M., Sylvester, R., De Pauw, M., Thomas, D., Bonadona, G., Pinedo, H.M. CYVADIC in advanced soft tissue sarcomas. An EORTC randomized study comparing two schedules. Management of soft tissue and bone sarcomas, vol. 16, Eds. Van Unnik, J.A.M., Van Oosterom, A.T., Raven Press: 147-160 (1986).

34. Van Oosterom, A.T., Bramwell, V.H.C., Mouridsen, H.T., Somers, R., Santoro, A., Buesa, J., Vendrik, C.P., Rouessé, J., Dombernowsky, P., Pinedo, H.M., Thomas, D., Sylvester, R. Review of the EORTC Soft tissue and bone sarcoma group's phase II studies in avanced soft tissue sarcomas. Management of soft tissue and one sarcomas, vol. 16, Eds. Van Unnik, J.A.M., Van Oosterom, A.T., Raven Press: 161-169 (1986).

35. Pinedo, H.M., Mouridsen, H.T., Bramwell, V.H.C., Somers, R., Mulder, J.H., Santoro, A., Van Oosterom, A.T., Sylvester, R., Thomas, D. For the EORTC Soft Tissue and Bone Sarcoma Group. Antracycline analogues in advanced soft tissue sarcomas. Two EORTC randomized phase II

35

studies of adriamycin vs carminomycin. Management of soft tissue and bone sarcomas, vol. 16, Eds. Van Unnik, J.A.M., Van Oosterom, A.T., Raven Press: 169-183 (1986).

36. Peters, G.J., Van Dijk, J., Van Groeningen, C.J., Laurensse, E.J., Leyva, A., Lankelma J., Pinedo, H.M. Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine. Adv. Exp. Med. Biol., Plenum Press l95B: 121-128 (1986).

37. Peters, G.J., Laurensse, E.J., Leyva, A., Pinedo, H.M. Modulation of cytotoxicity and metabolism of 5-fluorouracil in two intestine cell lines. Adv. Exp. Med. Biol., Plenum Press l95B: 113-120 (1986).

38. Snow, G.B., Vermorken, J.B., Pinedo, H.M. Present role of chemotherapy in the treatment of head and neck cancer. Tumors of the skull base. Extra- and intra-cranial surgery of skull base tumors. Eds. Scheunemann, H. et al.: 87-96 (1986).

39. Snow, G.B., Vermorken, J.B., Pinedo, H.M. Adjuvant chemotherapy: The EORTC trials. Head and neck oncoIogy, Eds. Bloom, H.J.G. et al. Raven Press, New York: 83-92 (1986).

40. Verwey, J., Pinedo, H.M. Randomized trials in soft tissue sarcomas in adults. Randomized trials in Cancer: A critical review by sites, M. Eds. Slevin, M.L. and Staquet, T. Raven Press, New York: 569-583 (1986).

41. Verwey, J., Pinedo, H.M. Chemotherapy in advanced soft tissue sarcomas. Soft tissue sarcomas; Eds. Pinedo H.M., Verwey J., Martinuss Nijhoff Publ., Boston: 81-88 (1986).

42. Den Hartigh, J., Verwey, J., Pinedo, H.M. Mitomycin C. Cancer Chemotherapy and Biological Response Modifiers Annual 9. Eds. Pinedo, H.M., Longo, D.L., Chabner, B.A. Elsevier Science Publishers BV, Amsterdam: 56-62 (1987).

43. Boven, E., Tierie, A.H., Stam, J., Pinedo, H.M. Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer: results of a phase II trial. Semin Oncol Dec: (6 suppl 7), 15: 18-29 (1988).

44. Cervantes, A., Van Groeningen, C.J., Pinedo, H.M. Kinetic theories and main mechanisms of drug resistence. Handbook of Chemotherapy in Clinical Oncology. Eds. Droz, J.P., Cvitkovic, E., Armand, J.P., Khoury, S.: 24-27 (1988).

45. Den Hartigh, J., Verwey, J., Pinedo, H.M. Antitumor antibiotics. Cancer Chemotherapy & Biological Response Modifiers Annual 10, Eds. Pinedo, H.M., Longo, D.L., Chabner, B.A., Elsevier Science Publ., Amsterdam (1988).

46. Van Oosterom, A.T., Santoro, A., Rouesse, J, Mouridsen, H.T., Steward, W.P., Somers, R., Buesa, J., Blackledge, G., Schutte, J., Wagener, T., Mulder, J.H., Bramwell, V.H.C., Pinedo, H.M., Thomas, D., Sylvester, R. Chemotherapy in advanced soft tissue sarcoma - the EORTC experience. Recent Concepts in Sarcoma Treatment, Eds. Ryan, J.R., Paker, L.O. Proc. Int. Symp. on Sarcomas, Tarpon Springs, Florida, Oct. 8-10, 1987: 184 190 (1988).

47. Boven, E., Pinedo, H.M. Chemotherapy in cancer treatment. Surgical Oncology, Ed. Veronesi U., Springer-Verlag, Heidelberg: 175-187 (1989).

48. Verweij, J., Van Groeningen, C.J., Pinedo, H.M. Chemotherapy in advanced soft tissue sarcomas. Treatment of soft tissue sarcomas. Eds. Pinedo, H.M. & Verweij J., Kluwer Academic Publishers, Boston: 75-92 (1989).

49. Peters, G.J., Van der Wilt, C.L., Van Groeningen, C.J., Nadal, J.C., Laurensse, E., Pinedo, H.M. Development of leucovorin/5-fluorouracil combinations. In: "Leucovorin modulation of fluoropyrimidines: A new frontier in cancer chemotherapy".

50. Pinedo, H.M., Rustum Y.M., Eds. International Congress and Symposium series no. 158. Royal Society of Medicine Serviced, London pp. 21-35, 163-171 (1989).

51. Van der Wilt, C.L., Pinedo, H.M., Peters, G.J. Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in murine colon cancer. Proceedings of the 9th symposium on pteridines & folic acid derivatives (1989).

52. Broxterman, H.J., Schuurhuis, G.J., Lankelma, J., Baak, J.P.A., Pinedo, H.M. Towards functional screening for multidrug resistant cells in human malignancies. Drug Resistance: Mechanisms and Reversal, Ed. Mihich E., John Libbey CIC, Roma - Milano - London: 309-319 (1990).

53. Verwey, J., Den Hartigh, J., Pinedo H.M. Antitumor antibiotics. Cancer chemotherapy: principles and practice. Eds. Chabner B.A., Collins J.M., Philadelphia: Lippincott: 382-96 (1990).

54. De Vries, E.G.E., Pinedo, H.M. Clinical implications of multidrug resistance to chemotherapy. Molecular and Clinical Advances in Anti Cancer Drug Resistance, Ed. Ozols, R.F.: 171-186 (1991).

55. Peters, G.J., Van Groeningen, C.J., Van der Wilt, C.L., Smid, K., Meijer, S., Pinedo, H.M. Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in patients with colon

36

cancer. Purine and Pyrimidin Metabolism in Man VII. Adv.Exp.Med.Biol. Eds: G.B. Elion, R.A. Harkness & N. Zollner Plenum Publishing Corporation, New York 309A: 131-134 (1991).

56. Pinedo, H.M., Schwartsmann, G. New agents. Medical management of breast cancer. Eds. Powles T.J. and Smith I.E., M. Dunitz, London: 167-76 (1991).

57. Ruiz van Haperen, V.W.T., Veerman, G., Pinedo, H.M., Vermorken, J.B., Peters, G.J. Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (Gemcitabine). Purine and Pyrimidine Metabolism in Man VII. Eds: Elion, G.B., Harkness R.A., Zollner, N. Adv.Exp.Med.Biol. Plenum Publishing Corporation, New York. 309A: 57-60 (1991).

58. Smets, L.A., Pinedo, H.M., Van de Velde, C.J.H. Chemotherapeutische principes. Oncologie, Eds. Zwaveling, F.T. Bosman, A.Schaberg, C.J.H. v.d. Velde, D.J.Th. Wagener, Bohn, Stafleu, Van Loghem: 161-172 (1991).

59. Verwey, J., Pinedo, H.M. Mitomycin C. Cancer Chemotherapy and Biological Response Modifiers Annual 12, Eds. Pinedo, H.M., Longo, D.L., Chabner, B.A. Elsevier Science Publishers B.V.: 59-65 (1991).

60. Van der Wilt C.L., Marinelli A., Cloos J., Smid K., Pinedo, H.M., Peters, G.J. Isolated liver perfusion versus hepatic artery infusion with 5-fluorouracil in a rat model: Effects of thymidylate synthase. In: Purine and pyrimidine metabolism in man VII. Advances in Experimental Medicine and Biology; vol. 309A,. Eds. Elion G.B., Harkness R.A., Zollner N., Plenum Publishing Company, New York.: 105-108 (1991).

61. Van der Wilt C.L., Pinedo H.M., Smid K., Cloos J., Noordhuis P., Peters, G.J. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase. Semin Oncol; 19 (suppl. 3): 16-25 (1992).

62. Van Groeningen C.J., Peters G.J., Pinedo H.M. Modulation of fluorouracil toxicity with uridine. Semin Oncol; 19 (suppl 3): 148-54 (1992).

63. Linn S.C., Giaccone G., Van Kalken C.K., Pinedo H.M., P-glycoprotein mediated multidrug resistance and its clinical relevance in cancer treatment. Forum 2: 642-657 (1992).

64. Peters, G.J., Van Groeningen, C.J., Van der Wilt, C.L., Meijer, S., Smid, K., Laurensse, E., Pinedo, H.M. Time course of inhibition of thymidylate synthase in patients treated with fluorourcil and leucovorin. Sem. Oncol., 19: 26-35 (1992).

65. Peters G.J., Van der Wilt, C.L., Gyergyay, F., Van Laar, J.A.M., Treskes, M., Van der Vijgh, W.J.F., Pinedo, H.M. Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil. Int.J. Radiation Oncology Biol. Phys. 22: 785-789 (1992).

66. Hendriks, H.R., Henrar, R.E.C., Pinedo, H.M., Schwartsmann, G. New Anticancer Drug Development within the EORTC-NDDO. Contrib Oncol., Basel, Karger, vol 42: 306-320 (1992).

67. Peters, G.J., Hoekman, K., Van Groeningen, C.J., Van der Wilt, C.L., Smid, K., Meijer, S., Pinedo, H.M. Potentiation of 5-Fluorouracil induced Inhibition of Thymidylate Synthase in Human Colon Tumors by Leucovorin is Dose Dependent. In: "Chemistry and Biology of Pteridines and Folates, Adv. Exp. Med. Biol., 338: 613-616 (1993).

68. Peters, G.J., Van der Wilt, C.L., Cloos, J., Pinedo, H.M. Development of a Simple Folylpoly-glutamate Synthetase Assay in Tissues and Cell Lines. Chemistry and Biology of Pteridines and Folates, Adv. Exp. Med. Biol., 338: 651-654 (1993).

69. Peters, G.J., Codacci-Pisanelli, G., Van der Wilt, C.L., Van Laar, J.A.M., Smid, K., Noordhuis, P., Pinedo, H.M. Comparison of continuous infusions and bolus injections of 5-fluorouracil with or without leucovorin; implications for inhibition of thymidylate synthase. In: Rustum Y.M.; Novel Approaches to selective treatments of human solid tumors; laboratory and clinical correlation. Plenum Publishing Corporation, New York, p. 9-20 (1993).

70. Pinedo, H.M. Dose effect relationship in breast cancer. Ann. Oncol. 4: 351-357 (1993).71. Pinedo, H.M., Smorenburg, C.H., Giaccone, G. New chemotherapeutic agents: a selection of

some of the most promising new drugs. Molecular Oncology and Clinial Applications p.10 (1993).72. Pinedo, H.M., Van Groeningen, C.J. The role of systemic chemotherapy in multimodality therapy

of soft tissue sarcoma. Acta Chir. Austriaca 25: 260-262 (1993).73. Potmesil, M., Pinedo, H.M., Camptothecins: New Anticancer Agents, CRC Press, Inc. (1994).74. Vermorken, J.B., Bolis, G., Van Rijswijk, R.E.N., Kobierska, A., Chevallier, B., Burg, M.E.L.,

Zanaboni, F., Lentz, M.A., Burger, C.W., Kenemans, P., Pinedo, H.M., High-dose intensity regimens with epirubicin in ovarian cancer. Sem. Oncol., 21, 1; suppl. 17-22 (1994).

75. Giaccone, G., and Pinedo, H.M.. Anticancer agents currently in phase I and II trials. Oncology Today, 9, 14-19, Jan. (1994)

37

76. Giaccone, G. Pinedo, H.M. Drug resistance, The international monitor,9, 83-86 (1994).77. Honkoop, A.H., Pinedo, H.M. High dose chemotherapy in the treatment of breast cancer Int. J.

Oncol. 6, 911-918, (1995).78. Borst, P., Pinedo, H.M. Drug Resistance. Eds. Peckham, S., Pinedo, H.M., Veronesi, U. Oxford

Publishing, Oxford Textbook of Oncology. (1995).79. Honkoop, A.H., Pinedo, H.M. Chimiothérapie à haute dose dans le traitement du cancer du sein,

Cahiers d'Oncologie: 73-76 (1995).80. Pinedo, H.M., Giaccone, G. P-glycoprotein- A marker of cancer-cell behavior, New Eng.J Med.,

333: 1417-1419 (1995).81. Van der Wilt C.L., Marinelli, A., Pinedo, H.M., Cloos, J., Smid, K., Van de Velde, C.J.H., Peters,

G.J. The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat. Eur. J. Cancer. 31A (5): 754-760, 1995.

82. Van Triest, B., Van Groeningen, C.J., Pinedo, H.M. Current chemotherapy possibilities in the treatment of colorectal cancer, Eur. J. Cancer. 31A (7-8): 1193-1197, jul-aug 1995.

83. Giaccone, G., Linn, S.C., Pinedo, H.M. Multidrug resistance in breast cancer - Mechanisms, Strategies (Russian). Eur. J. of Cancer. 31A (Suppl. 7):S 15-S 17, 1995.

84. Huinink, W.T., Veenhof, C.H.N., Helmerhorst T., Bierhorst F., Dalesio O., Winograd B., Depauw L., Pinedo, H.M. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Sem. Oncol. 22 (3 Suppl 6): 97-100, Jun. 1995.

85. Vermorken, J.B., Ten Bokkel Huinink, W., Mandjes, I.A.M., Postma, T.J., Huizing, M.T., Heimans, J.J., Beijnen, J.H., Bierhorst, F., Winograd, B., Pinedo, H.M. High dose Paclitaxel with Granulocyte Colony-stimulating factor in patients with advanced breast cancer Refractory to Anthracycline Therapy: A European Cancer Centre Trial. Sem. Oncol. 22-4, Suppl 8, 16-22, aug. 1995.

86. Giaccone, G., Huizing, M., Postmus, P.E., Huinink, W.W.T., Koolen, M.G.J., Van Zandwijk, N., Vermorken, J.B., Beijnen, J.H., Dalesio, O., Pinedo H.M., Veenhof, C.H.N. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Sem. Oncol. 22 (4 Suppl 9): 78-82, aug. 1995.

87. Pinedo, H.M. Drug Resistance, illustration of the complexity of translational research, Steiner Award Lecture, Int. J. Cancer, 65 (5), 561-566 (1996).

88. Smitskamp-Wilms, E., Hendriks, H.R., Pizao, P.E., Giaccone, G., Pinedo, H.M., Peters, G.J. A Multilayered Postconfluent Tumor Cell Culture System for In Vitro Drug Screening. Contrib. Oncol., 51, 204-208, (1996).

89. Pinedo, H.M. Schornagel, J.H. Platinum and Other metal Coordination Compounds in Cancer Chemotherapy, Proceedings of the 7th International Symposium on Platinum and Other Metal Coordination Coumpounds in Cancer Chemotherapy, Plenum Press, (1996).

90. Pinedo, H.M. From Plasma Kinetics to Cellular Pharmacology, Stem Cells, 14: 16-17 (1996).91. Pinedo, H.M. From Plasma Kinetics to Cellular Pharmacology, The Oncologist, 1, 232-233 (1996)92. Giaccone, G., Pinedo, H.M. Drug resistance, The Oncologist, 1, 82-87, (1996).93. Giaccone, G., Pinedo, H.M., Reversal of MDR in Solid Tumors, Multidrug Resistance in Cancer

Cells, John Wiley & Sons, Ltd., 473-491, (1996). 94. Lankelma, J., Westerhoff, H.V., Heijn, M., Broxterman H.J., Pinedo, H.M., Cellular daunorubicin

transport in human cancer, Proceedings BioThermoKinetics 4 Conference, August 20-24, (1996).95. Giaccone, G., Pinedo, H.M. New chemotherapy agents in breast cancer. "New horizons in breast

cancer", Chapman & Hall Publ. London (1996)96. Pinedo, H.M. Developments in the management of patients with testicular cancer. In: Proceedings

of the 17th International Congress of Life Assurance Medicine. Eds. C.R.W. Gill, C. Trew. 97. Verheul, H.M.W., Pinedo, H.M. Clinical implications of drug resistance. Drug resistance in the

treatment of cancer, Cambridge Press.98. Pinedo, H.M., Giaccone, G. Chemotherapy, The Lancet, 349 (suppl II): 7-9, (1997).99. Moorsel van, C.J.A., Peters, G.J., Pinedo, H.M. Gemcitabine: Future Prospects of Single-Agent

and Combination Studies. The Oncologist, vol. 2, no. 3, p. 127-134, (1997).100. Peters, G.J., Kuiper, C.M., Van Triest, B., Van der Wilt, C.L., Van Laar, J.A.M., Jansen, G., Van

Groeningen, C.J., Pinedo, H.M. Determinantsof the therapeutic efficady of thymidylate synthase inhibitors. Plenum Publishing Corporation, New York, June, (1997).

101. Peters, G.J., Van Groeningen, C.J., Pinedo, H.M. Dihydropyrimide dehydrogenase in livers from mouse and rat, and in human liver, colon tumors and mucosa in relation to anabolism of 5j-fluorouracil in colon cancer cell lines. Plenum Publishing Corporation, New York, June (1997).

102. Peters, G.J., Van Groeningen, C.J., Pinedo, H.M. Dihydropyrimidine dehydrogenase in livers from

38

mouse and rat, and in human liver, colon tumors, and mucosa in relation to anabolism of 5-fluoracil. Adv.Experim.Med.Biol.431: 591-594 (1998).

103. Bergman, A.M., Pinedo, H.M., Veerman, G., Kuiper, C.M., Peters, G.J. Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines. Adv. Experim.Med.Biol. 431: 591-594 (1998).

104. Bergman, A.M., Pinedo, H.M., Ruiz van Haperen, V.W., Veerman, G., Kuiper, C.M., Peters, G.J. Cross resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Adv.Experim.Med.Biol. 431: 587-590 (1998).

105. Bergman, A.M., Pinedo, H.M., Veerman, G., Kuiper, C.M., Peters, G.J. Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines. In: Purine and Pyrimidine Metabolism in Man IX (ed. A. Griesmacher, P Chiba, NM Muller), Chapter 114, pp. 591-594. Plenus Press, New York. Adv.Exp.Med.Biol. 431, 591-594, (1998)

106. Van Moorsel, C.J., Veerman, G., Vermorken, J.B., Voorn, D.A., Kroep, J.R., Bergman, A.M., Pinedo, H.M., Peters, G.J. Mechanisms of synergism between gemcitabine and cisplatin. Adv.Experim.Med.Biol. 431: 581-585 (1998).

107. Peters, G.J., Kuiper, C.M., Van Triest, B., Backus, H., Van der Wilt, C.L., Van Laar, J.A., Jansen, G., Van Groeningen, C.J., Pinedo, H.M. Determinants of the therapeutic efficacy of thymidylate synthase inhibitors. Adv.Exp.Med.Biol. 431: 699-704 (1998).

108. Kroep, J.R., Van Moorsel, C.J., Veerman, G., Voorn, D.A., Schultz, R.M., Worzalla, J.F., Tanzer, L.R., Merriman, R.M., Pinedo, H.M., Peters, G.J. Role of deoxycytadine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytadine deaminase (dCDA) in antitumor activity of gemcitabine (dFdC).Adv.Experim.Med.Biol. 431: 657-660 (1998).

109. Pinedo, H.M. European drug development and its impact on national activities: the Dutch example.Cancer Chemother.Pharmacol, 42: 98-101 (1998).

110. Luykx-de Bakker, S.A., De Gruijl, T.D., Scheper, R.J., Wagstaff, J., Pinedo, H.M. Dendritic cells: A novel therapeutic modality. Ann.Oncol. 10: 21-27 (1999).

111. Kroep, J.R., Pinedo, H.M., Van Groeningen, C.J., Peters, G.J., Experimental drugs and drug combinations in pancreatic cancer. Annals of Oncol. (10) (suppl 4);S234-S238 (1999).

112. Lobbezoo, M.W., Krul, M.R., Pinedo. H.M., Discovery of new anti-cancer agents. Forum (Genova) 9 (3 Suppl. 3): 47-50 (1999).

113. Bergman, A.M., Cristalli, G., Vittori, S., Wang, J., Eriksson, S. Peters, G.J. Biological activity of 1-deazapurine nucleosides: role of deoxycytidine kinase? Nucleosides & Nucleotides 18. (1999)

114. Peters, G.J., Voorn, D.A., Kuiper, C.M., Van der Wilt, C.L., Noordhuis, P., Smid, K., Myhren, F., Sandvold, M., Hendriks, H.R. Cell specific cytotoxity and structure-activity relationship of lipohilic 1--D-arabinofuranosylcytosine (ara-C) derivates. Nucleosides&Nucleotides 18 (1999)

115. Van Riel, J.M.G.H., Van Groeningen, C.J., Pinedo, H.M. Current chemotherapeutic possibilities in pancreaticobiliairy cancer. Annals of Oncol. Suppl. 4: 157-61 (1999).

116. Van Riel, J.M.G.H., Giaccone, C., Pinedo, H.M. Pancreaticobiliairy cancer. Annals of Oncol. (1999).117. Kolfschoten, G.M., Pinedo, H.M., Scheffer, P.G., Schlüper, H.M.M., Erkelens, C.A.M., Boven, E.

Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynaecologic Oncology 76, 362-368 (2000)

118. Verheul, H.M.W., Hoekman, K., Jorna, A.S., Smith, E.F., Pinedo, H.M. Targeting Vascular Endothelial Growth Factor Blockade: Ascites and pleural effusion formation. The Oncologist Vol. 5, suppl. 1 (2000)

119. Pinedo, H.M., Slamon, Dennis, J. Translational Research: the role of VEGF in tumor angiogenesis. The Oncologist Vol. 5, suppl. 1 (2000)

120. Verheul, H.M.W., Pinedo, H.M,. The role of VEGF in tumor angiogenesis and Early Clinical Development of VEGF-Receptor Inhibitors. Clin Breast Cancer suppl1:S80-4, (2000.)

121. Van der Wilt, C.L., Kroep, J.R., Bergman, A.M., Loves, W.J.P., Alvarez, E., Talianidis, I., Eriksson, S., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv. Exp. Med. Biol. 486; 287 – 290)(2000).

122. Peters., G.J., De Bruin, M., Fukushima, M., Van Triest, B., Hoekman, K., Pinedo, H.M., Ackland, S.P. Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor. Adv. Exp. Med. Biol. 486; 291 – 294 (2000).

123. Backus, H.H.J., Wouters, D., Van der Wilt, C.L., Kuiper, C.M., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. Thymidylate synthase (TS) inhibition induces p53 dependent and independent cell death. Adv. Exp. Med. Biol. 486; 303 – 306 (2000).

124. Giaccone, G., Rosen L., Kuenen, B., Ruijter, R., Vijgh W.J.F. van der, Peters, G.J., Huisman, H.,Hoekman K., Scigalla, P., Smit, E.F., Pinedo, H.M. Dose finding study of cisplatin, gemcitabine

39

and SU-5416 in patients with advanced malignancies. Clin Cancer Res 6; 263 Suppl. 5 (2000).125. Lange, S.M. de, Groeningen C.J. van, Giaccone, G, Pinedo, H.M., Meijer, O.W.M., Langendijk,

J.A., Slotman,B.J. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Clin Cancer Res 6;371-suppl.5 (2000).

126. Backus,H.J.J., Vos,W., Bloemena,E., Dukers,D.F., Riel, J.M.G.H.van, Wouters D., Groeningen,C.J.van, Pinedo,H.M., Peters,G.J.Thymidilate Synthase (TS), p53 and Rb are related to survival in colorectal cancer patients with liver metastases.Clin Cancer Res 6; 427-suppl. 5 (2000).

127. Bruin M. de, Peters, G.J., Hoekman K., Pinedo, H.M. The role of platelet derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in prodrug activation in colon cancer cell lines.Clin Cancer Res 6; 432-Suppl.5 (2000).

128. Kroep, J.R., Loves, W.J.P., Wilt, C.L. van der, Alvare, E., Talianidis, I., Groeningen, C.J. van, Pinedo, H.M., Peters, G.J. Deoxycitidine kinase activity,protein and mRNA expressions are related to in vivo gemcitabine sensitivity: A possible role for clinical studies? Clin Cancer Res 6; 439-

129. Boven, E., Verschraagen, M., Zegers, I., Hausheer, F.H., Pinedo,H.M., Vijgh, W.J.F.van der. Phase I dose-finding and pharmacokinetics (PK) study of BNP7787 (dimesna) as a possible Protector of cisplatin-induced side-effects. Ann Oncol 11; 657P-suppl. 4 (2000).

130. Riel,J.M.G.H.,van,Groeningen,C.J.van, Giaccone G., Pinedo H.M. Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Oncology-Basel 59(2):89-97 (2000).

131. Haisma H., Beusechem V.W. van, Curiel D.T., Pinedo H.M., Gerritsen W.R. Targeted enzymes for molecular chemotherapy. Cancer Gene Ther. 7 (8) 021-(2000).

132. Boven, E., Van Hattum, A.H., Hoogsteen, I., Schlüper, H.M.M., Pinedo, H.M. New analogues of camptothecins – activity and resistance. In: Liehr J.G., Giovanella B.C., Verschraegen, C.F. (eds), The camptothecins: unfolding their anticancer potential. Annals New York Academy of Sciences ; 922: 175-7 (2000)

133. Giaccone, G., Pinedo, H.M. New chemotherapy agents in breast cancer. In ‘New horizons in breast cancer, J.S. Tobias, J. Houghton, IC, Henderson, eds. Chapman & Hall Publ. London: 91-93 (2001)

134. Pinedo, H.M. Advances in the use of angiogenesis inhibitors in cancer. Cancer J. 7 S107-S108 (2001)135. Pinedo, H.M., Van Groeningen, C.J. Emerging new opportunities for patients with hepatic

metastases from colorectal cancer or primary hepatocellular cancer. Oncologist, 6 (1): 12-13 (2001)136. Van den Eertwegh, A.J.M., Baars, A., Pinedo H.M. Adjuvant treatment of colorectal cancer:

towards tumor-specific immunotherapies. Cancer Met.Rev. 20, (1-2): 101-108 (2001)137. Pinedo, H.M., Winer L. Beyond Neutrophil Recovery Manipulation of the Tumor Microenviroment

by GM-CSF to Control Cancer. Oncology vol 16 no. 1 Suppl. 1 (2002)

138. Mauritz, R., Peters, G.J., Kathmann, G.A.M., Rosowsky, A., Pinedo, H.M., Jansen, G. Kinetics of reduced folate carrier- and membrane-associated folate receptor-mediated transport of antifolates. Chem. And Biol. Of Pterdines and Folates: 649-653 (2002)

139. Backus, H.H.J., Pinedo, H.M., Wouters, D., Koudijs, M.C., Ferreira, C.G., Peters, F.P. Role of P53 status on sensitivity to thymidylate synthase inhibitors and induction of apoptosis. Chem. And Biology of Pteridines and Folates: 433-437 (2002)

140. Peters, G.J., Backus, H.J.J., Dukers, D.F., Van Groeningen, C.J., Vos, W., Bloemena, W., Wouers, D. Van Riel, J.MG.H., Smid, K., Pinedo, H.M. 5-Fluorouracil induction of FAS and Apoptosis in colon cancer patients: relation of clinical outcome with thymidylate synthase, MCL-1 and RB. Chem. And Biol. Of Pteridines and Folates: 461-466 (2002)

141. Verheul, H.M.W., Pinedo, H.M. Anti-angiogenic Drugs. Principle & Practice of Oncology PPO Updates, vol. 16, no. 7 (2002)

142. Buter, J., Pinedo, H.M.,Neoadjuvant Chemoimmunotherapy in locally advanced breast cancer: A new avenue to be explored. Curr.Oncol.Rep. 5 (3):171-6. (2003)

143. Verheul, H.M.W., Pinedo H.M. The importance of platelets counts and their contents in cancer. Cur.Can.Res(2003)

144. Kakkar, A.K., Levine, M., Pinedo, H.M., Wolff, R., Wong,J. Venous Thrombosis in Cancer Patients: Insight from the Frontline Survey. Oncologist 8(4):381-388 (2003)

145. De Bruin, M., Van Capel, T., Smid, K., Van der Born, K., Fukushima, M., Hoekman, K., Pinedo, H.M., Peters, G.J. Role of Platelets derived Endothelial cell growth factor/Thymidine Phosphorylase in Fluoropyrimidine Sensitivity and Potential Role of Deoxyrobose-1-Phosphate Nucleosides,Nuclleotides and Nucleic Acids (2003)

146. Pinedo, H.M. Thrombosis, prevalence and new evidence on current perceptions of ris. Cancer Treat Rev. Jun;29 suppl 2:3-5 (2003).

147. Hoekman, K., Pinedo, H.M. Angiogenesis: A potential target for therapy of Soft-Tissue Sarcomas. (Kluwer, 2003)

148. De Gruijl, T.D., Scheper, R.J., Van den Eertwegh, A.J.M., Van Leeuwen, P.A.M., Pinedo, H.M., Clinical Studies on the Immunologie Effects of GM-CSF in Cancer. American Journal of Oncology Review (2004)

149. Verheul, H.M., Pinedo H.M., Inhibition of angiogenesis in cancer patients: Expert Opin Emerg

40

Drugs, May;10(2):403-12, (2005).150. Verheul H.M., Pinedo, H.M., Vascular endothelial growth factor and its inhibitors: Drugs Today

(Barc). 2003;39 suppl. C:81-93.151. Verheul, H.M., Pinedo H.M., Angiogenesis inhibitors: what is the clinical future? Prog Drug Res.

63:67-91 (2005) 152. Boddaert, M.S., Gerritsen, W.R., Pinedo, H.M., On our way to targeted therapy for cachexia in

cancer? Curr Opin Oncol. July;18(4):1627-1636 (2006)

41

PUBLICATIONS (Peer reviewed)

1972 – 19731. Pinedo, H.M., Renovascular hypertension, Thesis, Leiden. (1972).2. Pinedo, H.M., Van de Putte, L.B.M., Loeliger, W.A. Salicylate-induced consumption coagulopathy.

Ann. Rheum. Dis. 32: 66 (1973). 3. Pinedo, H.M., De Graeff, J., Struyvenberg, A. Prognosis in arteriosclerotic renovascular

hypertension. Clin.Sc. Mol. Med. 45: 309-310 (1973).

1974 - 19774. Pinedo, H.M., Van Hemel, J.O., Vrede, M.A.,Van der Sluys Veer, J. Acute myelofibrosis and

chromosome damage after procarbazine treatment. Br. Med. J. 3: 525 (1974). 5. Pinedo, H.M., Zaharko, D.A., Bull, J.M., Chabner, B.A., The reversal of methotrexate cytotoxicity

to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 36: 4418 (1976). 6. Pinedo, H.M., Dedrick, R.L.,Zaharko, D.A. Device for constant Sc infusion of methotrexate:

Plasma results in mice. Cancer Treat. Rep. 60: 889 (1976). 7. Pinedo, H.M., Zaharko, D.A., Chabner, B.A.,Bull, J.M. Evidence for early recruitment of

granulocyte precursors during high dose methotrexate-infusion in mice. Blood 48: 301 (1976).8. Pinedo, H.M., Zaharko, D.A., Bull, J.M., Chabner, B.A. The role of drug concentration, duration of

exposure and endogeneous metabolites in determining methotrexate cytotoxicity. Cancer Treat. Rep. 61: 709 (1977).

9. Pinedo, H.M., Zaharko, D.A., Bull, J.M., Chabner, B.A. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res. 37: 445 (1977).

10. Pinedo, H.M., Kenis, Y. Chemotherapy of advanced soft tissue sarcomas in adults. Cancer Treat. Rev. 14: 67 (1977).

11. Pinedo, H.M., Vendrik, C.P.J., Staquet, M., Kenis, Y., Sylvester, R. EORTC protocol for therapy of metastatic soft tissue sarcomas, a randomized trial. Eur. J Cancer: 13: 765 (1977).

1978 - 197912. Leyva, A., Baygell, P.D., Van Loenen, A.C., Van Asten, P., Pintus, C., Spreafico, F., Pinedo, H.M.

Characterization of methotrexate (MTX) recovered from the urine of high dose patients for purpose of clinical re-use. Eur. J Cancer 14: 1017 (1978).

13. Pinedo, H.M., Vendrik, C.P.J., Staquet, M., Sylvester, R. Study of diamminedichlorocisplatinum in advanced soft tissue sarcoma (protocol 62781). Eur. J Cancer 14: 1149 (1978).

14. Bramwell, V.H.C., Brugarolas, A., Mouridsen, H.T., Cheix, F., De Jager, R., Van 0osterom, A.T., Vendrik, C.P.J., Pinedo, H.M., Sylvester, R., De Pauw, M. EORTC phase II study of cisplatin in CYVADIC-resistant soft tissue sarcoma. Eur. J. Cancer 15: 1511 (1979).

15. Breed J.G.S., Zimmerman A.N.E., Meyler F.L., Pinedo H.M. The interval force relationship, a technique for the evaluation of the cardiac toxicity for anthracycline analogues. Cancer Treat. Rep. 83: 869 (1979).

16. Neijt J.P., Pinedo H.M. Hexa-CAF combination in pretreated ovarian carcinoma. N. Engl. J. Med. 300: 676 (1979).

17. Pinedo, H.M., Vendrik, C.P.J., Bramwell, V.H.C., Van Slooten, E.A., Deakin, D.P., Van Unnik, J.A.M., Staquet, M.J., Sylverster, R., Bonadonna, G. Evaluation of adjuvant therapy in soft tissue sarcoma, a collaborative multidisciplinary study. Eur.J. Cancer 15: 811 (1979).

18. Stoter, G., Vendrik, C.P.J., Struyvenberg, A., Sleijfer, D.Th., Schraffordt Koops, H., Van 0osterom, A.T., Pinedo, H.M., Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine and bleomycin in advanced testicular non-seminoma. Lancet 1: (8123) 941 (1979).

19. Vermeer, R.J., Pinedo, H.M. Partial remission of advanced adenoid cystic carcinoma obtained with adriamycin: A case report with a review of literature. Cancer 43: 1604 (1979).

198020. Breed, J.G.S., Zimmerman, A.N.E., Dormans, J.A.M.A., Pinedo, H.M. Failure of antioxi-dant

vitamin E to protect against adriamycin induced cardiotoxicity in the rabbit. Cancer Res. 40: 2033 (1980). 21. Buesa-Perez, J.M., Leyva, A., Pinedo, H.M. Effect of methotrexate on 5-phosphoribosyl-

-1-pyrophosphate levels in L1210 leukemia cells in vitro. Cancer Res. 40: 139 (1980). 22. Van Hoesel, Q.G.C.M., Pinedo, H.M. Complete remission of mediastinal tumors with cis-dichloro-

diammine-platinum (II) combination chemotherapy. Cancer Treat. Rep. 64: 319 (1980).

42

23. Hulshoff, A., Neijt, J.P., Smulders, C.F.A., Van Loenen, A.C., Pinedo, H.M. Determination of hexamethylmelamine and metabolites in plasma or serum by gas-liquid chromatography with nitrogen sensitive detector. J. Chromatogr. 181: 363 (1980).

24. Lankelma, J., Penders, P.G.M., Leyva, A., Pinedo, H.M. Determination of N-(phosphona-cetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography. Eur. J. Cancer 16: 1483 (1980).

25. Neijt, J.P., Van Lindert, A.C.M., Vendrik, C.P.J., Roozendaal, K.J., Struyvenberg, A., Pinedo, H.M. Treatment of advanced ovarian carcinoma with a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa~AF) in patients with and without previous treatment. Cancer Treat. Rep. 64: 323 (1980).

26. Vermorken, J.B., Van der Vijgh, W.J.F., Pinedo, H.M. Parmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichloro-diammine-platinum II). Res. Comm. Chem. Pathol. and Pharm. 28: 319 (1980).

198127. Den Hartigh, J., Van Oort, W.J., Bocken, M.C.Y.M., Pinedo, H.M. High performance liquid

chromatographic determination of the antitumor agent mitomycin C in human plasma. Anal. Chim. Acta 127: 47 (1981).

28. Holthuis, J.J.M., Pinedo, H.M., Van Oort, H.W. A sensitive high performance liquid chromatographic method for determination of the anti-neoplastic agents VP-l6-2l3 and VM-26 in biological fluids. Anl. Chim. Acta 130: 23 (1981).

29. Lankelma, J., Penders, P.G.M., Leyva, A., Pinedo, H.M. Determination of thioproline in plasma using high performance liquid chromatography. Cancer Letters 12: 131 (1981).

30. Lankelma, J., Penders, P.G.M., Leyva, A., Kleerberg, U.R., Kenny, J.B., Bramwell, V.H.C., McVie, J.G., Pinedo, H.M. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man. Eur. J. Cancer Clin. Oncol. 17: 1199 (1981).

31. Leyva, A., Nederbragt, H., Lankelma, J., Pinedo, H.M. Methotrexate cytotoxicity: Studies on its reversal by folates and nucleosides. Cancer Treat. Rep. 65: 45 (1981).

32. Nederbragt, H., Uitendaal, M.P., Grint, v.d., L., Leyva, A., Pinedo, H.M. Reversal of methotrexate inhibition of Ll2l0 leukemia cells in semi-solid medium. Cancer Res. 41: 1193 (1981).

33. Sylvester, R.J., Pinedo, H.M., De Pauw, M., Staquet, M.J., Buyse, M.E., Renard, J.,Bonadonna, G. Quality of institutional participation in multicenter clinical trials. N. Engl. J. Med. 305: 852 (1981).

198234. Lankelma, J., Penders, P.G.M., McVie, J.G., Leyva, A., Ten Bokkel Huinink, W.W., De Planque,

M.M., Pinedo, H.M. Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography. Eur. J. Cancer Clin. Oncol. 18: 363 (1982).

35. Lankelma, J., Laurensse, E., Pinedo, H.M. Flow-through tissue culture system with fast dynamic response. Analytical Biochemistry 127: 340 (1982).

36. Leyva, A., Appel, H.,Pinedo, H.M. Purine modulation of thymidine activity in Ll2l0 leukemia cells in vitro. Leukemia Res. 6: 483 (1982).

37. Van Maanen, J.M.S., Van Oort, W.J., Pinedo, H.M. In vitro and in vivo metabolism of VP-l6-2l3 in the rat. Eur. J. Clin. Oncol. 18: 885 (1982).

38. Schornagel, J.H., Leyva, A., Pinedo, H.M. Is there a role for thymidine in cancer chemotherapy? A review. Cancer Treat. Rev. 9: 331 (1982).

39. Uitendaal, M.P., Hubers, H.A.J.M., McVie, J.G.,Pinedo, H.M., Human tumor clonogenicity in agar is improved by cell-free ascites. Br. J. Cancer, 48:55 (1982).

40. Vermorken, J.B., van der Vijgh, W.J.V., Klein, I., Gall, H.E., Pinedo, H.M. Pharmacokinetics of free platinum species followed rapid 3-hr and 24-hr infusions of cis-dichloro-diammine-platinum (II) and its therapeutic implications. Eur. J. Cancer Clin. Oncol. 18: 1069 (1982).

198341. Den Hartigh, J., McVie, J.G., Van Oort, W.J., Pinedo, H.M. Pharmacokinetics of mitomycin C in

humans. Cancer Res., 43:5017, (1983.)42. Holthuis, J.J.M., Ronkes, F.H.G.H., Pinedo, H.M., Van Oort, W.J. Plasma assay for the

antineoplastic agent VP-l6-2l3 (Etoposide) using high performance liquid chromatography with electrochemical detection. J. Pharmaceutical Biochem. Analysis 1: 89 (1983).

43. Host, H., Joss, R, Pinedo, H.M., Bruntsch, U., Cavalli, F., Renard, G., Van Glabbeke, M., Rozencweig, M. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma. Eur. J. Cancer Clin. 0ncol. 19: 295 (1983).

43

44. Leyva, A., Appel, H., Pinedo, H.M. Thymidine sensitivity and deoxynucleotide pools of human lymphoid and melanoma cells in vitro. Adv. Exp. Med. Biol. l65B: 389-394 (1983).

45. Leyva, A., Kraal, I., Lankelma, J., Delemarre, J.F.M., Pinedo, H.M. High uridine phosphorylase activity in human melanoma tumor. Anti-cancer Research 3: 227-232 (1983).

46. Pinedo, H.M., Karim, A.B.M.F., Van Vliet, W.H., Vermorken, J.B. Daily cis-dichloro-diammine-platinum (II) as a ratio enhancer: A preliminary toxicity report. J. Cancer Res. Clin. Oncol. 105: 79 (1983).

47. Uitendaal, M.P., Hubers, H.A.J.M., McVie, J.G., Pinedo, H.M. Human tumour clonogeniaty in agar is improved by cell-free ascites. Br.J.Cancer 48: 55-59 (1983).

48. Uitendaal, M.P., Pinedo, H.M., Kirkels, W., Hubers, H.A.J.M, Herman, C.J. Growth kinetics of human tumor cell line colonies in CMRL-lob medium and in cell-free ascites. Int. J. Cell Cloning 1: 271 (1983).

49. Vermorken, J. B., Kapteijn, T.S., Hart, A.A.M., Pinedo, H.M. Ototoxicity of cis-diammine dichl-oroplatinum (II): Influence of dose, schedule and method of administration. Eur. J Cancer Clin. 0ncol. 19: 53 (1983).

50. Van der Vijgh, W.J.F., Van der Lee, H.B.J., Postma, G.J., Pinedo, H.M. Highly sensitive differential pulse amperometric detection of second generation anti-tumor platinum compounds in HPLC effluents. Chromatographia 17: 333-336 (1983).

51. Weenen, H., Lankelma, J., Penders, P.G.M., De Planque, M.M., Ten Bokkel Huinink, W.W., McVie, J.G., Pinedo, H.M., Pharmacokinetics of 4'-epi-doxorubicin in man. Investigational New Drugs 1: 59 (1983).

52. Boven, E., Vermorken, J.B., Van Slooten, H., Pinedo, H.M. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Cancer 53: 26-29 (1983).

198453. Elferink, F., Van der Vijgh, W.J.F., Van der Poort, S.E.J.M., Henzen-Logmans, S.C., Pinedo, H.M.

Influence of hydrolysis products of aqua(l,l-bis (aminomethyl) cyclohexane)-sulfatoplatinum(II) on toxicity in rats. Cancer Letters 25: 61-69 (1984).

54. Keizer, H.J., Karim, A.B.M.F., Njo, K.H., Tierie, A.H., Snow, G.B., Vermorken, J.B., Pinedo, H.M. Feasibility study on daily administration of cis-diammine-dichloroplatinum(II) in combination with radiotherapy (RTO 00027). Radiother. Oncol. 1, 3: 227-234 (1984).

55. Leyva, A., Van Groeningen, C.J., Kraal, I., Gall, H., Peters, G.P., Lankelma, J.,Pinedo, H.M. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res. 44: 5928-5933 (1984).

56. Leyva, A., Appel, H., Pinedo, H.M. Diverse deoxy-ribonucleotide profiles in cultured human cells with differential sensitivity to thymidine. Cancer Biochem. Biophys. 7: 231-238 (1984).

57. Leyva, A., Appel, H., Kraal, I., Pinedo, H.M. Differential metabolism of thymidine in human lymphoid and melanoma cells in vitro. Anticancer Res. 4: 173-178 (1984).

58. Leyva, A., Schornagel, J.H., Kraal, I., Pinedo, H.M. Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors. J. Cancer Res. Clin. Oncol. 107: 211-216 (1984).

59. Neijt, J.P., Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., Van Oosterom, A.T., Kooyman, C.D., Houwelingen, J.C., Pinedo, H.M., Combination Chemotherapy with or without hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer 53: 53, 7, 1467-1472 (1984).

60. Neijt, J.P., Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., Van Oosterom, A.T., Vriesendorp, R., Kooyman, C.D., Van Lindert, A.C.M., Hamerlynck, J.V.T., Van Houwelingen, J.C., Pinedo, H.M. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF versus CHAP-5) in advanced ovarian carcinoma. The Lancet II 8403: 594-600 (1984).

61. Neijt, J.P., Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., Van Oosterom, A.T., Vriesendorp, R., Pinedo, H.M. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. Radiother. and Oncol. 2: 19-29 (1984).

62. Peters, G.J., Laurensse, E., Lankelma, J., Leyva, A., Pinedo, H.M. Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluoro-uraci lnucleotide sugars. Eur. J. Cancer Clin. Oncol. 11: 1425-1431 (1984).

63. Peters, G.J., Laurensse, E., Leyva, A., Pinedo, H.M. Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. FEBS Letters (1451), 170,2: 277-280 (1984).

64. Peters, G.J., Kraal, I., Laurensse, E., Leyva, A., Pinedo, H.M. Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high performance liquid chromatography on a column with porous polymer packing. J. Chromatogr., 307: 464-468 (1984).

65. Pinedo, H.M., Bramwell, V.H.C., Mouridsen, H.T., Somers, R., Vendrik, C.P.J., Santoro, A., Buesa, J., Wagener, Th., Van Oosterom, A.T. Van Unnik, J.A.M., Sylvester, R., De Pauw, M., Thomas, D., Bonadonna, G., CYVADIC in advanced soft tissue sarcoma: A randomized study comparing two schedules. Cancer 53: 1825-1832 (1984).

44

66. Schornagel, J.H., Leyva, A., Pinedo, H.M. Methotrexate with thymidine protection or rescue in advanced head and neck cancer. A phase II study. Cancer Treat. Rep. 68, 3: 543-545 (1984).

67. Stoter, G., Vendrik, C.J.P., Struyvenberg, A., Sleyfer, D.Th., Vriesendorp, R., Schraffordt Koops, H., Van Oosterom, A.T., Ten Bokkel Huinink, W.W., Pinedo, H.M. The 5-year survival of patients with disseminated non-seminomatous testicular cancer treated with cis-platin vinblastine and bleomycin. Cancer 54, 8: 1521-1524 (1984).

68.Stoter, G., Van Oosterom, A.T., Mulder, J.H., De Pauw, M., Fossa, S.V., Pinedo, H.M. Combination chemotherapy with Cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder. Eur.J.Clin.Onc. 20,3: 315-317 (1984).

69.Uitendaal, M.P., Leyva, A., Schornagel, J., Pinedo, H.M. Effects of thymidine and inosine infusion on methotrexate activity in normal and P388-bearing mice. Eur. J. Cancer Clin. Oncol. 20: 1577-1532 (1984).

70.Vermorken, J.B., Van der Vijgh, W.J.F., Klein, I., Hart, A.A.M., Gall, H.E., Pinedo, H.M. Pharmacokinetics of free and total platinum species after short term infusion of cisplatin. Cancer Treat. Rep. 68, 3: 505-513 (1984).

71.Vermorken, J.B., Ten Bokkel Huinink, W.W., McVie, J.G., Van der Vijgh, W.J.F., Pinedo, H.M. Clinical pharmacology of cisplatin and some new platinum analogs, In: L. Lemberger Pharmacol. Therap, Am., Soc. Pharmac. Exp. Therap., Rockville Pike: 967-983 (1984).

72.Verwey, J., Boven, E., Van der Meulen, J., Pinedo, H.M. Recovery from mitomycin C induced haemolytic uraemic syndrom, a case report. Cancer 54: 2878-2881 (1984).

73.Van der Vijgh, W.J.F., Elferink F., Postma G.J.J, Vermorken J.B., Pinedo H.M. Determination of ethylenediamineplatinum (II) malonate in infusion fluids, human plasma and urine by high-performance liquid chromatography. J. of Chromatography 310: 335-342 (1984).

74.Weenen, H., Van Maanen, J.M.S., De Planque, M.M., McVie, J.G., Pinedo, H.M. Metabolism of 4'-modified analogs of doxorubicin. Unique glucuronidation pathway for 4'-epidoxorubicin. Eur. J. Cancer Clin. Oncol. 20, 7: 919-926 (1984).

75.Weenen, H., Pinedo, H.M., De Planque, M.M., Ten Bokkel Huinink, W.W., McVie, J.G.,Lankelma, J. Pharmacokinetics of carminomycin in Man: Biweekly schedule vs single dose every three weeks. Eur. J. Cancer Clin. Oncol. 20, 7: 915-918 (1984).

198576.Boven, E., Van der Vijgh, W.J.F., Nauta, M.M., Schluper, H.M.M., Pinedo, H.M. Comparative

activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res. 45: 86-90 (1985).

77.Boven, E., Nauta, M.M., Schluper, H.M.M., Elferink, F., Van der Vijgh, W.J.F., Pinedo, H.M. Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. Eur. J. Cancer Clin. Oncol. 21: 1253-1260 (1985).

78.Bramwell, V.H.C., Rouesse, J., Santoro, A., Buesa, J., Somers, R., Thomas, D., Sylvester, R., Pinedo, H.M. European experience of adjuvant chemotherapy for soft tissue sarcomas - a ran-domised trial comparing cyvadic with control. Cancer Treat. Symp. 3: 99-107 (1985).

79.Bruijn De, E.A., Van Oosterom, A.T., Tjaden, U.R., Reeuwijk, H.J.E.M., Pinedo, H.M. The pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res. 45: 5931-5936 (1985).

80.Elferink, F., Van der Vijgh, W.J.F., Pinedo, H.M. Analysis of antitumour [l,l-bis(aminomet-hyl)cyclohexane]-platinum(II) complexes derived from spiroplatin by high-performance liquid chromatography with differential pulse amperometric detection. J. Chromatogr. 320: 379-392 (1985).

81.Hartigh Den, J., Voortman, G., Van Oort, W.J., Weenen, Pinedo, H.M. Handling of biological samples in the determination of the antineoplastic drug mitomycin C. Journal Pharm. Biomed. Anal. 3, 5: 417-423 (1985).

82.Holdener, E.E., Hansen, H.H., Host, H., Bruntsch, U., Cavalli, F., Renard, J., Pinedo, H.M., Rozencweig, M. Epirubicin in colorectal cancer: A phase II study of the ECTG (EORTC). Invest. New Drugs 3, 1: 63-66 (1985).

83.Keizer, H.J., Pinedo, H.M. Cancer Chemotherapy: Alternative routes of drug administration. A Review. Cancer Drug Delivery 2, 2: 147-169 (1985).

84.Van Maanen, J.M.S., De Ruiter, C., De Vries, J., Kootstra, P.R., Gobas, F., Pinedo, H.M. The role of metabolic activation by cytochrome P-45O in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins. Eur. J. Cancer Clin. Oncol. 21, 9: 1099-1106 (1985).

85.Van Maanen, J.M.S., De Ruiter, C., Kootstra, P.R., Lafleur, M.V.M., De Vries, J., Retél, J., Pinedo, H.M. Inactivation of YXl74 DNA by the ortho-quinone derivative or its reduction product of the anti-tumor agent VP 16-213. Eur. J. Cancer Clin. 0ncol. 21, 10: 1215-1218 (1985).

86.Peters, G.J., Laurensse, E., Leyva, A., Pinedo, H.M. The concentration of 5-phosphoribosyl-l--pyrophosphate in monolayer tumor cells and the effect of various pyrimidine. Int. J. Biochem. 17: 95-99

45

(1985).

46

87.Rozencweig, M., Staquet, M., Hansen, H.H., Pinedo, H.M., McVie, J.G., Armand, J.P., Kenis, Y., Fox, B.W., Harrap, K., and Van Putten, L.M. EORTC guidelines for phase I trials in adults with single agents. Eur. J. Cancer Clin. Oncol. 21, 9: 1005-1007 (1985).

88.Verwey, J., Kester, D.M., Breet, W.P.M., Hillen, H.F.P., Pinedo, H.M. The absence of influence of acetylsolicylic acid (ASA) on the transient decreased in platelet counts observed after infusion of bleomycin and vinblastin. Eur. J. Cancer Clin. Oncol. 21: 1471-1474 (1985).

89.Verwey, J., Slater, R., Kamphorst, W., Pinedo, H.M. Neuroepithelioma (neuroblastoma) arising in an adult: A case report. Cancer Res. Clin. Oncol. 110: 165-169 (1985).

90.Van der Vijgh, W.J.F., Verbeek, P.C.M., Klein, I., Pinedo, H.M. Biliary excretion of platinum in rats after administration of cisplatin and aqua(l,l-bis(aminomethyl)cyclohexane)sulfatoplatinum (II) (spiroplatin), TNO-6). Cancer Letters 28: 103-109 (1985).

198691. Alberto, P., Rozencweig, M., Clavel, M., Siegenthaler, P., Cavalli, F., Gundersen, S., Bruntsch, U.,

Renard, J., Pinedo, H.M. Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. Cancer Chemother. Pharmacol. 16: 78-79 (1986).

92. Boven, E., Pinedo, H.M. Monoclonal antibodies in cancer treatment: where do we stand after ten years? Radiother. Oncol. 5: 109-117 (1986).

93. Boven, E., Nauta, M.M., Schluper, H.M.M., Erkelens, C.A.M., Pinedo, H.M. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. Cancer Chemother. Pharmacol. 18: 124-128 (1986).

94. Bruntsch, U., Dodion, P., Ten Bokkel Huinink, W.W., Hansen, H.H., Pinedo, H.M., Hansen, M., Renard, J., Van Glabbeke, M. Primary resistance of renal adenocarcinoma to 1,2,4 triglycidyl-urazol (TGU, NSC 332488), a new triexpoxide cytostatic agent - phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer Clin. Oncol. 22, 6: 697-699 (1986.

95. Dombernowsky, P., Mouridsen, H., Schutte, J., Santoro, A., Roussé, J., Somers, R., Stewart, W., Pinedo, H.M., Van Oosterom, A.T., Blackl edge, G., Thomas, D., Sylvester, R. Phase II study of ifosfamide + adriamycine in advanced soft tissue sarcoma in adults. A preliminary analysis. Cancer Chemother. Pharmacol. 2, 18: S. 17. (1986)

96. Elferink, F., Van der Vijgh, W.J.F., Klein, I., Pinedo, H.M. Interaction of cisplatin and carboplatin with sodium thiosulphate: reaction rates and protein binding. Clin. Chem. 32, 4: 641-645 (1986).

97. Elferink, F., Van der Vijgh, W.J.F., Pinedo, H.M. On-line differential pulse polarographic detection of carboplatin in biological samples after chromatographic separation. Anal. Chemistry 58: 2293-2296 (1986).

98. Van Groeningen, C.J., Leyva, A., Kraal, I., Peters, G.J., Pinedo, H.M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Treat. Rep. 70: 745-750 (1986).

99. Van Groeningen, C.J., Leyva, A., O'Brien, A.M.P., Gall, H.E., Pinedo , H.M. Phase I and pharmacokinetic study of 5-aza2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 46: 4831-4836 (1986).

100. Leyva, A., Schwartsmann, G., Boeije, L.C.M., Pinedo, H.M., De Waal, F. Growth inhibitory effects of 5-aza-2'-doxycytidine in HL-60 promyelocytic leukemia cells resistant to differentation induction. Biophys. Biochem. Res. Commun. 141: 629-635 (1986).

101. Van Maanen, J.M.S., De Ruiter, C., Kootstra, P.R., De Vries, J., Pinedo, H.M. Free radical formation from the antineoplastic agent VP 16-213. Free Rad. Res. Comms. 1 (4): 263-272 (1986).

102. Nauta, M.M., Boven, E., Schluper, H.M.M., Erkelens, C.A.M., Pinedo, H.M. Enhanced trans-plantability of human ovarian cancer lines in cyclophosphamide- pretreated nude mice. Br. J. Cancer 54: 331-335 (1986).

103. Peters, G.J., Laurensse, E., Leyva, A., Lankelma, J., Pinedo, H.M. Sensitivity of human, murine and rat cells to 5-fluorouracil and 5'deoxy-5-fluorouridine in relation to drug metabolizing enzymes. Cancer Res. 46: 20-28 (1986).

104. Peters, G.J., Laurensse, E.J., Leyva, A., Pinedo, H.M. Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities. Clin. Chim. Acta 158: 193-198 (1986).

105. Pinedo, H.M., Verweij, J. The treatment of soft tissue sarcomas with focus on chemotherapy, a review. Radiother. Oncol. 5: 193-205 (1986).

106. Pinedo, H.M. Review: Development of new anti-cancer drugs. Med. Oncol. & Tumor Pharmacother. 3: 63-69 (1986).

107. Vermorken, J.B., Van der Vijgh, W.J.F., Klein, I., Gall, H.E., Splinter T.A.W., Hart, A.A.M., Pinedo, H.M. Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (PlatinolR). Ther. Drug. Monitor. 8: 264-268 (1986).

108. Vermorken, J.B., Van der Vijgh, W.J.F., Klein, I., Gall, H.E., Van Groeningen, C.J., Hart, A.A.M.,

47

Pinedo, H.M. Pharmacokinetics of free and total platinum species following rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther. 39(2): 136-144 (1986).

48

109. Verwey, J., Van Lingen, A., Teule, J.J., Heidendal, G.A.K., and Pinedo, H.M. The cold pressor test during radionuclide ventriculography: a feasibility study in cancer patients. Med. Oncol. & Tumor Pharmacother. 3: 11-14 (1986).

110. Verwey, J., Stuurman, M., De Vries, J., Pinedo, H.M. The difference in pharmacokinetics of Mitomycin C, given either as single agent or as a part of combination chemotherapy. J. Cancer Res. Clin. Oncol., 112: 283-284 (1986).

111. Weenen, H., Osterop, A.P.R.M., Van der Poort, S.E.J.M., Lankelma, J., Van der Vijgh, W.J.F., Pinedo, H.M. Analysis of doxorubicin, 4'-epidoxorubicin and their metabolites by high pressure liquid chromatography. J. Pharm. Sc. 75: 1201-1204 (1986).

112. Winograd, B., Vermorken, J.B., Ten Bokkel Huinink, W.W., Simonetti, G., Gall, H.E., Knobf, M.K., Van der Vijgh, W.J.F., McVie, G.J., Pinedo, H.M. Phase I study of ethylenediamine platinum (II) malonate, JM-40 (NSC 146 068), a second generation platinum analog. Cancer Res. 46: 2148-2151 (1986).

1987113. Abele, R., Clavel, M., Monfardini, M., Bruntsch, U., Renard, J., Van Glabbeke, M., Pinedo, H.M.

for the EORTC Early Clinical Trials Group. Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck. Eur. J. Cancer Clin. Oncol. 23: 387-389 (1987).

114. Abele, R., Clavel, M., Dodion, P., Bruntsch, U., Gundersen, S., Smyth, J, Renard, J., Van Glabbeke, M., Pinedo, H.M. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deorycytidine (NSC 1227716) in patients with colorectal, head and neck, renal car-cinomas and malignant melanomas. Eur. J. Cancer in Clin. Oncol. 23: l92l-l924 (1987).

115. Beer, M., Cavalli, F., Kaye, S.B., Lev, L.L., Clavel, M., Smyth, J., Van Glabbeke, M., Renard, J., Pinedo, H.M. for the EORTC Early Clinical Trials Group. A phase II study of carboplatin in advance d or metastatic stomach cancer. Eur . J. Cancer Clin. Oncol . 23: 1565-1568 (1987).

116. Broxterman, H.J., Sprenkels-Schotte, C., Engelen, Ph., Leyva, A., Pinedo, H.M. Analysis of human ascites effect on clonogenic growth of human tumor cell lines and NRK-49F cells in soft agar. Int. J. Cell Cloning 5: 158-169 (1987).

117. Broxterman, H.J., Kuiper, C.M., Schuurhuis, G.J., Van der Hoeven, J.J.M., Pinedo, H.M., Lankelma, J. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein supplement. Cancer Letters 35: 87-95 (1987).

118. Dombernowsky, P., Buesa, J., Pinedo, H.M., Santoro, A., Mouridsen, H., Somers, R., Bramwell, V., Onsrud, M., Rouesse, J., Thomas, D., Sylvester, R. VP-l6 in advanced soft tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 23: 579-580 (1987).

119. Elferink, F., Van der Vijgh, W.J.F., Ten Bokkel Huinink, W.W., Vermorken, J.B., Klein, I., Winograd, B., Knobf, M.K.T., Simonetti, G., Gall, H.E., McVie, J.G., Pinedo, H.M. Pharmacoki netics of ethylenediaminemalonatoplatinum (II) (JM-4O) during phase I Trial. Br. J.Cancer 56: 479-483 (1987)

120. Elferink, F., Van der Vijgh, W.J.F., Klein, I., Vermorken, J.B., Gall, H.E., Pinedo, H.M. Pharmacokinetics of diammine(l,l-cyclobutanedi-carboxylato)-platinum(II) (carboplatin) after intravenous administration. Cancer Treat. Rep. 71: 1231-1237 (1987).

121. Elferink, F., Leeuwenkamp, O.R., Pinedo, H.M., Van der Vijgh, W.J.F. Electrochemistry of platinum complexes. I. Polarographic reduction mechanism with reference to electrochemical detection. J. Electronal. Chem. 238: 297-313 (1987).

122. Van Glabbeke, M., Renard, J., Pinedo, H.M., Cavalli, F., Vermorken, J., Sessa, C., Abele, R., Clavel, M., Monfordini, S. for the EORTC Early Clinical Trials Cooperative Group and the EORTC Data Center. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trials conducted by the EORTC Early Clinical Trials Group (ECTG). Eur. J. Cancer Clin. Oncol. 23, 11: 1707-1708 (1987).

123. Gundersen, S., Monfardini, S., Renard, G., Van Glabbeke, M., Pinedo, H.M Phase II trial of menogaril in advanced malignant melanoma. An EORTC trial. Eur. Cancer Clin. Oncol. 23: 1707-1708 (1987).

124. Van Harskamp, G., Boven, E., Vermorken, J.B., Van Deutekom, H., Stam, J., Njo, K.H., Karim, A.B.F.M., Tierie, A.H., Golding, R.P. Pinedo, H.M. Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer. Int. Radiat.Oncol.Phys. 13: 1735-1738 (1987).

125. Hegedus, L., Van der Vijgh, W.J.F., Klein, I., Kerpel Fronius, S., Pinedo. H.M. Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chem. & Pharm. 20: 211-212 (1987).

126. Van Hennik, M.B., Van der Vijgh, W.J.F., Klein, I, Elferink, F., Vermorken, J.B., Winograd, B., Pinedo, H.M. Comparative pharmacokinetics of cisplatin and three analogs in mice and man. Cancer Res. 47: 6297-6301 (1987).

49

127. Van Hoogenhuijse, J., Lankelma, J., Stam, J., Pinedo, H.M. Unchanged pharmacokinetics of VP-l6-2l3 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide. Eur. J.Cancer Clin. Oncol. 23, 6: 807-811 (1987).

50

128. Van Maanen, J.M.S., De Vries, J., Pappie, D., V.d. Akker, E., Lafleur, M.V.M., Retel, J., Van der Greef, J., Pinedo, H.M. Cytochrome P-450 mediated O-demethylation: a route in the metabolic activation of etoposide (VP 16-213). Cancer Res. 47: 4658-4662 (1987).

129. Maessen, P.A., Pinedo, H.M., Mross, K.B., Van der Vijgh, W.J.F. Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high performance liquid chromatography. J.Chromat. Biomed. 417: 339-346 (1987).

130. Maessen, P.A., Mross, K.B., Pinedo, H.M., Van der Vijgh, W.J.F. Metabolism of epidoxorubicin in animals: absence of glucuronidation. Cancer Chem. & Pharm. 20, 1: 85-87 (1987).

131. Mouridsen, H.T., Bastholt, L., Somers, R., Santoro, A., Bramwell, V., Mulder, J.H., Van Oosterom, A.T., Buesa, J., Pinedo, H.M., Thomas, D., Sylvester, R. Adriamycin versus Epirubicin in ancced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 23: 1477-1484 (1987).

132. Mross, K., Maessen, P., Van der Vijgh, W.J.F., Bogdanowicz, J.F., Kurth K.H., Pinedo, H.M. Absorption of epi-doxorubicin after administration in patients with in situ transitional cell carcinoma of the bladder. Eur. J. Cancer Clin. Oncol. 23: 505-508 (1987).

133. Peters, G.J., Laurensse, E., Leyva, A. Pinedo, H.M. A sensitive, non-radiometric assay for dihyroorotic acid de hydrogenase using anion-exchange high performance liquid chromatogra phy. Anal. Biochem. 161: 32-38 (1987).

134. Peters, G.J., Van Groeningen, C.J., Laurensse, E., Kraal, I., Leyva, A., Lankelma, J., Pinedo, H.M. Effect of pyrimidine nucleosides on body temperature of man and rabbit in relation to pharmacokinetic data. Pharm. Res. 4: 113-119 (1987).

135. Peters, G.J., Sharma, S.L., Laurensse, E., Pinedo, H.M. Inhibition of pyrimidine de novo synthesis by DUP 785 (NSC 368390). Invest. New Drugs 5: 235-244 (1987).

136. Peters, G.J., Van Groeningen, C.J., Laurensse, E., Lankelma, J., Pinedo, H.M. Uridine-induced hypothermia in mice and rabbits in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother. Pharmacol. 20: 101-108 (1987).

137. Peters. G.J., Laurensse, E., Leyva, A., Pinedo, H.M. Purine nucleosides as cell specific modulators of 5-fluoro-uracil metabolism and cytotoxicity. Eur. J. Cancer Clin. Oncol. 23: 1869-1881 (1987).

138. Peters, G.J., Van Dijk, J., Nadal, J.C., Van Groeningen, C.J., Lankelma, J., Pinedo, H.M. Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo I: 113-118 (1987).

139. Schuurhuis, G.J. Broxterman, H.J., Van der Hoeven, J.M., Pinedo, H.M., Lankelma, J. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil. Cancer Chemother. Pharmacol. 20: 285-290 (1987).

140. Schwartsmann, G., Pinedo, H.M. Clinical trials in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 23: 595-597 (1987).

141. Schwartsmann, G., Madan, K., Hein, Y., Pinedo, H.M., Leyva, A. Double minute chromatin bodies in HL-60 leukemia cells sensitive and resistant to differentiation inducing agents. Cell Biol. Int. Rep. 11: 651-655 (1987).

142. Schwartsmann, G., Boeije, L.C.M., Pinedo, H.M., Leyva, A. Reversal of resistance to differentiation induction in HL-60 promyelocytic leukemia cells by combination treatment. Eur. J. Cancer Clin. Oncol. 23: 739-743 (1987).

143. Schwartsmann, G., Pinedo, H.M., Leyva, A. Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment. Eur. J. Cancer Clin. Oncol. 23: 6, 739-743 (1987).

144. Snow, G.B., De Vries, N., Van Zandwijk, N., Pinedo, H.M. Second primary cancers in the lung in head and neck cancer patients: a challenge. Eur. J. Cancer Clin. Oncol. 23: 6, 83-886 (1987).

145. Verwey, J., Den Hartigh, J., Stuurman, M., De Vries, J., Pinedo, H.M. Relationship between clinical parameters and pharmacokinetics of mitomycin C. J. Cancer Res. and Clin. Oncol. 113: 91-94 (1987).

146. Verwey, J., Van der Burg, M.E.L., Pinedo, H.M. Mitomycin C induced haemolytic uremic syndrome. Six case reports and review of the literature on renal-, pulmonal and cardiac side effects of the drug. Radiotherapy and Oncology 8: 33-42 (1987).

147. Verwey, J., Kerpel Fronius, S., Stuurman, M., De Vries, J., Pinedo, H.M. The absence of interaction between furosemide and mitomycin C. Cancer Chemother. Pharmacol. 19: 84-86 (1987).

148. Verwey, J., De Vries, J., Pinedo, H.M. Mitomycin C induced renal toxicity, a dose dependent side effect? Eur. J. Cancer Clin. Oncol. 23: 195-199 (1987).

149. Verwey, J., Van Zanten, T., Souren, T., Golding, R., Pinedo, H.M. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 60: 4 (1987).

150. Van der Vijgh, W.J.F., Van Velzen, D., Van der Poort, S.E.J.M., Schluper, H.M.M., Mross, K., Feyen, J., Pinedo, H.M. Morphometric study of myocardial changes during puromycin aminonucleoside induced nephropathy in rats. Anticancer Res. 7: 1111-1116 (1987).

51

151. Van der Vijgh, W.J.F., Weenen, H., Van der Poort, S.E.J.M., Osterop, A.P.R.M., McVie, J.G., Pinedo, H.M. Pharmacokinetics of epirubicin. The Clinical Trials Journal 24: 23-27 suppl.1 (1987).

152. Winograd, B., Boven, E., Lobbezoo, M.W., Pinedo, H.M. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. In Vivo 1: 1-14 (1987).

1988153. Boven, E., Winograd, B., Fodstad, O., Lobbezoo, M.W., Pinedo, H.M. Preclinical phase II studies

in human tumor lines: a European multi-center study. Eur. J. Cancer Clin. Oncol. 24, 3: 567-573 (1988). 154. Broxterman, H.J., Kuiper, C.M., Schuurhuis, G.J., Tsuruo, T., Pinedo, H.M., Lankelma, J. Increase

of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-plycoprotein. Biochem. Pharmacol. 37, 12: 2389-2393 (1988).

155. Broxterman, H.J., Pinedo, H.M., Kuiper, C.M., Kaptein, L.C.M., Schuurhuis G.J., Lankelma, J. Induction of a rapid increase in ATP consumption by verapamil in multidrug resistant tumor cells. FASEB J. 2: 2278-2282 (1988).

156. Cervantes, A., Pinedo, H.M., Lankelma, J., Schuurhuis, G.J. The role of oxygen-derived five radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer Lett. 41: 169-177 (1988).

157. Clavel, M., Montfardini, S., Gundersen, S., Kaye, S., Siegethaler, P. Renard, J., Van Glabbeke, M., Pinedo, H.M. Phase II study of Iroplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy. Eur. J. Clin. Oncol. 24, 8: 1345-1348 (1988).

158. Dombernowsky, P., Clavel, M., Smyth, J.F., Howell, A., Van Glabekke, M., Renard, J., Pinedo, H.M. Phase II study of TCNU in advanced breast cancer. Eur. J. Cancer Clin Onc 24, 8: 1377-1378 (1988).

159. Van Glabbeke, M., Renard, J., Pinedo, H.M., Vermorken, J., Sessa, C., Abele, R., Clavel, M., Montfardini, S. for the EORTC Early Clinical Trials Group & EORTC Data Center. Iproplatin and carboplatin induced toxicities. Overview of Phase II clinical trials conducted by the EORTC Early Clinical Trials Cooperative Group and the EORTC Data Center. Eur. J. Cancer Clin. Oncol. 24, 2: 255-262 (1988).

160. Goey, S.H., Voerman, H.J., Strack van Schijndel, R.J.M., Van der Hoeven, J.J.M ., Wagstaff, J., Thijs, L.G., Pinedo, H.M. Swelling of metastatic tumours with high dose interleukin-2 therapy. N.Eng.J.Med. 318-643-644 (1988).

161. Van Groeningen, C.J., Pinedo, H.M., Heddes J., Kok, R.M., De Jong, A.P.J.M., Wattel, E., Peters, G.J., Lankelma, J., Pharmacokinetics of 5-fluorouracil assesses with a sensitive mass spectr-ometric method in patients on a dose escalation schedule. Cancer Res. 48: 6956-6961 (1988).

162. Holdener, E.E., Ten Bokkel Huinink, W.W., Decoster, G., Ludwig, C., Renard, G., Pinedo, H.M. Phase II trial of menogaril in advanced colorectal cancer. Invest. New Drugs 6: 227-230 (1988).

163. Joss, R.A., Monfardini, S., Hansen, H., Dombernowsky, P., Renard, J., Pinedo, H.M. Negative phase II trial of menogaril in advanced squamous, adeno- and large cell carcinoma of the lung. Eur. J. Cancer Clin.Oncol. 24: 263-265 (1988).

164. Keizer, H.G., Van Rijn, J., Pinedo, H.M., Joenje, H. Effect of onendogenous glutathione, superoxide dismutases, catalase, and glutathione peroxidase on adriamycin tolerance of Chinese hamster ovary cells. Cancer Res 48: 4493-4497 (1988).

165. Kerpel-Fronius, S., Verwey, J., Stuurman, M., Kanyar, B., Lelieveld, P., Pinedo, H.M. Pharmaco-kinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism. Cancer Chemother.Pharmacol. 22: 104-108 (1988).

166. Lankelma, J., Koopman, G. Van Grondelle, R., Pinedo, H.M. In-beamlight absorption measurement of anthracyclines in cells with a flow through system. Biochem. Biophys. Acta 964: 200-206 (1988).

167. Lankelma, J., Stuurman, M., Van Hoogenhuijze, J., Van Bochove, A., Vermorken, J.B. Verwey, J., Pinedo, H.M. The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. Eur. J. Cancer Clin. Oncol. 24: 175-180 (1988).

168. Laurensse, E., Pinedo, H.M., Peters, G.J. A sensitive nonradioactive assay for pyrimidine nucleoside phosphorylase using reverse-phase high-performance liquid chromatography. Clin Chem Chim Acta 178: 71-78 (1988).

169. Van Maanen, J.M.S., Lafleur, M.V.M., Van den Akker, E., De Ruiter, C., Kootstra, P.R., Pappie, D., De Vries, J., Retel, J., Pinedo, H.M. Effects of the ortho-quinone and catechol of the anti tumor drug VP-l6-2l3 on the biological activity of single-stranded and double stranded 0Xl74 DNA. Biochem. Pharmacol 37, 19: 3579-3589 (1988).

170. Van Maanen, J.M.S., Verkerk, U.H., Broersen, J., Lafleur, M.V.M. De Vries, J., Retel, J., Pinedo, H.M. Semi-Quinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-l6-213. Free Rad. Res. Comas. 4, 6:371-384 (1988).

171. Van Maanen, J.M.S., Retel, J., De Vries, J., Pinedo H.M. Mechanism of action of the antitumor

52

drug VP-l6-2l3: A review. JNCI 80, 19: 1526-1533 (1988). 172. Van Maanen, J.M.S., Van den Akker, E., De Vries, J., Pakkenist, T.R.J., Lankelma, J., Retel, J.,

Pinedo, H.M. Structure Bioactivation relationship of a series of podophyllotoxin derivatives. Eur. J. Cancer Clin Oncol. 24, 9: 1415-1419 (1988).

173. Maessen, P.A., Pinedo, H.M., Mross, K.B., Van der Vijgh, W.J.F. A new method for the determination of doxorubicin, 4'-epidoxorubicin and all known metabolites in tissue. J. Chromat. Biomed. Appl. 424: 103-110 (1988).

174. Mross, K., Maessen, P., Van der Vijgh, W.J.F., Gall, H., Boven, E., Pinedo, H.M. Pharmacoki-netics and metabolism of epirubicin and doxorubicin in humans. J. Clin. Oncol. 6: 517-526 (1988).

175. Nadal, J.C., Pinedo, H.M., Van Groeningen, C., Peters, G.J. In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed & Pharmacother 42: 387-393 (1988).

176. Peters, G.J. Van Dijk, J., Laurensse, E., Van Groeningen, C.J., Lankelma, J., Leyva, A., Nadal, J.C., Pinedo, H.M. In vitro biochemical and in vivo biological studies of the uridine "rescue" of 5-fluorouracil. Br. J. Cancer 57: 259-265 (1988).

177. Pinedo, H.M., Peters, G.J. 5-Fluorouracil; biochemistry and pharmacology. J. Clin. Oncol. 6, 10: 1653-1664 (1988).

178. Scheper, R.J., Bulte, W.J.M., Brakkee, J.G.P., Quak, J.J. V.d. Schoot, E., Palm, A.J.M., Meijer, C.J.L.M., Broxterman, H.J., Kuiper, C.M., Lankelma, J., Pinedo H.M. Monoclonal antibody JSB-l detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance. Int. J. Cancer. 42: 389-394 (1988).

179. Schroder, F.H., Klijn, G.M., Kurth, K.H., Pinedo, H.M., Splinter, T.A.W., De Boogt, H.J. Progress and controversies in oncological urology II. JNCI 80, 19 (1988).

180. Schwartsmann, G., Peters, G.J., Laurensse, E., De Waal, F.C., Loonen, A.H., Leyva, A., Pinedo, H.M. DUP-785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochem. Pharmacol. 37, 17: 3257-3266 (1988).

181. Schwartsmann, G., Winograd, B., Pinedo, H.M. The main steps in the development of anticancer agents. Rad. Oncol. Radioth. Oncol. 12: 301-313 (1988).

182. Schwartsmann, G., Van der Vijgh, W.J.F., Klein, I., Van Groeningen, C.J., Vermorken, J.B., Pinedo, H.M. Pharmacokinetics of brequinar sodium (NSC 368390; DUP 785) in cerebrospinal Fluid. Eur.J.Clin.Oncol. 24, 12: 1903-1904 (1988).

183. Sessa, C., Vermorken, J.B., Renard, J., Kaye, S., Smith, D., Ten Bokkel Huinink, W.W., Cavalli, F., Pinedo, H.M., for the Early Clinical Trials Group of the European Organization for Research and Treatment of Cancer. Phase II study of iproplatin (CHIP) in advanced ovarian carcinoma. J. Clin. Oncol. 6, 1: 98-105 (1988).

184. Verwey, J., Kerpel Fronius, S., Stuurman, M., Van Friet, A.J., Van Hattum, A.H., De Vries, J., Pinedo, H.M. Mitomycin C injucted organ toxicity in wistar rats. A study with special focus in the kidney. J. Cancer Res. and Clinical Oncol. 114: 137-141 (1988).

185. Verwey, J., Funke-Kupper, A.J., Teule, G.J.J., Pinedo, H.M. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med. Onc. Tumor Farm. 5, 3: 159-163 (1988).

186. Van der Vijgh, W.J.F., Elferink, F., Vermorken, J.B., Ten Bokkel Huinink, W.W, Klein, I., Gall, H., Simonetti, G., McVie, J.G., Pinedo, H.M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua(l,l-bis(aminomethylcyclohexane) sulfatoplatinum(11) (spiroplatin) during phase I trial. Eur. J Cancer Clin. Oncol., 24: 621-627 (1988).

187. Van der Vijgh, W.J.F., Van Velzen, D., Van der Poort, J, Schluper, H.M.M., Mross, K., Feijen, J., Pinedo, H.M. Morphometric study of myocardial changes during doxorubicin induced cardiomyopathy in mice. Eur.J.Clin.Oncol. 24, 10: 1603-1608 (1988).

1989188. Broxterman, H.J., Pinedo, H.M., Kuiper, C.M., Schuurhuis, G.J., Lankelma, J. Glycolysis in P-

glycoprotein overexpressing human tumor cell lines. Effects of resistance modifying and lysosomotropic agents. FEBS letters, 247, 2:405-410 (1989).

189. Broxterman, H.J., Pinedo, H.M., Kuiper, C.M., Van der Hoeven, J.J.M., De Lange, P., Quak, J.J., Scheper, R.J., Keizer, H.G., Schuurhuis, Lankelma, J. Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int. J. Cancer 43: 340-343 (1989).

190. Dalton, W.S., Grogan, T.M., Rybski, J.A., Scheper, R.J., Richter, L., Kailey, J., Broxterman, H.J., Pinedo, H.M., Salmon, S.E. Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73, 3: 747-752 (1989).

191. Van Groeningen, C.J., Peters, G., Pinedo, H.M. Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J. Cancer Clin.

53

Oncol 25: 45-49 (1989).

54

192. Van Groeningen C.J., Peters G.J., Leyva A., Laurensse E., Pinedo, H.M. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. JNCI. 81: 157-162 (1989).

193. Gundersen, P., Dombernowsky, P., Cavalli, F., Bruntsch, U.,Renard, J., Van Glabbeke, M., Pinedo, H.M. TCdNU (LS2667), a new active drug in the treatment of advanced colorectal cancer. Eur.J. of Cancer & Clin.Onc. 25: 1095-1099 (1989).

194. Van Hennik, M.B., Van der Vijgh, W.J.F., Klein, I., Vermorken, J.B., Pinedo, H.M. Human pharmacokinetics of carboplatin after oral administration. Cancer Chem. & Pharm. 23: 126-127 (1989).

195. De Kant, E., Pinedo, H.M., Laurensse, E., Peters, G.J. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium. Cancer Letters 46: 123-127 (1989).

196. Keizer, H.G., De Leeuw, S.J., Van Rijn, J., Pinedo, H.M., Joenje, H. Effect of inhibitors of flavoprotein activity on the cytotoxicity of adriamycin and mitomycin C in human lung tumor cells. Eur J Cancer Clin Oncol. 25: 1113-1119 (1989).

197. Keizer, H.G., Schuurhuis, G.J., Broxterman, H.J., Lankelma, J., Schoonen, W.G.E.J. Van Rijn, J., Pinedo, H.M., Joenje, H. Correlation of multidrug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49: 2988-2993 (1989).

198. Keizer, H.G., De Leeuw, J., Van Rijn, J., Pinedo, H.M., Joenje, H. Effect of artificial electron acceptors on the cytotoxicity of mitomycin C and doxorubicin in human lung tumor cells. Eur.J. C-ancer & Clin.Onc. 25, 7: 1113-1118 (1989).

199. Laurensse, E.J., Braakhuis, B.J.M., Pinedo, H.M., Peters G.J., Fluoro-pyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors. Adv. Exp.Med.Biol. 253B: 327-334 (1989).

200. Nadal, J.C., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Investigational New Drugs 7: 163-172 (1989).

201. Peters, G.J., Braakhuis, B.J.M., De Bruyn, E.A., Laurensse, E.J., Van Walsum, M., Pinedo, H.M. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolic ezymes. Br. J. Cancer 59: 327-334 (1989).

202. Peters, G.J., Laurensse, E., De Kant, E., Nadal, J.C., Pinedo, H.M. The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of Brequinar (DUP-785; NSC 368390). Adv.Exp.Med. Biol. 253B: 375-382 (1989).

203. Peters, G.J., Laurensse, E., Van Groeningen C.J., Meijer, S., Pinedo, H.M. In vitro and in vivo inhibition of thymidylate synthase of human colon cancer by 5-fluorouracil. Adv.Exp.Med.Biol. 253A: 439-445 (1989).

204. Schuurhuis, G.J., Broxterman, H.J., Cervantes, A., Van Heijningen, H.M., De Lange, J.H.M., Baak, J.P.A., Pinedo, H.M., Lankelma, J. Quantitive determination of factors contributing to doxorubicin resistance in multidrug resistant cells. JNCI. 81: 1887-1892 (1989).

205. Schwartsmann, G., Bork, E., Vermorken, J.B., Nieboer, C., Dodion, P., Ten Bokkel Huinink, W.W., Hansen, N., Armand, J.P., Winograd, B., Gall, H., Seldenrijk, A., Pinedo, H.M. Mucocutaneous side-effects of brequinar sodium. Cancer 63, 2: 243-248, (1989).

206. Schwartsmann, G, Van de Vijgh, W.J.F., Van Hennik, M.B., Klein, I., Vermorken, J.B., Dodion, P, Ten Bokkel Huinink, W.W., Joggi, G., Gall, H., Crespeigne, N, Simonetti, G, Winograd, B., Pinedo, H.M. Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study. Eur J Cancer Clin. Oncol. 25: 1675-1682 (1989).

207. Stoter, G., Koopman, A., Vendrik, C.P.J., Struyvenberg, A., Sleyfer, D.Th., Willemse, P.H.B., Schraffordt Koops, H., Van Oosterom, A.T., Ten Bokkel Huinink, W.W., Pinedo, H.M. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine and bleomycin. J.Clin.Onc. 7: 1099-1104 (1989).

208. Van der Valk, P., Van Kalken, C.K., Ketelaars, H., Broxterman, Scheffer, G., Kuiper, C.M., Tsuruo, T., Lankelma, J., Meijer, C.J.L.M., Pinedo, H.M. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann.Oncol. 1: 56-64 (1990).

209. Wagstaff, J., Vermorken, J.B., Schwartsmann, G., Scheper, R.J., Hack, C.E., Nuijens, J.H., Eerenberg-Belmer, A.J.M., Pinedo, H.M. A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to Interleukin-2. Cancer Treat Rev. 126 (suppl.A): 105-109 (1989).

1990210. Boven, E., Erkelens, C.A., Luning, M., Pinedo, H.M. Activity of GR30921X (NSC 382057) and

GR63178A (NSC D611615) in human ovarian cancer lines. Br. J. Cancer 61 (5): 709-11 (1990).211. Broxterman, H.J., Pinedo, H.M., Schuurhuis, G.J., Lankelma J. Cyclosporin A and Verapamil have

different effects on energy metabolism in multidrug-resistant tumor cells. Br. J. Cancer 62: 85-88 (1990).

55

212. De Jong J., Schoofs P.R., Onderwater R.C.A., Van der Vijgh W.J.F., Pinedo H.M., Bast A. Isolated mouse atrium as a model to study anthracycline cardiotoxicity. The role of the beta-adrenoceptor system and reactive oxygen species. Research Communications in Chemical Pathology and Pharmacology 68, 3: 275-289 (1990).

213. Keizer, H.G., Pinedo, H.M., Schuurhuis, G.J., Joenje, H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmac.Ther. 47: 219-231 (1990).

214. Kuiper, K., Broxterman, H.J., Baas, F., Schuurhuis, G.J., Haisma, H., Scheffer, G., Lankelma, J., Pinedo, H.M. Drug transport variants without P-Glycoprotein over expression from a human squamous lung cancer cell line after selection with doxorubicin. J of Cellular Pharmacology 1: 1 (1990).

215. Mans, D.R.A., Retèl, J., Van Maanen, J.M.S., Lafleur, M.V.M., Van Schaik, M.A., Pinedo, H.M., Lankelma, J. Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded X174 DNA. Br.J.Cancer 62: 54-60 (1990).

216. Peters, G.J., Schwartsmann, G., Nadal, J.C., Laurensse, E.J., Van Groeningen, C.J., Pinedo, H.M. In vivo inhibition of the pyrimidine de novo enzyme dihydrorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res 50: 4644-4649 (1990).

217. Peters, G.J., Van der Wilt, C.L., Smid, K., Ruiz van Haperen, V., Veerman, G., Laurensse, E., Pinedo, H.M. Pyrimidine metabolism in murine colon cancer models; relevance for chemotherapy with antimetabolites. Biochem. Pharmacol. 9: 3655-373 (1990).

218. Peters, G.J., Pinedo, H.M., Ferwerda, W., De Graaf, T.W., Van Dijk, W. Do antimetabolites interfere with the glycosylation of cellular glycoconjugates. Eur. J. Cancer 26: 516-523 (1990).

219. Peters, G.J., Nadal, J.C., Laurensse, E.J., De Kant, E., Pinedo, H.M. Retention of in vivo antipyrimidine effects of brequinar sodium (DUP-785;NSC 368390) in murine liver, bone marrow and colon cancer. Biochemical Pharmacol. 39: 135-144 (1990).

220. Schuurhuis, G.J., Broxterman, H.J., Van Heijningen, Th.H.M., Van Kalken, C.K., Vermorken, J.B., Spoelstra, E.C., Lankelma, J., Pinedo, H.M. Cremophor EL reverses multidrug resistance. Br.J. Cancer 62: 85-88 (1990).

221. Schuurhuis, G.J., Broxterman, H.J., Van Kalken, C.K., Kuiper, C.M., Lankelma, J. Differential sensitivity of multidrug resistant and sensitive cells to resistance modifying agents and the relation with reversal of anthracycline resistance. Int.J. Cancer 46: 330-336 (1990).

222. Schuurhuis G.J., Broxterman, H.J., Pinedo, H.M., Van Heijningen Th.H.M., Van Kalken, C.K., Vermorken, J.B., Spoelstra E.C., Lankelman, J. The polyoxythelene castor oil Cremophor EL modifies multidrug resistance. Br.J.Cancer. 62: 591-594 (1990).

223. Schuurhuis, G.J., Broxterman, N.J., Kuiper, C.M., Pinedo, H.M., Lankelma, J. Differential sensitivity of multidrug resistant and sensitive cells to resistance modifying agents and the relation with reversal of anthracycline resistance. Int.J. Cancer 46: 330-336 (1990).

224. Schwartsmann, G, Dodion, P, Vermorken, J.B., Ten Bokkel Huinink, W.W., Joggi, J., Winograd, B, Gall, H., Simonetti, G., Van der Vijgh, W.J.F., Van Hennik, M.B., Crespeigne, N., Pinedo, H.M. Phase I study of Brequinar sodium (NSC368390) in patients with solid malignancies. Cancer Chemother. Pharmacol. 25: 345-351 (1990).

225. Thijs, L.G., Hack, C.E., Strack van Schijndel, R.J.M., Nuijens, J.H., Wolbin, G.J., Eerenberg--Belmer, A.J.M., Van der Valk, H., Wagstaff, J., Pinedo, H.M. Activation of the complement system by high-dose immunotherapy with recombinant IL-2: Relation to the development of side effects. J Immunology 144: 2419-2424 (1990).

226. Van der Valk, P., Van Kalken, C.K., Ketelaars, H., Broxterman, H.J., Scheffer, G.L., Kuijper, C.M., Tsuruo, T., Lankelma, J., Meyer, C.L.J.M., Pinedo, H.M., Scheper, R.J. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann.Oncol. 1: 45-64 (1990).

227. Verwey, J., Pinedo, H.M. Mitomycin C: mechanism of action, usefulness and limitations. Anti Cancer Drugs 1: 5-13 (1990).

228. Van der Vijgh, W.F.J., Maessen, P.A., Pinedo, H.M. Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother. Pharmacol. 26: 9-12 (1990).

1991229. Baars J.W., Wagstaff J., Boven E., Vermorken J.B., Van Groeningen C.J., Scheper R.J., Fonk

J.C.M., Nijman J.W., Franks C.R., Damsma, O., Pinedo H.M. A phase I study of sequential human recombinant interferon-gamma and recombinant interleukin-2 in patients with metastatic solid tumors. JNCI 83: 1408-1410 (1991).

230. Broxterman, H.J., Pinedo, H.M. Energy metabolism in multidrug resistant tumor cells. J. Cell Pharmacol. 2: 239-247 (1991).

231. Geijssen, G.J., Pieters, R., Veerman, A.J.P., Pinedo, H.M., Peters, G.J. Do inhibitors of IMP

56

dehydrogenase have a future in cancer chemotherapy? Int.J.of Purine and Pyrimidine Research 2: 17-26 (1991).

232. Van Groeningen C.J., Peters G.J., Nadal J.C., Laurensse E.J., Pinedo H.M. Clinical pharmacology study of orally administered uridine. JNCI 83: 437-441 (1991).

233. Hack C.E., Wagstaff J., Strack van Schijndel R.J.M., Eerenberg A.J.H., Pinedo H.M., Thijs L.G., Nuijen J.H. Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. Thrombosis Haemostasis 65, 1991, p. 497-503.

234. Haisma H.J., Pinedo H.M., Kessel M.A.P., Van Muijen M.A.P., Roos J.C., Plaizier M.A.B.D., Martens H.J.M., De Jager R., Boven E. Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. JNCI 83: 1813-1819 (1991).

235. Van der Hem, K.G., Van Groeningen C.J., Pinedo H.M. Late relapse of testicular cancer. A case report and a review of the literature. Neth J Med 39: 353-355. (1991)

236. Hoekman, K., Wagstaff, J., Van Groeningen, C.J., Vermorken, J.B., Boven, E., Pinedo, H.M. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high dose chemotherapy in patients with advanced breast cancer. JNCI 83: 1546-1553 (1991).

237. Hoekman, K., Van Blomberg-Van der Flier, B.M.E., Wagstaff, J., Drexhage, H.A., and Pinedo, H.M. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 338: 541-2 (1991).

238. Hoekman, K., Boven, E., Van Groeningen, C.J., Smit, J.M., Vermorken, J.B., Wagstaff, J., Pinedo, H.M. Intensieve chemotherapie in combinatie met de hematopoietische groeifactor GM-CSF bij de behandeling van patienten met een mamma-carcinoom.Ned.Tijdschr. Geneeskd. 135: 415-419 (1991).

239. Van Kalken C.K., Van der Hoeven, J.J.M., De Jong, J., Giaccone, G., Schuurhuis, G.J., Maessen, P.A., Blokhuis, W.M.D., Van der Vijgh, W., Pinedo, H.M. Bepridil in combination with anthracyclines in the attempt to reverse anthracycline-resistance in cancer patients. Eur J of Cancer 27, 6: 739-744 (1991).

240. Van Kalken, C.K., Pinedo, H.M., Giaccone, G. Multidrug resistance from the clinical point of view. Eur.J. of Cancer 27: 1481-1486 (1991).

241. Van Kalken, C.K., Van der Valk P, Hadisaputro, M.M.N., Pieters, R., Broxterman, H.J., Kuiper, C.M., Scheffer, G.L., Veerman, A.J.P., Meyer, C.J.L.M., Scheper, R.J, Pinedo, H.M. Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney. Ann. Oncol. 2: 55-62 (1991).

242. Keepers, Y.P., Pizao, P.E., Peters, G.J., Van Ark-Otte, J., Winograd, B., Pinedo, H.M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur.J. Cancer. 27: 897-900 (1991).

243. Leeuwenkamp, O.R., Neijt, J.P., Van der Vijgh, W.J.F., Pinedo, H.M. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (Di)mesna and Thiosulphate. Eur.J.Cancer 27: 1243-7 (1991).

244. Maas, I.W.H.M., Boven, E., Pinedo, H.M., Schlüper, H.M.M., Haisma, H.J. The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J of Cancer 48: 749-756 (1991).

245. Molthoff, C.F.M., Calame, J.J., Pinedo, H.M., and Boven, E. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int.J.Cancer 47: 72-79 (1991).

246. Molthoff, C.F.M., Pinedo, H.M., Schlüper, M.M., Boven, E. Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian cancer bearing nude mice. Cancer Immunol. Immunother. 34: 191-197 (1991).

247. Peters, G.J., Van Groeningen, C.J., Laurensse, E.J., Pinedo, H.M. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxyuridine-5'-monophosphate. Eur.J.Cancer 277: 263-267 (1991).

248. Peters, G.J., Van Groeningen, C.J., Laurensse, E.J., Pinedo, H.M. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68: 1903-1909 (1991).

249. Schuurhuis, G.J., Broxterman, H.J., De Lange, J.H.M., Pinedo, H.M., Van Heijningen, T.H.M., Kuiper, C.M., Scheffer, G.L., Scheper, R.J., Van Kalken, C.K., Baak, J.P.A., Lankelma, J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br.J.Cancer 64: 857-861 (1991).

250. Schwartsmann, G., Wanders, J., Koier, I.J., Franklin, H.R., Dalesio, O., Hornstra, H.W., Van Glabbeke, M., Renard, H., Van Oosterom, A.T., Kaye S.B., Pinedo, H.M. EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents. Eur.J. Cancer 27: 1162-8 (1991).

251. Schwartsmann G., Pinedo H.M.,. Multicenter vs single center phase II evaluation of 4'-iodo-4'-deoxydoxorubicin in advanced breast cancer. Ann Oncol 2: 703-703 (1991).

252. Spoelstra E.C., Pinedo, H.M., Dekker, H. Peters, G.J., and Lankelma, J. Measurement of in vitro

57

cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. Cancer Chemother Pharmacol 27: 320-325 (1991).

58

253. Tanis, B.C., Vermorken, J.B., Ten Bokkel Huinink, W.W., Klein, I., Gall, H., Van Oosterom, A.T., Simonetti, G., McVie, J.G., Van der Vijgh, W.J.F., Pinedo, H.M. Phase I study of Spiroplatin. Eur.J. Cancer 27, 3: 268-273 (1991).

254. Treskes M., Holwerda U., Klein I., Pinedo H.M.,Van der Vijgh W.J.F. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 42: 2125-2130 (1991).

1992255. Baars, J.W., Wagstaff, J., Hack, C.E., Wolbink, G.-J., Eerenberg-Belmer, A.J.M., Pinedo, H.M.

Angioneurotic oedema and urticaria during therapy with interleukin-2. Ann. Oncol. 3: 243-244 (1992).256. Baars, J.W., Hack, C.E., Pinedo, H.M., Eerenberg-Belmer, A.J.M., Wolbink, G.J.J., Thijs, L.G.,

Strack van Schijndel, R.J., Van der Vall, H.L.J.A., Wagstaff, J. The activation of polymorphonuclear neutrophils and its relationship to complement activation during immunotherapy with recombinant interleukin-2. Br J Cancer 65: 96-101 (1992).

257. Baars, J.W., Fonk, J.C.M., Scheper, R.J., Von Blomberg v.d. Vlier, B.M.E., Bril, H., V.d. Valk, P., Pinedo, H.M., Wagstaff, J. Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma. A pilot study. Biotherapy 4: 289-297 (1992).

258. Baars, J.W., De Boer, J.P., Wagstaff, J., Roem, D., Eerenberg-Belmer, A.J.M., Nauta, J., Pinedo, H.M., Hack, C.E. Interleukin-2 induces activation of coagulation and fibronolysis: resemblance to the changes seen during experimental endotoxaemia. Br. J. Haematol. 82: 295-301 (1992).

259. Baars, J.W., Coenen, J.L.L.M., Wagstaff, J., Van der Valk, P., Pinedo, H.M. Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), ant its exacerbation during intravenous therapy with IL-2. Br. J. Cancer 66: 698-699 (1992).

260. Boven E., Hendriks H.R., Erkelens C.A.M., Pinedo H.M. The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian xenografts. Br J Cancer 66: 1044-1047 (1992).

261. Van Groeningen, C.J., Peters, G.J., Pinedo, H.M. Modulation of fluorouracil toxicity with uridine. Sem. Oncol. 19 (sup.3); 148-154 (1992).

262. Haisma, H.J., Boven, E., Van Muijen, M., De Vries, R., Pinedo, H.M. Analysis of an anti-CEA monoclonal antibody-alcaline phosphatase conjugate for specific activation of the prodrug etoposi-de-phosphate. Cancer Immunol Immunotherapy 34: 343-348 (1992).

263. Haisma, H.J., Boven, E., Van Muijen, M., De Jong, J., Van der Vijgh, W.J.F., Pinedo, H.M. A monoclonal antibody-ß-glucuronidase conjugate as activator of the prodrug epirubicin-glucoronide for specific treatment of cancer. Br. J. Cancer 66: 474-478 (1992).

264. Haisma, H.J., Pinedo, H.M., Silva, C.A., Boven, E. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens. J. Immunol. Meth. 154: 55-60 (1992).

265. Van der Hem K.G., Boven E., Van Hennik M.B., Pinedo H.M. Malignant Leydig cell tumor of the testis in complete remission on o,p'-dichlorodiphenyl-dichloroethane. J Urol 148: 1256-1259 (1992).

266. Hendriks, H.R., Plowman, J., Berger, D.P., Paull, K.D., Fiebig, H.H., Fodstad, O., Dreef-Van der Meulen, H.C., Henrar, R.E.C., Pinedo, H.M., Schwartsmann, G. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann. Oncol. 3: 755-763 (1992).

267. Van Kalken, C.K., Giaccone, G., Van der Valk, P., Kuiper, C.M., Hadisaputro, M.M.N., Bosma, A.A., Scheper, R.J., Meijer, C.J.L.M., Pinedo, H.M. Multidrug resistance gene expression in the human fetus. Am.J. Pathology 141: 1063-1072 (1992).

268. De Lange, J.H.M., Schipper, N.W., Schuurhuis, G.J., Ten Kate, T.K., Van Heijningen, Th.H.M., Pinedo, H.M., Lankelma, J., Baak, J.P.A. Quantification by laser scan microscopy of intracellular doxorubicin distributrion. Cytometry 13: 571-576 (1992).

269. Lopez Lopez, R., Peters, G.J., Van Loenen, A.C., Pizao, P.E., Van Rijswijk, R.E.N., Wagstaff, J., Pinedo, H.M. The effect of schedule, protein binding and growth factors on the activity of suramin. Int. J. Cancer 51: 921-26 (1992).

270. Los, G., Smals, O.A.G., Van Vugt, M., Van der Vlist, M., Den Engelse, L., McVie, J.G., Pinedo, H.M. A rational for carboplatin treatment and regional hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 52: 1252-1258 (1992).

271. Mans, D.R.A., Schuurhuis, G.J., Treskes, M., Lafleur, M.V.M., Retèl, J., Pinedo, H.M., Lankelma, J. Modulation by D,L-Buthionine-S,R-Sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines. Eur. J. Cancer 28a: 1447-1452 (1992).

272. Meijs, W.E., Herscheid, J.D.M., Haisma, H.J., Pinedo, H.M.: Evaluation of Desferal as a Bifunctional Chelating Agent for Labeling Antibodies with Zr-89: Appl.Radiat. Isot. 43, 12: 1443-1447 (1992).

59

273. Molthoff, C.F.M., Pinedo, H.M., Schlüper, H.M.M., Boven, E. Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. Int. J. Cancer 50: 474-480 (1992).

274. Molthoff, C.F.M., Pinedo, H.M., Schlüper, H.M.M., Rutgers, D.H., Boven, E. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Int. J. Cancer 51: 108-115 (1992).

275. Molthoff, C.F.M., Pinedo, H.M., Schlüper, H.M.M., Nijman, H.W., Boven, E. Comparison of the pharmacokinetics and the biodistribution of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Br. J. Cancer 65: 677-683 (1992).

276. Molthoff C.F.M., Buist R., Kenemans P., Pinedo H.M., Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med 33: 2000-2005 (1992).

277. Peters, G.J., Kraal, I., Pinedo, H.M. In vitro and in vivo studies on the combination of brequinar sodium (Dup-785; NSC 368390) with 5-fluorouracil; effects of uridine. Br. J. Cancer 65: 229-233 (1992).

278. Pinedo, H.M., Van Rijswijk, R.E.N. Suramin awakes? [Editorial]. J. Clin. Oncol. 10: 875-877 (1992).279. Pizao, P.E., Lyaruu, D.M., Peters, G.J., Van Arke-Otte, J., Winograd, B., Giaccone, G., Pinedo,

H.M. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. Br. J. Cancer 66: 660-665 (1992).

280. Pizao, P.E., Winograd, B., Peters, G.J., Leyva, A., Giaccone, G., Pinedo, H.M. In vitro chemosensitivity testing of multilayered microcultures. Anticancer Res. 12: 1319-1322 (1992).

281. Van Rijswijk, R.E.N., Van Loenen, A.C., Wagstaff, J., Meijer, E., Lopez, R., Van Groeningen, C.J., Heimans, J.J., Pinedo, H.M. Suramin: rapid loading and weekly maintenance regimens for cancer patients. J. Clin. Oncol. 10: 1788-94 (1992)

282. Rodenhuis S., Baars, J.W., Schornagel J.H., Vlasveld L.T., Mandjes I., Pinedo H.M., Richel D.J. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann. Oncol. 3: 855-860 (1992).

283. Scheper, R.J., Broxterman, H.J., Scheffer, G.L., Meijer, C.J.L.M., Pinedo, H.M. Drug transporter proteins in clinical multidrug-resistance. Clin. Chim. Acta 206: 25-32 (1992).

284. Tanis, B.C., Vermorken, J.B., Ten Bokkel Huinink, W.W., Van Oosterom, A.T., Splinter, T.A.W., Vendrik, K.J., Sleijfer, D.T.H., Van der Burg, M.E.L. Van der Putten, E., Pinedo, H.M. Multicenter phase II study of Spiroplatin. Oncology 49: 99-103 (1992).

285. Ten Bokkel Huinink W.W., Clavel M., Rodenhuis S., Guastalla J.P., Franklin H.R., Koier I., Vlasveld, T., Dalesio O., Van Tinteren H., Pinedo H.M. Mitoxantrone and GM-CSF, a phase I study with an escalated dose of mitoxantrone in breast cancer. Path. Biol 39: 962 (1992).

286. Treskes M., Holwerda U., Nijtmans L.G.J., Pinedo H.M., Van der Vijgh, W.J.F. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother. Pharmacol. 29: 467-470 (1992).

287. Treskes M., Boven E., Holwerda U., Pinedo H.M., Van der Vijgh, W.J.F. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 52: 2257-2260 (1992).

288. Van der Wilt, C., Pinedo, H.M., Smid, K., Cloos, J., Noordhuis, P., Peters, G.J. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase. Sem. Oncol. 19 (sup.3): 16-25 (1992).

289. Van der Wilt, C., Pinedo, H.M., Smid, K. Peters, G.J. Elevation of thymidylate synthase following 5-Fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res.: 148-154 (1992).

290. Versantvoort, C.H.M., Broxterman, H.J., Pinedo, H.M., De Vries, E.G.E., Feller, N., Kuiper C.M., Lankelma, J. Energy-dependent processes involved in defective drug accumulation in multidrug resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 52:17-23 (1992).

1993291. Baars, J.W., Wagstaff, J., Van Groeningen, C.J., Vermorken, J.B., Bijvank, E.M., Pinedo, H.M.,

Nauta, J.J.P. Phase II study of Interferon-γ and Interleukin-2: Tachyphylaxis of toxicity to the liver during increasing immune enhancement. JNCI 5: 410-411 (1993).

292. Beijnen, J.H., Rosing, H., Ten Bokkel Huinink, W.W., Pinedo, H.M., High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma. J.of Chromatography 617: 111-117 (1993).

293. Boven, E., Schipper, H., Erkelens, C.A.M., Hatty, S.A., Pinedo, H.M. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br. J. of Cancer 68: 52-62 (1993).

60

294. Boven, E., Venema-Gaberscek, E., Erkelens, C.A.M., Bissery, M.C., Pinedo, H.M. Antitumor activity of taxotere (RP 56076, NSC 628503), a new taxol analog, in experimental ovarian cancer. Ann. of Onc. 4: 321-324 (1993).

295. Dercksen, M.W., Hoekman, K., Ten Bokkel-Huinink, W.W., Rankin, E.M., Dubbelman, R., Van Tinteren, H., Wagstaff, J, Pinedo, H.M. Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. Br. J. of Cancer 68: 996-1003 (1993).

296. Van Gijn, R., Rosing, H., ten Bokkel Huinink, W.W., Van Tellingen, O., Vermorken, J.B., Liefting, A.J.M., Bruno, R., Pinedo, Beijnen, J.H. Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography, 614: 299-306, Biomedical Applications (1993).

297. Van Gijn, Kuijs, S., R., Rosing, H., Dubbelman, A.C., Van Tellingen, O., Ten Bokkel Huinink, W.W., Pinedo, H.M., Beijnen, J.H. Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection. J. of Pharmaceutical & Biomedical Analysis 11/12: 1345-1348 (1993)

298. Van Groeningen, C.J., Peters, G.J., Pinedo, H.M. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann. Oncology, 4: 317-320 (1993).

299. Hendriks, H.R., Pizao, P.E., Berger, D.P., Kooistra, K.L., Bibby, M.C., Boven, E., Dreef-Van der Meulen, H.C., Henrar, R.E.C., Fiebig, H.H., Double, J.A., Hornstra, H.W., Pinedo, H.M., Workman, P., Schwartsmann, G. EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A, 6: 897-906 (1993).

300. Huizing, M.T., Keung, A.C.F., Rosing, H., Van der Kuij, V., Ten Bokkel Huinink, W.W., Mandjes, I.M., Dubbelman, A.C. Pinedo, H.M., Beijnen, J.H. Pharmacokinetics of Paclitaxel and Metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J . Clin. Onc. 11: 2127-2135 (1993).

301. Van Kalken, C.K., Broxterman, H.J., Pinedo, H.M., Feller, N., Dekker, H., Lankelma, J., Giaccone, G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 67: 284-289 (1993).

302. Kuiper, C.M., Schuurhuis, G.J., Lankelma, J., Feller, N., Pinedo, H.M., Broxterman, H.J. Probing for MDR in acute myeloid leukemia and comparison of different diagnostic methods. Cancer Res. 53: 1-5 (1993).

303. Los, G., Tuyt, L., Van Vugt, M., Schornagel, J., Pinedo, H.M. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. Cancer Chemother. Pharmacol. 32: 425-433 (1993).

304. Los, G., Van Vugt, M.J.H., Den Engelse, L., Pinedo, H.M. Effects of temperature on the interacton of cisplatin and carboplatin with cellular DNA. Biochemical Pharmacology 7: 1229-1237 (1993).

305. Olthof, C.G., Baars, J.W., Wagstaff, J., Pinedo, H.M., Donker, A.J.M., Schneider, H., De Vries, P.M.J.M. Determination of capillary leakage due to recombinant interleukin-2 by means of non-invasive conductivity measurements. European J. Applied Physiology 67: 168-173 (1993).

306. Peters, G.J., Lankelma, J., Kok, R.M., Noordhuis, P., Van Groeningen, C.J., Van der Wilt, C.L., Meijer, S., Pinedo, H.M. Prelonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother. Pharmacol. 31: 269-276 (1993).

307. Peters, G.J., Hoekman, K., Van Groeningen, C.J., Van der Wilt, C.L., Smid, K., Meijer, S., Pinedo, H.M. Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent. Adv.Exp.Med.Biol. 338: 613-616, (1993).

308. Peters, G.J., Wets, M., Keepers, Y.P.A.M., Oskam, R., Van Ark-Otte, J., Noordhuis, P., Smid, K., Pinedo, H.M., Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Intern. J. of Cancer 54: 450-455 (1993).

309. Peters, G.J., Van der Wilt, C.L., Cloos, J., Pinedo, H.M. Development of a simple folylpolyglutamate synthase assay in tissues and cell lines. Adv.Exp.Med.Biol 338: 651-654, (1993).

310. Peters, G.J., Laurensse, E., Steinbusch, H.W.M., De Vente, J. Smid, K., Van der Wilt, C.L., Pinedo, H.M. Development, characterization and application of an antibody against 5-fluoro-2'deoxy-5'monophosphate, the active metabolite of 5-fluorouracil. Anticancer Research 13: 835-840 (1993).

311. Pieters, R.C., Vermorken, J.B., Gall, H.E., Nauta, J.J.P., Van Loenen, A.C., Van Groeningen, C.J., Van Rijswijk, R.E.N., Brenninkmeijer, J.H.E., Pinedo, H.M. A double-blind randomized cross-over study to compare the anti-emetic efficacy of 250 mg with 500 mg methylprednisolone succinate (solumedrol) as a single i.v. dose in patients with non-cisplatin chemotherapy. Oncology 50: 316-322 (1993).

312. Pizao, P.E., Peters, G.J., Van Ark-Otte, J., Smets, L.A., Smitskamp-Wilms, E., Winograd, B., Pinedo, H.M., Giaccone, G. Cytotoxic effects of anticancer agents on subconfluent and

61

multilayered postconfluent cultures. Eur. J.of Cancer 29A: 1566-1573 (1993).

62

313. Scheper, R.J., Broxterman, H.J. Scheffer, G.L., Kaaijk, P., Dalton, W.S., Van Heijningen, T.H.M., Van Kalken, C.K., Slovak, M.L., De Vries, E.G.E., Van der Valk, P., Meijer, C.J.L.M., Pinedo, H.M. Overexpression of Mr110,000 vesicular protein in non-P-glycoprotein mediated multidrug-resistance. Cancer Res. 53: 1475-1479 (1993)

314. Schuurhuis, G.J., Van Heijningen, T.H.M., Cervantes, A., Pinedo, H.M., De Lange, J.H.M., Keizer, H.G., Broxterman, H.J., Baak, J.P.A., Lankelma, J. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br. J.of Cancer 68: 898-908 (1993).

315. Versantvoort, C.H.M., Schuurhuis, G.J., Pinedo H.M., Eekman, C.A., Kuiper, C.M., Lankelma, J., Broxterman, H.J. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br. J.of Cancer 68: 939-946 (1993).

316. Westerhof, G.R., Schornagel, J.H., Rijnboutt, S., Pinedo, H.M., Jansen, G. Identification of a reduced folate/methotrexate carrier in human KB cells wxpressing high levels of membrane-assiciated folate binding protein. Adv. Exp. Med. Biol. 338: 771-774 (1993).

317. Van der Wilt, C.L., Pinedo, H.M., De Jong, M., Peters, G.J. Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase. Biochem Pharmacol 45:1177-1179(1993).

318. Van der Wilt, C.L., Smid, K. Aherne, G.W., Pinedo, H.M., Peters, G.J. Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines. Adv. Med. Biol. 338: 605-608 (1993).

319. Van der Wilt, C.L., De Jong, M., Braakhuis, B.J.M., Pinedo, H.M., Peters, G.J. The interval between methotrexate and leucovorin determines the efficacy of 5-flurorouracil modulation in vitro and in vivo. Adv.Exp.Med.Biol. 338: 609-612 (1993).

1994320. Beijnen, J., Huizing, M., Ten Bokkel Huinink, Veenhof, C., Vermorken, J.B., Giaccone, G., Pinedo,

H.M., Bio-analysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (taxol), Sem. Oncol. 21, suppl.8, n.5, 53-62, (1994).

321. Giaccone, G., Huizing, Bokkel Huinink, W.W. ten, Koolen, M., Postmus, P., Van Kralingen, J., Van Zandwijk, N., Vermorken, J.B., Beijnen, J., Dalesio, O., Pinedo, H.M., Veenhof, C. Preliminary results of two dose finding studies of paclitaxel (taxol) and carboplatin in non-small cell lung and ovarian cancers, a European Cancer Centre effort.Sem. Oncol. 21, suppl.8, n.5, 34-38 (1994).

322. Haisma H.J., Muijen, M. van, Pinedo, H.M., Boven, E., Comparison of two anthra-cycline-based prodrugs for activatrion by a monoclonal antibody-ß-glucuronidase conjugate in the specific treatment of cancer, Cell Biophysics, volumes 24/25, (1994).

323. Hoekman, K., Van Doorn, J., Gloudemans, T., Hoekstra, O.S., Maassen, J.A., Vermorken, J.B., Wagstaff, J., Pinedo, H.M. Tumour-induced hypoglycaemia: A case report. Ann. of Oncology 5: 277-281 (1994).

324. Jansen, W.J.M., Pinedo, H.M., Kuiper, C.M., Lincke, C., Bamberger, U., Heckel, A., Boven, E. Biochemical modulation of 'classical' multidrug resistance by BOBW22BS, a potent derivative of dipyridamole. Ann. Oncol. 5; 733-739 (1994).

325. Leeuwen, F.E. van, Chorus A.M.J., Belt-Dusebout, A.W. van den, Hagenbeek, A., Noyon, R., Van Kerkhoff, E.H.M., Pinedo, H.M., Somers, R. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J. Clin. Onc. 12; 5: 1063-1073 (1994).

326. Linn S.C., Giaccone G., Van Kalken C., Van der Valk P., Kuiper C.M., Pinedo H.M. Complete remission of colorectal cancer: a pitfall in a multidrug resistance reversal trial. The Lancet 343, 1648-1649, 1994.

327. Linn, S.C., Van Kalken, C.K., Van Groeningen, C.J., Kuiper, C.M., Pinedo, H.M., Giaccone, G. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J. Clin. Onc.; 4: 812-819 (1994).

328. Lopez Lopez, R. Van Rijswijk, R.E.N., Wagstaff, J. Pinedo, H.M., Peters, G.J., The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effect of suramin. Eur. .J. Cancer 30A; 1545-1549 (1994).

329. Lopez Lopez, R., Langeveld, C.H.N., Pizao, P.E., Van Rijswijk, R.E.N., Wagstaff, J., Pinedo, H.M., Peters, G.J. Effect of suramin on adenaylate cyclase and protein kinase C. Anti Cancer Drug Design 9; 279-290 (1994).

330. Lopez Lopez, R, Peters, G.J., Smitskamp-Wilms, E., Virizuela, j.A., Van Ark-Otte, J., Pinedo, H.M., Giaccone, G. In vitro sequence-dependent synergistic effect of suramin and captothecin. Eur. J. Cancer 30A; 11, 1670-1694 (1994).

63

331. Mülder, H.S., Lankelma, J., Dekker, H., Broxterman, H.J., Pinedo, H.M. Quantitation of daunorubicin efflux against a concentration gradient in non-P-Glycoprotein multidrug resistant lung cancer cells. Int. J. Cancer 59, 275-281 (1994).

332. Oldenburg, J., Begg, A.C., Van Vugt, M.J.H., Ruevekamp, M., Schornagel, J.H., Pinedo, H.M., Los, G. Characterization of Resistance Mechanisms to cis-Diamminedichloroplatinum (II) in Three Sublines of the CC531 Colon Adenocarcinoma Cell Line in Vitro. Cancer Res. 54: 487-493 (1994).

333. Ogylvie, A.C., Baars, J.W., Eerenberg, A.J.M., Hack, C.E., Pinedo, H.M., Thijs, L.G., Wagstaff, J. A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. Br. J. Cancer, 69: 596-598 (1994).

334. Peters, G.J., Van der Wilt, C.L., Van Groeningen, C.J. Meijer, S. Smid, K., Pinedo, H.M., Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil. J. Clin. Oncol. 12; 2035-2042 (1994).

335. Pinedo, H.M., Van Groeningen, C.J., Vinorelbine: a horse of a different color? J. Clin. Oncol. 12, 9; 1745- 1747 (1994).

336. Pizao, P.E., Smitskamp-Wilms, E. Van Ark-Otte, J. Beijnen, J., Peters, G.J., Pinedo, H.M., Giaccone, G. Antiproliferatieve activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochem. Pharmacol. 4 8; 1145-1154 (1994).

337. Ruiz van Haperen, V.W.T., Veerman, G., Eriksson, S., Boven, E., Stegmann, A.P.A., Hermsen, M., Vermorken, J.B., Pinedo, H.M., Peters, G.J., Development and molecular characterization of a 2'2'-difluorodeoxycytidine-resitant variant of the ovarian carcinoma cell line A2780. Cancer Res. 54; 4138-4143 (1994).

338. Ruka, W., Priario, J., Wagener, T., Burgers, M., Van Unnik, J., Contesso, G., Thomas, D., Van Glabbeke, M., Markham, D., Pinedo, H.M. Adjuvant CYVADIC chemotherapy for adult soft tissue carcinoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 12; 6: 1137-1149 (1994).

339. Smitskamp-Wilms, E., Peters, G.J., Pinedo, H.M., Van Ark-Otte, J. Giaccone, G., Chemo-sensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem. Pharmacol. 47 ; 1325-1332 (1994).

340. Spoelstra, E.C., Westerhoff, H.V., Pinedo, H.M., Dekker H., Lankelma, J., The multidrug resistance reverter verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur.J. Biochem. 221: 363-373, (1994).

341. Spoelstra, E.C., Westerhoff, H.V., Pinedo, H.M., Dekker, H., Lankelma, J. Verapamil as a substrate for P-glycoprotein; a model for competition between verapamil and daunorubicin for the active efflux pump. European J.of Biochemistry 93: 1002/1 (1994).

342. Treskes, M., Boven, E., Van de Loosdrecht, A.A., Wijffels, J.F.A.M., Cloos, J., Peters, G.J., Pinedo, H.M., Van der Vijgh, W.J.F. Effects of the modulating agent WR 2721 on myelotoxicity and antiumour activity in carboplatin treated mice. Eur. J. Cancer, 30A; 183-187 (1994).

343. Versantvoort, C.H.M., Broxterman, H.J., Lankelma, J., Feller, N., Pinedo, H.M. Competitive inhibition by genistein and ATP dependence of daunorubicin trasprot intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 48, 1129-1136 (1994).

344. Zaman, G.J.R., Flens, M.J. Van Leusden, M.R., De Haas, M., Mülder H.S., Lankelma, J., Pinedo, H.M., Scheper, R.J., Baas, F., Broxterman, H.J., Borst, P. The human multidrug resistance-asso-ciated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci.; 91 (1994).

1995345. Broxterman, H.J., Feller, N., Kuiper, C.M., Boven, E., Versantvoort, C.H.M., Teerlink, T., Pinedo,

H.M., Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts. Int. J. Cancer 61, 880-886 (1995).

346. Codacci-Pisanelli, G., Wilt, C.L. van der, Pinedo, H.M., Franchi, F., Noordhuis, P., Braakhuis, B.J.M., Van Laar, J.A.M., Peters,J. Antitumour activity, toxicity and inhibition of thymidylate syntahse of prolonged administration of 5-fluorouracil in mice, Eur.J. Cancer 31A, 9, 1517-1525 (1995).

347. Dercksen, M.W., Hoekman, K., Visser, J.J., Ten Bokkel Huinink, W.W., Pinedo, H.M., Wagstaff, J. Hypotension induced by interleukin-3 in patients on angiotensin-converting enzyme inhibitors, The Lancet, Vol. 345, 448, (1995).

348. Dercksen, M.W., Gerritsen, W.R., Rodenhuis, S., Dirkson, M.R., Slaper-Cortenbach, I.C.M., Schaasberg, W.P., Pinedo, H.M., Von dem Borne, A.E.G.Kr., Van der Schoot, C.E. Expression of adhesion molecules on C34+ cells: CD34+I-selectin+ cells predicts a rapid platelet recovery after peripheral blood stem cell transplantation. Blood, 85: 3313-3319, (1995).

64

349. Dercksen, M.W., Rodenhuis S., Dirkson M.K. Schaasberg W.P., Baars J.W., Wall, E. van der, Slaper-Cortenbach I.C. Pinedo, H.M, Von dem Borne, A.E., Van der Schoot, C.E. Subsets of CD 34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation, J. Clin. Oncol. 13(8): 1922-1932 (1995).

350. Dercksen, M.W., Weimar, I.S., Richel, D.J., Breton-Gorius, J., Vainchenker, W., Slaper-Cortenbach, I.C.M., Pinedo, H.M., Von dem Borne, A.E.G.Kr., Gerritsen, W.R., Van der Schoot, C.E. The value of flow cytometric analysis of platelet glycoprotein expression on CD 34 positive cells measured under conditions that prevent P-selectin mediated binding of platelets Blood 86 (10), 3771-3782 (1995).

351. Feller, N., Kuiper, C.M., Lankelma, J., Ruhdal, J.K., Scheper, R.J., Pinedo, H.M., Broxterman, H.J. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry, Br. J. Cancer 72, 543-549 (1995).

352. Feller, N., Broxterman, H.J. Währer, D.C.R., Pinedo, H.M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutahione depletion, FEBS Letters, 368, 385-388 (1995).

353. Giaccone, G., Linn, S.C., Pinedo, H. M. Multidrug Resistance in Breast Cancer: Mechanisms, Strategies, Eur. J. Cancer, 31A. suppl. 7, S15-S17 (1995).

354. Pinedo, H.M., Giaccone, G. P-glycoprotein- A marker of cancer-cell behavior, New Eng.J Med., 333: 1417-1419 (1995).

355. Haisma, H.J., Muijen M. van, Scheffer, G., Scheper R.J., Pinedo, H.M., Boven, E. A monoclonal antibody against human ß-glucuronidase for application in antibody-directed enzyme prodrug therapy, Hybridoma, 14(4) (1995).

356. Huizing, M.T., Van Warmerdam, L.J.C., Rosing, H., Bokkel Huining, W.W. ten, Stewart, M.B., Pinedo, H.M., Beijnen, J.H., Limited sampling strategies for investigating Paclitaxel pharmacokinetics in patients receiving 175 mg/m2 as a 3-hour infusion, Clin. Drug Invest.9 (6): 344-353 (1995).

357. Huizing, M.T., Sewberath Misser, V.H., Pieters R.C. Bokkel Huinink, W.W. ten, Veenhof, C.H.N., Vermorken, J.B., Pinedo, H.M., Beijnen, J.H. Taxanes: A new class of Antitumor Agents, Cancer Investigation 13 (4), 381-404 (1995).

358. Huizing, M.T., Vermorken, J.B., Rosing, H., Bokkel Huinink, W.W. ten, Mandjes, I., Pinedo, H.M. Beijnen, J.H., Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann. Oncol. 6, 699-704 (1995).

359. Izquierdo, M.A., Zee, A. van der, Vermorken, J.B., Valk, P. van der, Beliën, J.A.M., Giaccone, G., Scheffer, G.L., Flens, M.J., Pinedo, H.M., Kenemans, P., Meijer, C.J.L.M., De Vries, E.G.E., Scheper, R.J., Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst. 87, 1230-1237 (1995).

360. Giaccone, G., Huizing, M., Postmus P., Ten Bokkel Huinink, W.W., Koolen, M., Van Zandwijk, N., Vermorken, J.B., Beijnen, Dalesio, O., Pinedo, H.M., Veenhof, C. Dose finding and sequencing study of paclitaxel and carboplatin in non small cell lung cancer, Sem. Oncol. 22(9), 78-82. (1995)

361. Jansen, W.J.M., Pinedo, H.M., Van der Wilt, C.L., Feller, N., Bamberger, U., Boven, E. The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and bemcitabine in vitro and in huma tumor xenografts, Eur. J. Cancer, Vol 31 A, nos. 13-14: 2313-2319. (1995)

362. Linn, S.C., Giaccone, G., Van Diest, P.J., Blokhuis, W.M.D., Van der Valk, P., Van Kalken, C.K., Kuiper, C.M., Pinedo, H.M., Baak, J.P.A. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann. Oncol. 6: 679-685, 1995.

363. Mülder, H.S., Dekker, H., Pinedo, H.M., Lankelma, J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for doxorubicin, daunorubicin and idarubicin, Biochem. Pharmacol. 50 (7), 967-974 (1995).

364. Peters, G.J., Smitskamp-Wilms, E., Veerman G., Pizao, P., Ruiz van Haperen, V.W.T., Pinedo, H.M. Three dimensional cell cultures as a model system to evaluate the biological activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Nucleosides & Nucleotides 14 (3-5), 661-664 (1995).

365. Peters, G.J., Wilt, C.L. van der, Triest, B. van, Codacci-Pisanelli, G., Johnston, P.G., Van Groeningen, C.J., Pinedo, H.M. Thymidylate synthase and drug resistance, Eur. J. Cancer 31A, 7/8, 1299-1305 (1995).

366. Peters, G.J., Noordhuis, P., Komissarov, A., Holwerda, U., Kok, R.M., Van Laar, J.A.M., Van der Wilt, C.L., Van Groeningen, C.J. , Pinedo, H.M., Quantification of 5-fluorouracil inccorporation into RNA of human and murine tumors as measured with a sensitive gaschromatography-mass spectrometry assay, Anal. Biochem. 231, 157-163 (1995).

367. Postma, T.J., Vermorken, J.B., Liefting, A.J.M., Pinedo, H.M., Heimans, J.J. Paclitaxel-induced

65

neuropathy, Ann. Oncol. 6, 489-494 (1995).368. Rubio, G.J., Pinedo, H.M., Virizuela, J., Van Ark-Otte, J., Giaccone, G. Effects of suramin on

human lung cancer cell lines, Eur. J. Cancer 31A(2): 244-251, (1995).369. Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A., Slovak, M.L., Pinedo, H.M., Meijer,

C.J.L.M., Clevers, H.C., Scheper, R.J., The drug resistance-related protein LRP is the human major vault protein, Nature Med. 1(6) (1995).

370. Schuurhuis, G.J., Broxterman, H.J., Ossenkoppele, G.J., Baak, J.P.A., Eekman, C.A., Kuiper, C.M., Feller, N., Heijningen, T.H.M., Klumper, E., Pieter, R., Lankelma, J., Pinedo, H.M. Functional Multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-ß-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia., Clinical Cancer Research 1(1): 81-93 (1995).

371. Smitskamp-Wilms, E., Giaccone, G., Pinedo, H.M., Van der Laan, B.F.A.M., Peters, G.J. DT-diaphorase activity in normal and neoplastic human tissues; and indicator for EO9 sensitivity?, Br. J. Cancer, 72, 917-921 (1995).

372. Triest, B. van, Telleman, F., Pinedo, H.M., Wilt C.L. van der, Peters, G.J., Cross resistance to thymidylate synthase inhibitors in p-glycoprotein and non-p-glycoprotein cell lines, Adv. Exp. Med. Biol. 370: 189-193 (1995).

373. Westerhoff, G.R., Rijnboutt, S., Schornagel J.H., Pinedo, H.M., Peters, G.J. Jansen, G. Functional activity of the reduced folate carrier in KB, MA104 and IGROV-I cells expressing folate-binding protein. Cancer Res 55, 3795-3802 (1995).

374. Westerhoff, G.R., Schornagel, J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters, G.J., Pinedo H.M. Carrier and receptor mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol., 48 (3), 459-471 (1995).

375. Van der Wilt, C.L., Marinelli, A., Pinedo, H.M., Cloos, J., Smid, K., Van de Velde, C.J.H., Peters, G.J. The effect of different routes of administration of 5-fluorouracil on inhibition of thymidylate synthase in rat tissues. Eur. J. Cancer, 31 A (5): 754-760 (1995).

376. Van der Wilt, C.L., Cloos, J., Jong, M. de, Pinedo, H.M., Peters, G.J., Screening of colon tumor cells and tissues for folypolyglutamate synthetase activity, Oncol. Res. 7,(6): 317-312 (1995).

1996 377. Abrahams, P.J., Houweling, A., Cornelissen-Steijger P.D.M., Arwert, F., Pinedo, H.M., Van der Eb,

A.J. Inheritance of abnormal expression of SOS-like response in Xeroderma pigmentosum and hereditary cancer-prone syndromes, Cancer Res. 56-11: 2621-2625 (1996).

378. Broxterman, H.J., Lankelma, J., Pinedo, H.M., How to probe clinical tumor samples for P-glycoprotein and multidrug resistance protein, Eur. J. Cancer, Vol. 32A(6): 1024-1033 (1996).

379. Broxterman, H.J., Sonneveld, P., Feller, N., Ossenkoppele, G.J., Währer, D.C.R., Eekman, C.A., Schoester, M., Lankelma, J., Pinedo, H.M. Löwenberg, B., Schuurhuis, G.J., Quality control of multidurg resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity, Blood Vol. 87(11): 4809-4816 (1996).

380. Giaccone, G., Ark-Otte, J. van, Rubio, G.J., Gazdar A.F., Flens, M.J., Scheper, R.J., Pinedo H.M. MRP is frequently expressed in human lung-cancer cell lines, in non-small cell lung cancer and in normal lung. Int. J. Cancer 66, 760-767 (1996).

381. Honkoop, A.H. Hoekman, K., Wagstaff, J., Boven, E., Van Groeningen, C.J., Giaccone, G., Vermorken, J., Pinedo, H.M. Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients, Ann. Oncol., 7: 35-39 (1996).

382. Honkoop, A.H., Hoekman, K., Wagstaff, J., Van Groeningen, C.J., Vermorken, J.B., Boven, E., Pinedo, H.M. Continuous infusion of subcutaneous injection of granulocyte-macrophage colony stimulating factor; increased efficacy and reduced toxicity when given subcutaneously. Br. J. Cancer, (1996).

383. Houba, P.H.J., Leenders, R.G.G., Boven, E., Scheeren, J.W., Pinedo, H.M.,Haisma H.J., Characterization of novel anthracycline prodrugs activated by human ß-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem.Pharmacol 52: 455-463 (1996)

384. Kievit, E., Pinedo, H.M., Schlüper, H.H.M., Haisma, H.J., Boven, E., Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumor uptake and efficacy of radio-immunotherapy in human ovarian cancer xenografts, Br. J. Cancer, 73: 457-464 (1996).

385. Linn, S.C., Honkoop, A.H., Hoekman, K., Van der Valk, P., Pinedo, H.M., Giaccone, G. P53 and P-glycoprotein are often coexpressed and are associated with poor prognosis in breast cancer. Br. J. Cancer, 74: 63-68 (1996).

386. Meijs W.E., Haisma, H.J., Van der Schors, R., Wijbrandts R., Van den Oever, K., Klok, R.P.,

66

Pinedo, H.M., Herscheid, J.D. A facile method for labeling proteins with zirconium isotopes. Nucl. Med. Biol. 23: 439-448 (1996).

387. Mülder, H.S., Pinedo, H.M., Timmer, A.T., Rao, B.R., Lankelma, J., Multidrug resistance-modifying components in human plasma with potential clinical clinical significance. J. Exp Th. & Oncol., 1, (1996).

388. Ruiz van Haperen, V.W.T., Veerman, G., Vermorken, J.B., Pinedo, H.M., Peters, G.J. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphophate and uridine 5'-triphophate in relation to chemosensitivity for 2', 2'-difluorodeoxycytidine, Biochem. Pharmacol. Vol 51: 911-918 (1996)

389. Van Laar, J.A.M., Rustum, Y.M., Van der Wilt, C.L., Smid, K., Kuiper, C.M., Pinedo H.M., Peters, G.J. Tumor size and origin determine atitumor activity of cisplatin of 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas, Cancer Chemother. Pharmacol., (1996).

390. Veerman, G., Ruiz van Haperen, V.W.T., Vermorken, J.B., Pinedo, H.M., Peters, G.J. Superior therapeutic acitivity of prolonged compared to bolus administration of 2',2'-difluorodeoxycytidine (gemcitabine) in vivo against murine colon tumors. Br.J. Cancer (1996)

391. Veerman, G., Ruiz van Haperen, V.W.T., Vermorken, J.B., Noordhuis, P., Braakhuis, B.J.M., Pinedo, H.M., Peters, G.J. Antitumor activity of prolonged as compared with bolus administration of 2',2'diflu -orodeoxycitidine in vivo against murine colon tumors, Cancer Chemother. Pharmacol.38 (4) 335-342 (1996).

1997392. Apolinario, R.M., Valk, P.J., Jong, J.S., Van Ark-Otte, J., Dingemans, A.M., Mourik, J.C. van,

Postmus, P.E., Pinedo, H.M., Giaccone, G. Prognostic value of the expression of p-53, Bcl-2 and Bax oncoproteins and neovascularization in patients with radically resected non-small cell lung cancer. J.Clin.Oncol. 15 (6): 246-266 (1997).

393. Broxterman, H.J., Lankelma, J., Pinedo, H.M., Eekman, C.A., Währer, D.C.R., Ossenkoppele, G.J., Schuurhuis, G.J. Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia, 11 (7): 1110-1118 (1997).

394. Broxterman, H.J., Schuurhuis, G.J., Lankelma, J., Oberink, J.W., Eekman, C., Claessen, A.M.E., Hoekman, K., Poot, M., Pinedo, H.M. Highly sensitive and specific detection of P- glycoprotein function for haematoological and solid tumour cells using a novel nucleic acid stain. Brit. J. of Cancer 76(8): 1029-1034 (1997).

395. Feller, N., Hoekman, K., Kuiper, C.M., Linn, S.C., Verheul, H.M.W., Wolthers, B.G., Popp-Snijders, C., Pinedo, H.M. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Clin. Cancer Res. 3 (3): 389-394 (1997).

396. Giaccone, G., Linn, S.C., Welink, J., Catimel, G., Stieltjes, H., Van der Vijgh, W.J.F., Eeltink, C., Vermorken, J.B., Pinedo, H.M. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3(11): 2005-2015 (1997).

397. Honkoop, A.H., Pinedo, H.M., de Jong, J.S., Verheul, H.M.W., Linn, S.C., Hoekman, K., Wagstaff, J., van Diest, P.J. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am. J.Clin.Path. 107 (2): 211-218 (1997).

398. Honkoop, A.H., Van der Wall, E., Fellers, N., Schuurhuis, G.J., Van der Vijgh, W.J.F., Boven, E., van Groeningen, C.J., Giaccone, G., Hoekman, K., Vermorken, J.B., Wagstaff, J., Pinedo, H.M. Multiple cycles of high-dose doxorubicin and cyclosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. Ann.Oncology 8: 1-6 (1997).

399. Hooijberg, J.H., Broxterman, H.J., Heijn, M., Fles, D.L.A., Lankelma, J., Pinedo, H.M. Modulation by (iso) favonoids of the ATPase activity of the multidrug resistance protein. FEBS Letters 413: 344-348 (1997).

400. Huizing, M.T., Giaccone, G., van Warmerdam, L.J.C., Rosing, H., Bakker, P.J.M., Vermorken, J.B., Postmus, P.E., Van Zandwijk, N., Koolen M.G.J., Huinink, W.W.T.B., Van der Vijgh, W.J.F., Bierhorst, F.J., Dalesio, O., Pinedo, H.M., Veenhof, C.H.N., Beijnen, J.H. Pharmacokinetics of paclitaxel and carboplatin dose-escalating and dose-sequencing study in non-small-cell lung cancer. J. Clin. Oncol. 15 (1) : 317-329 (1997).

401. Jansen, W.J.M., Zwart, B., Hulscher, S.T.M., Giaccone, G., Pinedo, H.M., Boven, E. CPT-11 in human colon cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int.J. Cancer, 70: 335-340 (1997).

402. Jansen, W.J.M., Kolfschoten, G.M., Erkelens, C.A.M., Van Ark-Otte, J., Pinedo, H.M., Boven, E. Antitumor activity of CPT-11 in experimental human ovarian cancer and soft tissue sarcoma. Int. J.Cancer, 73: 891-896 (1997).

403. Jansen, G., Mauritz, R., Assaraf, Y.G., Sprecher, H., Drori, S., Kathman, I., Westerhof. G.R., Priest, D.G., Bunni, M., Pinedo, H.M., Schornagel, J.H., Peters, G.J. Regulation of carrier mediated transport of folates and antifolates in methotrexate sensitive and resistant cell lines.

67

Advanc. Enzym Reg. 35: 59-76 (1997).404. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., Pries, D.G., Noordhuis,

P., Schornagel, J.H., Pinedo, H.M., Peters, G.J., Assaraf, Y.G. A novel mechanism of antifolate resistance based on increased RFC-mediated folic acit transport in human CCRF-CEM leukemia cells. J.Biol.Chem. (1997)

68

405. Kievit, E., Van Gog, F.B., Schluper, H.M.M., Van Dongen, G.A.M.S., Pinedo, H.M., Boven, E. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 1-131 or re-186 in human ovarian cancer xenografts. Int. J. of Rad. Oncol, Biology, Physics 38(4): 813- 823 (1997).

406. Kievit, E., Pinedo, H.M., Schluper, H.M.M., Boven, E. Addition of cisplatin improves efficacy of 1- 131-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int. J. of Rad. Oncol, Biol., Physics 38(2): 419-428 (1997).

407. Linn, S.C., Pinedo, H.M., Van Ark-Otte, J., Van der Valk, P., Hoekman, K., Honkoop, A.H., Vermorken J.B., Giaccone, G. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer, 71, 787-795 (1997).

408. Meijs, W.E., Haisma, H.J., Klok, R.P., Vangog, F.B., Kievit, E., Pinedo, H.M., Herscheid, J.D.M. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J.Nucl. Med. 38 (1): 112-118 (1997)

409. Pinedo, H.M., Hoekman, K., Feller, N., Broxterman, H.J. Proposed methology for evaluating the expression and function of multidrug resistance proteins in clinical tumor specimens. Anti-Cancer Drugs 7: 117-120 (1997).

410. Van der Wilt, C.L., van Groeningen, C.J., Pinedo, H.M., Smid, K., Hoekman, K., Meijer, S., Peters, G.J. 5-Flourouracil - Leucovorin induced inhibition of thymidylate synthase in normal tissues of mouse and man. J. Cancer Res. Clin. Oncol 123: 595-601 (1997).

411. Van Moorsel, C.J.A., Peters, G.J., Pinedo, H.M. Gemcitabine: future prospects of single-agent and combination studies. The Oncologist: 127-134 (1997)

412. Verheul, H.M.W., Hoekman, K., Luyckx-de Bakker, S., Eekman, C.A., Folman, C.C., Broxterman, H.J., Pinedo, H.M. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3 (12 part 1): 2187-2190 (1997)

1998413. Abrahams, P.J., Houweling, A., Cornelissen-Steijger, P.D.M., Jaspers, N.G.J., Darroudi, F.,

Meijers, C.M., Mullenders, L.H.F., Filon, R., Arwert, F., Pinedo, H.M., Natarajan, A.P.T., Terleth, C., Van Zeeland, A.A., Van der Eb, A.J. Impaired DNA repair capacity in skin fibroblasts from various hereditary cancerprone syndromes. Mutat. Res. 407: 189-201 (1998).

414. Boven, E., Pinedo, H.M., Van Hattum, A.H., Scheffer, P.G., Peters, W.H., Erkelens, C.A., Schluper, H.M., Kuiper, C.M., Van Ark-Otte, J., Giaccone, C. Characterization of human soft tissue sarcoma xenografts for use in secondary drug screening. Br. Journal of Cancer 78, 1586-1593, (1998)

415. Dingemans, A.M.C., Pinedo, H.M., Giaccone, G. Clinical resistance to topoisomerase-targeted drugs. Biochem. Biophys. Acta 1400: 275-288 (1998).

416. De Boer, F., Dräger, A.M., Van der Wall, E., Pinedo, H.M., Schuurhuis, G.J. Changes in L- selectin expression on CD 34-positive cells upon cryopreservation of peripheral blood stem cell transplants. Bone Marrow Transpl. 22 (11): 1103-1110 (1998).

417. Haisma, H.J., Brakenhoff, R.H., Van der Meulen-Muileman, I., Pinedo, H.M., Boven, E. Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human Beta-glucuronidase. Cancer Immunol. ther. 45(5): 266-272 (1998).

418. Honkoop, A.H., Van Diest, P.J., De Jong, J.S., Linn, S.C., Giaccone, G., Hoekman, K., Wagstaff, J., Pinedo, H.M. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breastcancer. Br. J. Cancer 77 (4): 621-626 (1998).

419. Honkoop, A.H., Wagstaff, J., Pinedo, H.M. Management of stage III Breast Cancer. Oncology: 55:218227 (1998).

420. Jansen, W.J.M., Hulscher, T.M., Van Ark-Otte, J., Giaccone, G., Pinedo, H.M., Boven, E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br. J.Cancer 77 (3), 359-365 (1998).

421. Haisma, H.J., Sernee, M.F., Brakenhof R.H., Van der Meulen-Muileman I.H., Pinedo, H.M., Boven, E. Construction and characterization of a fusion protein of single-chain anti CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood, 92(1): 184-190 (1998).

422. Houba, P.H., Boven, E., Erkelens, C.A., Leenders, R.G., Scheeren, J.W., Scheeren, J.W., Pinedo, H.M., Haisma, H.J. The efficiacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. Br.J.Cancer, 78: 1600-1606 (1998).

423. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M.A., Priest, D.G., Noordhuis, P., Schornagel, J.H., Pinedo, H.M., Peters, G.J., Assaraf, Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.J.Biol.Chem. 273: 30189-30198 (1998).

424. ievit, E., Van Gog F.B., Schluper, H.M., Van Dongen G.A., Pinedo, H.M., Boven, E. [186Re]-

69

labeled mouse and chimeric monoclonal antibody 323/A3: a comparision of the efficacy in experimental human ovarian cancer.Nucl.Med.Biol., 25(1): 37-45 (1998).

70

425. Mauritz, R., Bekkenk, M., Rots, M.G., Pieters, R., Mini, E., Veerman, A.J.P., Pinedo, H.M., Peters, G.J., Jansen, G. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia blast cells.Clin.Cancer Res.4: 2399- 2410 (1998).

426. Pinedo, H.M., Verheul, H.M.W., Folkman J. Involvement of platelets in tumor angiogenesis? Lancet, 352 (9142): 1775-1777 (1998).

427. Smitskamp-Wilms, E., Pinedo, H.M., Veerman, G., Ruiz van Haperen, V.W.T., Peters, G.J. Postconfluent multilayered cell line cultures for selective screening of Gemcitabine. Eur. J. Cancer, 34 (6): 921-926 (1998).

428. Van Ark-Otte, J., Kedde M.A., Van der Vijgh, W.J., Dingemans, A.M., Jansen, W.J., Pinedo, H.M., Boven, E., Giaccone, G. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br. J.Cancer, 77 (12): 2171-2176 (1998).

429. Van Ark-Otte, J., Samelis, G., Rubio, G., Saez, J.B.L., Pinedo, H.M., Giaccone, G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol. Rep.5(1): 249-255 (1998).

430. Verheul, H.M.W., Pinedo, H.M., Tumor growth: A putative role for platelets? The Oncologist 3(2):II (1998)

1999431. Bergman, A.M., Pinedo, H.M., Jongsma, A.P.M., Brouwer, M., Van Haperen, V.W.T.R., Veerman,

G., Leyva, A., Eriksson, S., Peters, G.J. Decreased resistance to gemcitabine (2’,2’-difluorodeoxycitidine) of cytosine arabinosideresistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase Bioch.Pharmacol. 57(4): 397- 406 (1999).

432. Broxterman, H.J., Sonneveld, P., Pieters, R., Lankelma, J., Eekman, C.A., Schoester, M., Ossenkoppele, G.J., Löwenberg, B., Pinedo, H.M., Schuurhuis, G.J., Do P-Glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia 13(2): 258-265 (1999)

433. Haisma, H.J., Pinedo, H.M., van Rijswijk, A., van der Meulen-Muileman, I., Sosnowski, B.A., Ying, W., van Beusechem, V.W., Tillman, B.W., Gerritsen, W.R., Curiel, D.T. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM Gene Therapy 6, 1469-1474 (1999)

434. Hoekman, K., van Doorn, J., Gloudemans, T., Masseen, J.A., Pinedo, H.M., Hypoglycaemia associated with the production of insulin-like growth factor II and insulin-like growth factor binding protein 6 by a haemangiopericytoma Clininal Endocrinology 51, 247-253 (1999)

435. Honkoop, A.H., Luykx-de Bakker, S.A., Hoekman, K., Meyer, S., Meyer, O.W., Van Groeningen, C.J., Van Diest, P.J., Boven, E., Van der Wall, E., Giaccone, G., Wagstaff, J., Pinedo, H.M., Prolonged neo-adjuvant chemotherapy with GM-CSF in locally advanced breast cancer. The Oncologist 4(2): 106-111 (1999).

436. Hooijberg J.H., Broxterman, H.J., Kool, M., Assaraf, Y.G., Peters, G.J., Noordhuis, P., Scheper R.J., Borst, P., Pinedo, H.M., Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 Cancer. Res. 1;59 (11):2532-2535 (1999)

437. Hooijberg, J.H., Broxterman, H.J., Scheffer, G.L., Vrasdonk, C., Heijn, M., De Jong, M.C., Scheper, R.J., Lankelma, J., Pinedo, H.M., Potent interaction of flavopiridol with MRP1. Br J Cancer 81 (2), 269-276 (1999)

438. Houba, P.H., Boven, E., Van der Meulen-Muileman, I.H., Leenders, R.G., Scheeren, J.W., Pinedo, H.M., Haisma, H.J. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts Biochem.Pharmacol. 15;57(6):673-680 (1999)

439. Jansen G., Peters, G.J., Pinedo, H.M., Priest, D.G., Assaraf, Y.G. Folypolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J. Nat. Cancer Inst. 59, 2047-2048 (1999)

440. Kroep, J.R., Giaccone, G., Voorn, D.A., Smit, E., Beijnen, J.H., Rosing, H., Van Moorsel, C.J.A., Van Groeningen, C.J., Postmus, P.E., Pinedo, H.M., Peters, G.J., Gemcitabine and paclitaxel; pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J. Clin. Oncol. 17; 2190-2197 (1999)

441. Kroep, J.R., Peters, G.J., Van Moorsel, C.J.A., Catik, A., Vermorken, J.B., Pinedo, H.M., Van Groeningen, C.J., Gemcitabine-cisplatin : a schedule finding study. Annals of Oncology 10, 1503-1510 (1999)

442. Kroep J.R., Pinedo, H.M., Van Groeningen, C.J., Peters, G.J. Experimental drugs and drug combinations in pancreatic cancer. Ann. Oncol.10:4, 234-238. (1999)

443. Lankelma, J., Dekker, H., Fernandez-Luque, R., Luykx, S., Hoekman, K., Van der Valk, P., Van Diest, P.J., Pinedo, H.M., Doxorubicin gradients in human breast cancer. Clinical Cancer Res. 5: 1703-1707 (1999)

71

444. Luykx-de Bakker, S.A., Verheul, H.M.W., De Gruijl, T.D., Pinedo, H.M., Prolonged neo-adjuvant treatment in locally advanced tumours: a novel concept based on biological considerations Ann. Oncology 10(2):155-160 (1999)

72

445. Peters, G.J., Smitskamp-Wilms, E., Smid, K., Pinedo, H.M., Jansen, G. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD 1694) and GW 1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res. 59, 5529- 5535 (1999).

446. Van Moorsel, C.J.A., Bergman, A.M., Veerman, G., Voorn, D.A., Ruiz van Haperen, V.W.T., Kroep, J.R., Pinedo, H.M., Peters, G.J., Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukemia cell lines. Biochim. Biophys. Acta. (1999)

447. Van Moorsel, C.J.A. Pinedo, H.M., Veerman, G., Vermorken, J.B., Postmus, P.E., Peters, G.J. Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice. Eur. J. Cancer 35; 808-814, (1999)

448. Van Moorsel, C.J.A., Pinedo, H.M., Veerman, G., Guechev, A., Smid, K., Loves, W.J.R., vermorken, J.B., Postmus, P.E., Peters, G.J. Combination chemotherapeutic studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Bioch. Pharmacol. 57 (4): 407-415 (1999).

449. Van Moorsel, C.J.A., Kroep, J.R., Pinedo, H.M., Veerman G., Voorn, D.A., Postmus, P.E., Vermorken, J.B., Van Groeningen, C.J., Van der Vijgh, W.J.F. , Peters, G.J. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors Ann. Oncol. 10 (4): 441-448 (1999)

450. Van Moorsel, C.J.A., Pinedo H.M., Veerman G., Bergman, A.M., Vermorken, J.B., Van der Vijgh, W.J.F., Peters, G.J., Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines Br.J.Cancer. 6:80 (7) : 981-990 (1999)

451. Tillman, B.W., De Gruijl, T.D., Luykx-de Bakker, S.A., Scheper, R.J., Pinedo, H.M., Curiel T.J., Gerritsen, W.R., Curiel D.T. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector J. Immunol. 1; 162 (11): 6378-6383 (1999)

452. Tolis, C., Peters, G.J., Ferreira, C.G., Pinedo, H.M., Giaccone, G., Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines Eur. J. Cancer 35; 796- 807, (1999)

453. Van der Vliet, H.J.J., Nishi, N., Koezuka, Y., Peyrat, M.A., Von Blomberg, B.M.E., Van den Eertwegh, A.J.M., Pinedo, H.M., Giaccone, C., Scheper, R.J. Effects of a-galactosylceramide (KRN7000), IL-2 and IL-7 on phenotype and cytokine profile of human Va24+V11+-T cells. Immunology. 98 (4); 557-563 (1999).

454. Van Triest, B., Pinedo, H.M., Hensbergen, Y., Smid, K., Telleman, F., Schoenmakers, P.S., Van der Wilt, C.L., Van Laar, J.A.M., Noordhuis, P., Janssen, G., Peters, G.J. Thymidylate synthase levels as main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors in 13 non-selected colon cancer cell lines Clin.Cancer Res. 5(3):643-654 (1999)

455. Verheul H.M.W., Panigrahy D., Flynn E., Pinedo H.M., D’Amato R.J. Treatment of the Kassabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival and tumor growth inhibition. Pediatric Res. 46(5): 562- 565. (1999)

456. Vermorken, J.B., Claessen, A.M.E., van Tinteren, H., Gall, H.E., Ezinga, R., Meijer, S., Scheper, R.J., Meijer, C.J.L.M., Bloemena, E., Ransom, J.H., Hanna jr, M.G., Pinedo, H.M. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 353: 345-350 (1999).

2000457. Baars, A., Claessen, A.M.E., Eertwegh, A.J.M. van den, Gall, H.E., Stam, A.G.M., Meijer, S.,

Giaccone G., Meijer, C.J.L.M., Scheper, R.J., Wagstaff, J., Vermorken, J.B., Pinedo, H.M. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann. Oncol. 11; 965-970 (2000).

458. Backus, H.H.J., Pinedo, H.M., Wouters, D., Kuiper, C.M., Jansen, G., Van Groeningen, C.J., Peters, G.J. Differences in the induction of DNA damage, cell cycle arrest and cell death by 5-fluorouracil and antifolates. Oncol. Research, 12; 231-239 (2000).

459. Backus, H.H.J., Wouters, D., Van der Wilt, C.L., Kuiper, C.M., Van Groeningen, C.J., Pinedo, H.M., Peters G.J. Thymidylate synthase inhibition induces p53 dependent and independent cell death. Adv Exp Med Biol 486:303-306 (2000)

460. Backus, H.H.J., Pinedo, H.M., Wouters, D., Padron, J.M., Molders, N., Van der Wilt, C.L., Van Groeningen, C.J., Jansen, G., Peters, G.J. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int. J. Cancer 87: 771-778 (2000)

461. Bergman, A.M., Giaccone, G., Van Moorsel, C.J.A., Mauritz, R., Noordhuis, P., Pinedo, H.M., Peters, G.J. Cross-resistance in the 2’, 2’-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.Eur. J. Cancer 36:1974-1983 (2000)

73

462. Boven, E., Van Hattum, A.H., Hoogsteen, I., Schluper, H.M.M., Pinedo, H.M. New analogues of camptothecins – Activity and resistance. Ann NY Acad SCI 922: 175-177 (2000)

74

463. Broxterman H.J., Sonneveld P., Van Putten W.J.L., Lankelma J., Eekman C.A., Ossenkoppele G.J., Pinedo H.M., Löwenberg B., Schuurhuis G.J. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/ cytosine arabinoside-based induction therapy. Leukemia 14, 1018-1024 (2000)

464. De Boer F., Drager A.M., van Haperen M.J.A.M., Pinedo H.M. The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilisation regimens. Br. J. Haematol. 111 (4): 1138-1144 (2000).

465. Ferreira,C.,Tolis,C.,Span,S.,Peters,G.J.,Kummer,A.J.,Pinedo,H.M.,Giaccone, C., Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signallingpathway. Clin. Canc. Res. 6: 203-212 (2000)

466. Giaccone,G.,Smit,E.F. Van Meerbeeck , J.P., Splinter, T., Golding, R.P., Pinedo,H.M., Laan, D., Van Tinteren, H., Postmus, P.E., Aphase I/II, study on gemcitabine and paclitaxel in advanced non-small cell lung cancer patients. Ann. Oncol 11: 109-112 (2000)

467. Haisma, H.J., Grill, J., Curiel, D.T., Hoogeland, S., Van Beusechem, V.W., Pinedo, H.M., Gerritsen, W.R. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer gene therapy 7: 901-904 (2000)

468. Haisma H., Beusechem V.W. van, Curiel D.T., Pinedo H.M., Gerritsen W.R. Targeted enzymes for molecular chemotherapy. Cancer Gene Ther. 7 (8) 21- (2000)

469. Heideman, D.A., Snijders, P.J., Craanen, M.E., Bloemena, E. Van Beusechem, V.W., Pinedo, H.M., Meijer, C.J., Meuwissen, S.G., Curiel, D.T., Haisma, H.J., Gerritsen, W.R. EpCAM is a marker for (pre)malignant lesions of the stomach, and a good target for specific gene transfer towards gastric carcinoma cells. Gastroenterology 118: 3849 (2000)

470. Hooijberg, J.H., Pinedo, H.M., Vrasdonk, C., Priebe, W., Lankelma, J., Broxterman, H.J.The effect of gluthathione on the ATPPase activity of MRP1 in its natural membranes. FEBS Letters 469, 47-51 (2000)

471. Kolfschoten, G.M., Pinedo, H.M., Scheffer, P.G., Schlüper, H.M.M., Erkelens, C.A.M., Boven, E. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol. Oncol. 76: 362 – 368 (2000).

472. Kolfschoten, G.M., Hulscher, T.M., Pinedo, H.M., Boven, E. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br. J.Cancer, 83, 921-927 (2000). .

473. Kroep, J.R., Giaccone, G., Tolis, C., Voorn, D.A., Loves, W. JP., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. Sequence dependent effect of paclitaxel on gemcitabine metabolism inrelation to cell cycle and cytotoxicity in non-small cell lung cancer cell lines. Br J Cancer 83; 1069 –1076 (2000)

474. Lankelma, J., Luque, R.F., Dekker, H., Schinkel, W., Pinedo, H.M. A Mathemetical model of drug transport in human breast cancer. Microvascular Res.59, 149-161 (2000)

475. Nishi, N., Van der Vliet, H.J.J., Koezuka, Y., Von Blomberg, B.M.E., Scheper, R.J., Pinedo, H.M., Giaccone, G., Human Va24+V11+-T cells expanded in vitro. Human Immunol. 61:357-365 (2000)

476. Peters, G.J., Van Triest, B., Backus, H.H.J.,Kuiper, C.M., Van der Wilt, C.L., Pinedo, H.M. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor Raltitrexed. Eur. J. Cancer 36; 916 – 924.(2000).

477. Peters G.J., De Bruin, M., Fukushima, M., Van Triest B., Hoekman, K., Pinedo, H.M., Ackland, S.P. Thymidine phosphorylase in angiogenesis and drug resistance – Homology with platelet- derived endothelial cell growth factor.Adv Exp Med Biol 486: 291-294 (2000)

478. Pinedo, H.M. Van den Eertwegh A.J.M. Aggressive combination therapy to cure patients with metastatic cancer. Lancet Oncology 1:72-73 (2000)

479. Pinedo, H.M. Gruijl, T.D., Wall, E. van der, Buter, J. Biological Concepts of Prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors. Oncologist 5; 496-500 (2000).

480. Pinedo, H.M., Buter, J. The hidden treasure of the primary tumor: Extended neoadjuvant chemotherapy plus GM-CSF in locally advanced cancer. Clin.Cancer Res. 5:497-500 (2000)

481. Van Beusechem, V.W., Van Rijswijk, A.L.C.T., Van Es, H.H.G., Haisma, H.J., Pinedo, H.M., Gerritsen, W.R. Recombinant adenovirus vectors with knobless fibres for targeted gene transfer. Gene Therapy 7: 1940-1946 (2000)

482. Van den Eertwegh, A.J.M., Pinedo, H.M. New Developments in Autologous Tumor Cell Vacination Therapy for Renal Cell Carcinoma. Current Oncology Reports 2000, 2

483. Van der Vliet H.J.J., Nishi N., De Gruijl T.D., Von Blomberg B.M.E., Van den Eertwegh A.J.M., Pinedo, H.M., Giaccone G., Scheper R.J. Human natural killer T cells acquire memory-activated phenotype before birth. Blood 95: 2440-2442 (2000)

484. Van der Wilt, C.L., Kroep, J.R., Bergman, A.M., Loves, W.J.P., Alvarez, E., Talianidis, I., Erikson, S., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. The role of deoxycytidine kinase in

75

gemcitabine cytotoxicity. Adv exp. Med. Biol. 486: 287-290 (2000).

76

485. Van Groeningen, C.J., Peters, G.J., Schornagel, J.H., Gall, H., Noordhuis, P., De Vries, M.J., Turner, S.L., Swart, M.S., Pinedo, H.M., Hanauske, A.R., Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J. Clin Oncol. 18:2772-2779 (2000)

486. Van Groeningen, C.J. van, Vijgh, W.J.F. van der, Baars, J.J., Stieltes, H., Huibregtse, K., Pinedo, H.M. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin.Cancer Res. 6; 1342-1346 (2000).

487. Van Hattum, A.H., Pinedo, H.M., Schlüper, H.M.M., Hausheer, F.H., Boven, E. The new highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J.Cancer 88, 260-266 (2000)

488. Van Moorsel, C.J.A., Pinedo, H.M., Smid, K., Comijn, E.M., Voorn, D.A., Veerman, G., Lakerveld, B., Van der Vijgh, W.J.F., Giaccone, G., Postmus, P.E., Peters, G.J. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur. J. Cancer 36; 2420 –2429 (2000).

489. Van Moorsel, C.J.A., Bergman, A.M., Veerman, G., Voorn, D.A., Ruiz van Haperen, V.W.T., Kroep, J.R., Pinedo, H.M., Peters, G.J., Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukemia cell lines. Biochim. Biophys. Acta. 1474: 5-12 (2000)

490. Van Riel J.M.G.H., Van Groeningen C.J., Albers H.M., Cazemier M., Meijer S., Bleichrodt R., Van den Berg F.G., Pinedo H.M., Giaccone G.Hepatic arterial 5-fluorouracil in patients with liver metastases of colectoral cancer: Single-centre experience in 145 patients. Annals. Oncol. 111: 1563-1570 (2000)

491. Van Riel J.M.G.H., van Groeningen C.J., Giaccone G., Pinedo H.M.Hepatic arterial chemotherapy for colorectal cancer metatstic to the liver.Oncology 59 (2); 89-97 (2000)

492. Van Triest, B., Pinedo, H.M., Blauwgeers, J.L.G., Van Diest, P.J., Schoenmakers, P.S., Voorn, D.A., Smid, K., Hoekman, K., Hoitsma, H.F.W., Peters, G.J., Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and profileration markers in colorectal cancer. Clin Cancer Res. 6, 1063-1072 (2000)

493. Van Triest, B., Pinedo, H.M., Giaccone, G., Peters, G.J. Downstream molecular determinants of response to 5-fluorouacil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385-391 (2000)

494. Van Triest, B., Loftus, B.M., Pinedo, H.M., Backus, H.H.J., Schoenmakers, P., Telleman, F., Tadema, T., Aherne, G.W., Van Groeningen, C.J. Zoetmulder, F.A.M., Taal, B.G., Johnston, P.G. Peters, G.J., Thymidylate syntase expression in patients with colorectal carcinoma using a polyclonal thymidylate syntase antibody in comparison to the TS106 monoclonal antibody. Journal of Histochem. Cytochem. 48: 755-760 (2000)

495. Verheul, H.M.W. Jorna, A.S., Hoekman, K., Lupu, F., Broxterman, H.J., Van der Valk, P, Kakkar, A.K., Pinedo, H.M.. Vascular endothelial factor stimulated endothelial cells promote adhesion and activation of platelets. Blood 96, 13, 4216-4221, (2000).

496. Verheul, H.M.W., Pinedo, H.M. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clinical Breast Cancer 1, suppl.1, S20-S27 (2000)

497. Verheul, H.M.W., Hoekman, K., Lupu, F., Broxterman, H.J., Van der Valk, P., Kakkar, A.K., Pinedo, H.M. Platelet and coagulation activation with vascular endothelial growth cancer factor generation in soft tissue sarcomas. Clin Cancer Res 6, 166-171 (2000)

2001498. Backus, H.H.J., Van Riel, J.M.G.H., Van Groeningen, C.J., Vos, W., Dukers, D.F., Bloemena, E.,

Wouters, D., Pinedo, H.M., Peters, G.J. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann. Oncol. 12 (6):779-785 (2001)

499. Backus, H.H.J., Dukers, D.F., Vos, W., Bloemena, E., Wouters, D., Van Riel, J.M.G.H., Smid, K., Meijer, S., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.Ann.Oncol 12; 209–216 (2001).

500. Bergman, A.M., Munch-Petersen, B., Jensen, P.B., Sehested, M., Veerman, G., Voorn, D.A., Pinedo,H.M., Peters, G.J. Collateral sensitivity to gemcitabine (2’,2’- difluorodeoxycytdine) and cytosine arabinoside of multidrug resistant variants of human small cell cancer cell lines. Biochem. Pharmacol., 61; 1401-1408 (2001)

501. Bergman, A.M., Pinedo, H.M., Peters, G.J. Steroids affect collateral sensitivity to gemcitabine of multidrug resistant human lung cancer cells. Eur.J.Pharmacol. 416; 19-24 (2001)

502. Bos, R., Zhong, H., Hanrahan, C.F., Mommers, E.C.M., Semenza, G.L., Pinedo, H.M., Abeloff, M.D., Simons, J.W., Van Diest, P.J., Van der Wall, E. Levels of HIF-1α during Breast Carcinogenesis. J Natl Cancer Inst 93 (4):309-314 (2001)

77

503. De Boer, F., Drager, A.M., Kessler, F.L., Ossenkoppele, G.J., Jonkhoff, A.J., Huijgens, P.C., Van der Wall, E., Pinedo, H.M., Schuurhuis, G.J. CD34 subpopulation marker analysis combined with early apoptosis assessment reveals that L-selectin may be an important derminant of platelet engraftment after autologous stem cell transplantation. Blood 98 (11): 765 Part 1 (2001)

504. Dumez, H., Giaccone, G., Yap, A., Barbier, N., Pfister, C., Cohen, P., Reese, S.F., Van Oosterom, A.T., Pinedo, H.M. Preliminary results of a phase 1 and pharmacokinetic study of LAF389 in patients with refractory solid tumors. Clinical cancer Research 7 (11): 2278, suppl. S (2001)

505. Duyndam,M.C.A.,Hulscher,T.M., Fontijn,D., Pinedo,H.M.,Boven,E. Induction of vascular Endothelial Growth Factor expression and Hypoxia-inducible Factor 1alpha protein by the oxidative stressor arsenite. J.Biol.Chem. 276 (51): 48066-48076 (2001)

506. De Graaf M., Van Veen I.C., Van der Meulen-Muileman I.H., Gerritsen W.R., Pinedo H.M., Haisma H.J.Cloning and Characterization of human liver cytosolic ß-glycosidase. Biochem J. 356:907-910 (2001).

507. De Gruijl T,D., Van Den Eertwegh A.J.M., Haisma H.J., Pinedo H.M.,Gerritsen W.R. Targeted adenoviral transduction and activation of cutaneous dendritic cells:studies in a human skin explant model. Cancer Gene Ther. 8 (9) (2001)

508. Ferreira, C.G., Van der Valk, P., Span, S.W., Ludwig, I., Smit, E.F., Kruyt, F.A.E., Pinedo, H.M., Van Tinteren, H., Giaccone, G. Expression on X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin. Cancer Res. 7 (8):2468-2474 (2001).

509. Grill, J., Van Beusechem, V.W., Van de Valk, P, Dirven, C.M.F., Leonhart, A., Pherai, D.S., Haisma, H.J.,Pinedo, H.M., Curiel, D.T., Gerritsen, W.R. Combined targeting of adenoviruses to integrins and EGFR increases gene transfer into primary glioma cells en spheroids. Clin. Cancer Res. 7 (3):641-650 (2001)

510. Hanna, M.G., Jr., Hoover, H.C., Vermorken, J.B., Harris, J.E., Pinedo, H.M. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19 (17-19): 2576-2582 (2001).

511. Heideman, D.A.M., Snijders, P.J.F., Craanen, M.E., Bloemena, E., Meijer, C.J.L.M., Meuwissen, S.G.M., Van Beusechem, V.W., Pinedo, H.M., Curiel, D.T., Haisma, H.J., Gerritsen, W.R. Targeting of adenoviral vectors towards gastric and esophageal adenocarcinooma cells. Gastroentrology 12-(5): 3119, Suppl 1 (2001)

512. Heideman, D.A.M., Snijders, P.J.F., Craanen, M.E., Bloemena, E., Meijer, C.J.L.M., Meuwissen, S.G.M., Van Beusechem, V.W., Pinedo, H.M., Curiel, D.T., Haisma, H.J., Gerritsen, W.R. Selective gene delivery towards gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy 8 (5):342-351 (2001)

513. Houba, P.H.J., Boven, E., Van der Meulen-Muileman, I.H., Leenders, R.G.G., Scheeren, J.W., Pinedo,H.M., Haisma, H.J. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumor-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br. J. Cancer 84: 550-557 (2001).

514. Houba, P.H.J. Boven, E., Van der Meulen-Muileman, I.H., Leenders, R.G.G., Scheeren, J.W., Pinedo, H.M., Haisma, H.J. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal anitbody ß-glucuronidase conjugate. Int. J. Cancer 2001; 91: 550 – 554 (2001).

515. Van Beusechem, V.W., Grill, J., Mastenbroek, D.C.J., Haisma, H.J., Wickham, T.J., Roelvink, P.W., Pinedo, H.M., Gerritsen, W.R. Highly specific adenovirus vectors for targeted cancer gene therapy. Cancer Gene Therapy 8 (9): 16 (2001)

516. Van der Vliet,H.J.J., Von Blomberg, B.M.E. Nishi, N. Reijm, M., Voskuyl, A.E., Van Bodegraven, A.A, Polman, C.H., Rustemeyer,T., Lips, P., Van den Eertwegh, A.J.M., Giaccone, G., Scheper, R.J., Pinedo, H.M., Circulating Vα24+ natural killer T cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin.Immunol. 2; 144-148 (2001).

517. Van der Vliet, H.H.J., Nishi, N., Koezuka, Y., Van Blomberg, B.M.E., Van den Eertwegh, A.J.M., Porcelli, S.A., Pinedo, H.M., Scheper, R.J., Giaccone, G,. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J. of Immunol. Methods 247(1-2): 61-72 Jan (2001)

518. Van Hensbergen, Y., Luykx-de Bakker, S.A., Heideman, D.A.M., Pinedo, H.M., Van Diest, P.J. Rapid stereology based quantitative immunohistochemistry of dendritic cells in lymph nodes: a methodological study. Anal Cell Pathol 22(3): 143-9 (2001).

78

2002519. Baars, A, Van Riel, J.M.G.H., Cuesta, M.A., Jaspars, E.H., Pinedo, H.M., Van den Eertwegh, A.J.M.

Metastectomy and active specific immunotherapy for a large single melanoma metastasis. Hepatogastroenterology. 49 (45):691-693 (2002).

520. Baars, A., Claessen A.M., Wagstaff, J., Giaccone, G., Scheper, R.J., Meijer, S., Schakel, M.J., Gall, H.E., Meijer, C.J., Vermorken, J.B., Pinedo, H.M., Van den Eertwegh, A.J. A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br.J.Cancer. 22;86(8):1230-1234 (2002)

521. Backus, H.J.J., Van Groeningen, C.J., Vos, W., Dukers, D.F., Bloemena, E., Wouters, D., Pinedo, H.M., Peters, G.J. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J.Clin.Pathol. (55): 206-211 (2002).

522. Backus, H.H.J., Pinedo, H.M. Wouters, D., Koudijs, M., Ferreira, C.G.,Peters, G.J. Role of P53 status on sensitivity to Thymidylate synthase inhibitors and induction of apoptosis.Chemistry and Biology of Pteridines and Folates (proc.12th Intern Symp;Eds.S.Milstein,G.Kapatos,R.A.Levine,B.Shane)Kluwer Academis Publishers,Boston,USA pp.433-437, 2002

523. Bergman, A.M., Pinedo H.M., Peters G.J. Determinants of resistance tot 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 5(1):19-33 (2002)

524. Bodar, E., Buter, J., De Gruijl, T.D., Van der Wall, E.W.A., Pinedo, H.M., Immunologic and biologic properties of the primary tumor during prolonged neoadjuvant chemoimmunotherapy. Oncology-NY 16 (1): 32-39 suppl.1 (2002)

525. Boven, E., Verschraagen, M., Hulscher, T.M., Erkelens, C.A.M., Hausheer, F.H., Pinedo, H.M., Van der Vijgh, W.J.F. BNP7787, a novel protector against platinum-related toxities, does nit affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur.J.Cancer . 38 (8): 1148-56 (2002)

526. Codacci-Pisanelli, G., Van der Wilt, C.L., Smid, K., Noordhuis, P., Voorn, D. , Pinedo, H.M., Peters, G.J. High-dose 5-fluorouacil with uridine-disphoglucose rescue increases thymidylate synthase inhibition but no 5-fluorouracil incorporation into RNA in murine tumors. Oncology ;62(4):363-370.(2002)

527. De Boer, F., Dräger, A.M., Pinedo, H.M., Kessler, F.L., Van der Wall, E., Jonkhoff, A.R., Van der Lelie, J., Huijgens, P.C., Ossenkoppele, G.J., Schuurhuis, G.J. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decrease threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 29, 249-255 (2002).

528. De Boer, F., Kessler, F.L., Netelenbos, T., Zweegman, S., Huijgens, P.C., van der Wall, E., van der Linden, J.A., Pinedo, H.M., Schuurhuis, G.J., Dräger, A.M. Homing and clonogenic outgrowth of CD34(+)peripheral blood stem cells: a role for L-selectin?. Exp.Hematol. 30(6): 590-597 (2002).

529. De Boer, F., Dräger, A.M., Pinedo, H.M., Kessler, F., Monnee-van Meijen, M., Van der Wall, E., Netelenbos,T., Oberink, J.W., Huijgens, P.C., Schuurhuis, G.J. Early apoptosis largely accounts for functional impairment of CD34 positive cells in frozen-thawed stem cell grafts. J .Hematother.Stem Cell Res 11 (6):951-63 (2002)

530. De Graaf, M., Veen, I.C. van, Meulen-Muileman, I.H., Oosterhoff, D.,Gerritsen, W.R., Haisma,H.J.,Pinedo, H.M., A fully human anti-EP-CAM SCFV-beta glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br. J.Cancer 86, 811-818 (2002)

531. De Graaf, M., Boven, E., Scheeren, H.W., Haisma, H.J., Pinedo, H.M. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 8(15):1391-13403 (2002).

532. De Graaf, M., van der Meulen-Muileman, I.H., Pinedo,H.M., Haisma, H.J. Expression of scFvs and scFv fusion proteins in eukaryotic cells. Methods Mol Biol. 178:379-387 (2002).

533. De Groot, F.M.H., Broxterman, H.J., Adams, H.P.H.M., Van Vliet, A., Tesser, G.I., Elderkamp, Y.W., Schraa, A.J., Kok, R.J., Molema, G., Pinedo, H.M., Scheeren, H.W. Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasman-cleavalbe Doxorubicin Prodrug. Mol.Cancer Ther. 1: 901-911 (2002)

534. De Gruijl, T.D., Luykx-de Bakker, S.A., Tillman, B.W., Van den Eertwegh, A.J.M., Buter, J., Lougheed, S.M., Van der Bij, G.J., Mahmoud Safer, A., Haisma, H.J., Curiel, D.T., Scheper, R.J., Pinedo, H.M., Gerritsen, W.R. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J.Immunol. 1:169(9):5322-31(2002)

535. De Lange, S.M., Van Groeningen, C.J., Meijer, O.W.M., Cuesta, M.A., Langendijk, J.A., Van Riel,J.M.G.H., Pinedo, H.M., Peters, G.J., Meijer, S., Slotman, B.J., Giaccone, G. Gemcitabine Radiotherapy in patients with Locally Advanced Pancreatic Cancer. Eur J Cancer .38(9):1212-1217 (2002)

536. Dirven, C.M., Grill, J., Lamfers, M.L., Van der Valk, P., Leonhart, A.M., Van Beusechem, V.W., Haisma H.J., Pinedo, H.M., Curiel, D.T., Vandertop, W.P., Gerritsen, W.R. Gene therapy for meningioma : improved gene delivery with targeted adenoviruses. J. Neurosurg. 97(2) :441-449 (2002).

79

537. Duyndam, M.C.A., Hilhorst, M.C.G.W., Schlüper, H.M.M., Verheul, H.M.W., Kraal, G., Pinedo, H.M., Boven, E. VEGF165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am.J.Pathol. 160:537-548. (2002)

538. Duyndam, M.C.A. ,Hulscher S.T.,Van der Wall E., Pinedo H.M., Boven, E. Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite. J Biol Chem. Dec 13 (2002).

539. Giaccone, G., Punt, C.J.A., Ando, Y., Ruijter, R., Nishi, N., Peters, M., Von Blomberg, B.M.E., Scheper, R.J., Van der Vliet, H.J.J., Van den Eertwegh, A.J.M., Roelvink, M., Beijnen, J., Zwierzina, H., Pinedo, H.M. A phase I study of the NKT cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin.Cancer Res. 8(12):3702-9, (2002)

540. Grill, J., Lamfers, M. L.M., Van Beusechem V.W., Dirven, C.M., Pherai, D.S., Kater, G.M., Van der Valk, P., Vogels, R., Vandertop W.P., Pinedo H.M., Curiel D.T., Gerritsen W.R. The Organotypic Multicellar Sheroid is a Relevant Three-Dimensional Model to Study Adenovirus Replication and Penetration in Human Tumors in vitro Mol Ther. 6 (5);609-14 (2002)

541. Heideman, D.A.M., van Beusechem, V.W., Offerhaus, G.J.A., Wickham Th.J., Roelvink, P.W., Craanen, M.E., Pinedo, H.M., Meijer, C.J.L.M., Gerritsen W.R. Selective Gene transfer into primary human gastric tumors using epithelial cell adhesion molecule targeted adenoviral vectors with ablated native tropism. Human Gene Therapy 13: 1677-1685 (2002)

542. Kolfschoten, G.M., Hulscher, T.M., Duyndam, M.C.A., Pinedo, H.M., Boven, E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to cisplatin. Biochem.Pharmacol. 63, 733-743 (2002)

543. Kolfschoten, G.M., Hulscher, T.M., Schrier, S.M., Van Houten, V.M.M., Pinedo, H.M., Boven, E. Time dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol.Oncol. 84 (3): 404-412 (2002)

544. Kroep, J.R., Loves, W.J.P., Van der Wilt, C.L., Alvarez, E., Talianidis, I., Boven, E., Braakhuis, B.J.M., Van Groeningen, C.J., Pinedo, H.M., Peters, G.J. Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity. Mol.Cancer Ther. 1: 371-376 (2002)

545. Kuenen B.C.,Rosen L.Smit E.F., Parson M.R.N.,Ruyter R.Huisman H.Kedde M.A.,Noordhuis.P., Van der Vijgh W.J.F., Peters G.J., Cropp G.F., Scigalla, P.,Pinedo,H.M., Giaccone,G. Dose finding and pharmacokinetic study of cisplatin, gemcitabineand SU5416 in patients with solid tumors. J.Clin.Oncol. 20 (6):1657-1667 (2002).

546. Kuenen B.C., Levi M., Meijers J.C.M., Kakkar A.K., Van Hinsbergh V.W.M., Kostense P.J., Pinedo, H.M., Hoekman K. Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients. Arterioscler.Thromb.Vas.Biol. 22: 1500-1505 (2002).

547. Lamfers, M.L.M., Grill, J., Dirven, C.M.F., Van Beusechem, V.W., Geoerger, B., Van den Berg, J., Alemany, R., Fueyo, J., Curiel, D.T., Vassal, G., Pinedo, H.M., Vandertop, W.P., Gerritsen, W.R. Potential of the conditionally replicative adenovirus Ad5-∆24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 62(20):5736-42 (2002)

548. Madhusudan, S., Baselga, J., Conte, P.F., Pinedo, H.M., Braybrooke, J.P., Harris, A.L. A multicentre phase II study of SU5416, a tyrosine kinase inhibitor, in locally advanced or metastatic melanoma. Br J Cancer 86 (suppl. 1) (2002).

549. Masterson, A.J., Sombroek, C.C., de Gruijl, T.D., Graus, Y.M.F., van der Vliet, H.J.J., Lougheed, S.M., Van den Eertwegh A.J.M., Pinedo, H.M., Scheper R.J. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors.Blood 15 (100): 701-703 (2002)

550. Mauritz, R., Peters, G.J., Priest, D.G., Assaraf, Y.G., Drori, S., Kathmann, I., Noordhuis, P., Bunni, M. A., Rosowsky, A., Schornagel, J.H., Pinedo, H.M., Jansen, G. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem.Parmacol 63 (2): 105-115 (2002)

551. Nanayakkara, P.W.B, van Doorn, J., van den Berg, F.G., van Groeningen, C.J., Pinedo, H.M., Hoekman, K. Treatment of haemangiopericytoma-associated hypoglycaemia with embolisation. Eur J. intern Med. 13 (5): 340-343 (2002).

552. Noorda E.M., Vrouenraets B.C., Nieweg O.E., Pinedo H.M., Kroon B.B. Isolated limb perfusion with melphalan for femoral metastases of breast cancer: case report. J Surg Oncol 2002 Dec:8 1(4):209-212

553. Oosterhoff, D., Pinedo, H.M., Van der Meulen, I.H., De Graaf, M., Sone, T., Kruyt, F.A., Van Beusechem, V.W., Haisma, H.J., Gerritsen, W.R. Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Br.J.of Cancer (87): 659-664. (2002)

80

554. Peters, G.J. Backus, H.H.J., Dukers, D.F., Van Groeningen, C.J., Voss, W., Bloemena, E., Wouters, D., Van Riell, J.M.G.H., Smid, K.. Pinedo, H.M. 5- Fluorouracil induced Fas and Apoptosis in liver metastases of colorectal cancer patientsss; relation of clinical outcome with thymidylate synthase, Mcl-I and Rb expression. Chemistry and Biology of Pteridines and Folates (proc.12th Intern Symp; Eds.S.Milstein,G.Kapatos,R.A.Levine,B.Shane)Kluwer Academis Publishers,Boston,USA pp.461-466, 2002.

555. Peters, G.J., Backus, H.H., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C.L., Smid, K., Lunec, J., Calvert, A.H., Marsh, S., McLeod, H.L. Bloemena, E., Meijer, S., Jansen, G., van Groeningen C.J., Pinedo, H.M. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim.Biophys Acta. 18:1587(2-3):194-205 (2002).

556. Sombroek, C.C., Stam, A.G.M., Masterson, A.J., Lougheed, S.M., Schakel, M.J.A.G.,Meijer, C.J.L.M.,Pinedo, H.M., Van den Eertwegh, A.J.M., Scheper, R.J., De Gruijl, T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dentritic cell differentiation. J.Immunol 168(9):4333-4343 (2002)

557. Van Beusechem,V.W., Grill,J., Mastenbroek, J.,Wickham,T.J., Roelvink,P.W., Hausma, H.J., Lamfers, M.L.M.,Dirven,C.M.F., Pinedo,H.M. Efficient and selective gene transfer into primary human brain tumors using single-chain antibodytargeted adenoviral vectors with ablated native tropism. J. Virology 76 2753-2762 (2002)

558. Van Beusechem, V.W., Van den Doel, P.B., Grill, J., Pinedo, H.M., Gerritsen, W.R. A conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 62,6165-6171 (2002)

559. Van Hattum, A.H., Schlüper H.M.M., Hausheer, F.H., Pinedo, H.M., Boven, E. The Novel Camptothecin Derivative BNP1350 in experimental Human Ovarian Cancer: Determination of efficacy and possible mechanisms of resistance. Int.J.Cancer 1;100(1):22-29. (2002)

560. Van Hattum, A.H., Pinedo, H.M., Schlüper, H.M.M., Erkelens, C.A.M, Tohgo, A., Boven, E. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem.Pharmacol. (64): 1267-1277.

561. Van Hattum, A.H., Hoogsteen I.J., Schlüper, H.M.M., Maliepaard, M., Scheffer, G.L., Scheper, R.J., Kohlhagen, G., Pommier, Y., Pinedo, H.M., Boven, E. Induction of breast cancer resistance protein by the camptothecin derivative DX-895f is associated with minor reduction of antitumour activity. Br.J.Cancer (87): 665-672.

562. Van Hensbergen,Y., Broxterman H.J., Elderkamp Y., Lankelma,J., Beers, J.C.C.,Heijn, M., Boven, E., Hoekman, K., Pinedo,H.M., Doxorubicin-CNGRC-peptide conjugate with doxorubicin prodrug properties.Biochem. Pharmacol. 63: 897-908 (2002)

563. Van Hensbergen, Y., Broxterman, H.J., Hanemaaijer, R., Jorna, A.S., Van Lent, N.A., Verheul, H.M.W., Pinedo, H.M., Hoekman, K. Soluble aminopeptidase N/CD13 in malignant and non-malignant effusions and intra-tumoral fluid. Clin.Cancer Res. 8: 3747-3754 (2002)

564. Van Riel J.M.G.H., van Groeningen, C.J., Kedde M.A., Gall, H., Leisink, J.M.A., Gruia,G., Pinedo, H.M., Van der Vijgh, W.J.F., Giaccone G. Continuous administration of irinotecan by hepatic arterial infusion: a phase 1 and pharmacokinetic study. Clin. Cancer Res. 8 (2): 405-412 (2002)

565. Van der Vliet H.J.J., von Blomberg B.M.E.,Hazenberg M.D.,Nishi N., Otto S.A., van Benthem B.H.,Prins M.,Claessen F.A.,van den Eertwegh A.J.M.,Giaccone G., Miedema F., Scheper R.J., Pinedo H.M. Selective decrease in circulating Vα11+natural killer T cells during HIV-1 infection. J.Immunol. 168 (3): 1490-1495 (2002).

566. Van der Vliet, H.J.J., Pinedo, H.M., Von Blomberg, B.M.E., Van den Eertwegh, A.J.M., Scheper, R.J., Giaccone, G. Natural Killer T cells. Lancet Oncology (3): 574 (2002)

567. Witlox, M.A., Van Beusechem, V.W., Grill, J., Haisma, H.J., Schaap, G., Bras, J. Van Diest, P. De Gast, A., Curiel, D.T., Pinedo, H.M., Gerritsen, W.R., Wuisman, P.I. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med, 5: 510-516 (2002)

2003568. Baars, A., Buter, J., Pinedo, H.M. Making use of the primary tumour. BioEssays 2003;25:79-86569. Backus, H.J.J., Wouters, D., Ferreira, C.G., Van Houten, V.M.M., Brakenhoff, R., Pinedo, H.M.,

Peters, G.J. Thymidylate synthase inhibition triggers apoptosis via caspase-8 and –9 in both wild-type and mutan p53 colon cancer cell lines. Eur.J.Cancer 39 (2003) 1310-1317

570. Bergman, A.M., Pinedo, H.M., Talianidis, I., Veerman, G., Loves, W.J.P., Van der Wilt, C.L., Peters, G.J. Increased sensitivity to gemcitabine of P-glycoprotein and multi-drug resistance associated protein overexpressing human cancer cell lines. Br.J.Cancer 88, 1963-1970 (2003)

571. Bos, R., Van der Groep, P. Greijer, A.E., Shvarts, A., Meijer, S., Pinedo, H.M., Semenza, G.L., Van Diest, P.J., Van der Wall, E. Levels of Hypoxia-Inducible Factor-1α Independently Predict Prognosis in Lymph Node-Negative Breast Cancer Carincoma. Cancer 97 (6): 1573-1581 (2003).

81

572. Bos, R., Van Diest, P.J., Van der Groep P., Greijer, A.E., Hermsen, M.A.J.A., Heijnen, I., Meijer, G.A. Baak, J.P.A., Pinedo H.M., Van der Wall, E.,, Shvarts, A. Protein expression of B-cell lymphoma gene (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1x (HIF—1x.),. Oncogene 4:22(55):8948-51 (2003)

573. Brandao, J.G., Scheper, R.J., Lougheed, S.M., Curiel, D.T., Tillman, B.W., Gerritsen, W.R., Van den Eertwegh, A.J.M., Pinedo, H.M., Haisma, H.J., De Gruijll, T.D. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 22;21 (19-20):2268-72 (2003)

574. Braybrooke J.P., Boven, E., Bates, N.P., Ruijter, R., Dobbs, N., Cherverton, P.D., Pinedo, H.M. Talbot D.C. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, examesylate (DX-8951f), using a weekly 30-minute intravenouw infusion, patients with advanced solid malignancies. Ann Oncol. 14;(6):913-921. (2003)

575. De Bruin M., Van Capel T., Van der Born K., Kruyt F.A., Fukushima M., Hoekman K., Pinedo H.M., Peters G.J. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensivity. Br J Cancer 88 (6):957-864 (2003).

576. De Bruin M., Smid K., Laan A.C., Noordhuis P., Fukusima M., Hoekman K., Pinedo H.M.,Peter G.J. Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorlyse overexpressing cells. Biochem Biophys Res Comm. 2003 Fen 14;301(3):675-9

577. De Graaf, M., Pinedo, H.M., Quadir, R., Haisma, H.J., Boven, E. Cytosolic β-glycosidases for activation of glycoside prodrugs of daunorubicin. Biochem.Pharm. 65: 17875-1881 (2003)

578. Duyndam M.C., Hulscher S.T., Van der Wall E., Pinedo H.M., Boven E. Evidence for a Role of p38 Kinase in Hypoxia-inducible Factor 1- independent Induction of Vascular Endothelial Growth Factor Expression by Sodium Arsenite. J Biol Chem 28:278(9):6885-95 (2003)

579. Kakkar, A.K., Levine, M., Pinedo H.M., Wolff, R., Wong, J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. The Oncologist, 8 (4), 381-388 (2003).

580. Kroep, J.R., Van Groeningen, C.J., Cuesta, M.A., Craanen, M.E., Hoekstra, O.S., Comans, E.F., Bloemena, E., Hoekstra, C.J., Golding, R.P., Twisk, J.W., Peters, G.J., Pinedo, H.M., Lammertsma, A.A. Positron emission tomography using 2-deoxy-2 [18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol.Imaging Biol. 5 (5), 337-346 (2003).

581. Kuenen, B.C. Levi,M., Meijers, J.C.M., Van Hinsbergh, V.W.M., Berkhof J., Kakkar, A.K. Giaccone, G., Hoekman, K. Pinedo H.M. Potential Role of Platelets in Endothelal Damage Observed During Treatment With Cisplatin, Gemcitabine and the Angiogenesis Inhibitor SU5416. J. Clin.Oncol 1;21(11):2192-8 (2003)

582. Lankelma, J., Fernandez-Luque, R., Dekker, H., Pinedo H.M. Simulation model of doxorubicin activity in islets of human breast cancer cells. Journal BBA 1622; 169-178 (2003)

583. Noorda,E.M.,Vrouenraets,B.C.,Nieweg,O.E.,Pinedo,H.M.,Kroon,B.B. Isolated limb perfusion with melphalan for femoral metastases of breast cancer:case report. J.Surg.Oncol.81:209-212 (2003)

584. D., Witlox., M.A., Van Beusechem, V.W. Haisma.H.J., Schaap, G.R., Bras.J., Kruyt, F.A.E., Molenaar, B. Boven, E., Wuisman,P.I.J.M. Pinedo, H.M., Gerritsen, W.R.,Gene-Directed Enzyme Produg Therapy for Osteosarcoma:Sensitization to CPT-11 in vitro and in vivo by Adenoviral Mediated Expression of a Gene Encoding Secreted Carboxylesterase–2. Mol.Can.Ther. vol. 2; 765-771 (2003)

585. Peters, G.J., Noordhuis, P. Van Kuilenburg, A.B.P., Schornagel, J.H. Gall, H., Turner, S.L., Swart, M.S., Voorn, D., Van Geenip, A.H., Wanders, J., Holwerda U., Smid, K., Pinedo, H.M., Giaccone, G., Fumoleaau, P., Van Groeningen, C.J. Pharmacokineticss of S-1, an oral formulation off Ftoraffur,, oxonic acid and 5-chloro-2,44-dihhydroxypyridine in patientss with solid tumors. Cancer Chemo.Pharmacol. 52 (1) 1-12 (2003)

586. Pinedo, H.M., Buter, J., Luykx-de Bakker, S.A., Pohlmann, P.R., Van Hensbergen, Y., Heideman, D.A.M., Van Diest, P.J., De Gruijll, T.D., Van der Wall, E. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: Effect on tumour-draining lymph node dendritic cells. Eur.J.Cancer 39(8):1061-7 (2003)

587. Stam, A.G.M., Santegoets, S.J.A.M., Westers, T.M., Sommbroek, C., Janssen, J.W.M., Tillman, B.W., Van de Loosdrecht, A., Pinedo, H.M., Curiel, D.T., Ossenkoppele, G.J., Scheper, R.J., De Gruijl, T.D. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human Chronic Myeloid Leukemia-derived dendritic cells upon cytokine deprivation. Br. J.Cancer: oct 6;89(7)1162-5(2003)

588. Van Beusechem, V.W., Mastenbroek, D.C.J., Van den Doel, P.B., Lamfers M.L.M., Grill, J., Würdinger, T., Haisma, H.J., Pinedo, H.M., Gerritsen, W.R. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gen Ther. 10, 1982-1911 (2003)

82

589. Van Moorsel, C.J.A., Voorn, D.A., Smid, K., Bergman A.M., Pinedo, H.M., Peters, G.J., Effects of gemcitabine cisplatinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int J Oncol.;22 (1):201-7 (2003)

590. Van der Vliet H.J.J., Molling, J.W., Nishi, N., Masterson, A.J., Kölgen ,W., Porcelli, S.A., Van den Eertwegh, A.J.M., Von Blomberg, M.E., Pinedo, H.M., Giaccone, G., Scheper, R.J. Polarization of V α24 + Vß11 + NKT cells of healthy volunteers and career patients using α -galactosylceramide-loaded and encironmentally instructed dendritic cells. Cancer Res. 63, 4101-4106 (2003)

591. Verheul, H.M.W., Pinedo, H.M. The importance of platelet counts and their contents in cancer. Clin.Cancer.Res. 9 (9), 3219-3221 (2003)

2004592. De Bruin M., Van Capel T., Smid K., Fukushima M., Hoekman K., Pinedo H.M., Peters G.J. The

effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor in expression of thymidine phosphorylase. Eur.J.Pharm. 391:93-99 (2004)

593. De Bruin M., Peters, G.J., Oerlemans, R., Assaraf, Y.G., Masterson, A.J., Adema, A.D. Dijkman, B.A.C., Pinedo, H.M.,Jansen G. Sulphasalazine down-regulates the expression of the angiogenic factors platelet derived endothelial cell growth factor / thymidine phosphorylase and interleukin 8 in human monocytic-macrophage THP-1 and U937 cells. Molecular Pharmacol. July (2004)

594. De Bruin M., Van Capel T., Smid K.,Van der Born K., Kruyt F.A., Fukushima M., Hoekman K., Pinedo H.M., Peters G.J. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensivity and potential role of deoxyribose-1-phosphate. Nucleosides,Nucleotides&Nucleic Acids. Volume 23, nr 8-9 – 1485-1490 (2004)

595. De Bruin M., Smid K., Van der Ent M.A., Fukushima M., Pinedo H.M., Peters G.J. Upregulation of Platelet derived endothelial cell growth factor/thymidine phosphorylase by interferon alfa. Nucleosides,Nucleotides&Nucleic Acids. Volume 23, nr 8-9 – 1367-1370 (2004)

596. De Graaf M, Nevalainen, T.J., Scheeren, H.W., Pinedo, H.M., Haisma, H.J., Boven, E. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor selective chemotherapy. Biochem Pharma 1;68 (11):2273-81 (2004)

597. De Graaf, M., Pinedo, H.M., Oosterhoff, D., Van der Meulen-Muileman, I.H.., Gerritsen, W.R., Haisma, H.J. Boven, E. Pronounced antitumor efficacy by extracellular activation off a doxorubicin-glucoronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. Human Gene Ther. 15:299-238 (2004)

598. De Lange, S.M., Van Groeningen, C.J., Kroep, J.R., Van Bochove, A., Snijders, J.F., Peters, G.J., Pinedo, H.M., Giaccone, G. Phase II trial of cisplatin and gemcitabine in patients with advanced gas cancer. Ann.Oncol 15(3): 484-4 (2004)

599. Hansma, A.H, Van Hensbergen Y., Kuenen, B.C., Van Dienst, P.J., Hanemaijer, R., Meijer, S., Pinedo, H.M., Hoekman, K. A patient with a VEGF and endostatin producing gastrointestinal autonominerve tumor. J Clin Pathol. May;57(5):536-8 (2004)

600. Hoekman, K., Pinedo, H.M. Angiogenesis: a potential target for therapy of soft tissue sarcomas. Cancer Treat.Res. 120: 169080 (2004)

601. Kroep, J., Pinedo, H.M. Giaccone, G., Van Bochove, A., Peters, G.J., Van Groeningen, C.J., Phase II study of Cisplatin preceding gemcitabine in patients with advanced esophagel cancer. Ann. Oncol. 15(2):230-5 (2004)

602. Mauritz R., Beumer I.J., Marsh S., McLeod H.L., Smid K., Van Groeningen C.J., Pinedo H.M., Peters G.J. Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides,Nucleotides&Nucleic Acids. Volume 23, nr 8-9 – 1381-1384 (2004)

603. Noordhuis, P., Holwerda, U., Van der Wilt, C.L., Van Groeningen, C.J., Smid, K., Meijer, S., Pinedo, H.M., Peters, G.J. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 15: 1025-1032 (2004)

604. Pohlmann,P.R, Suchil Bernal, L., Fuentes Alburo, A., Buter, J., Gallardo Rincon, D., Mohar, A., Mayordomo,J.I., Van der Hoeven, J.M., Vander Wall, E., De Gruijl, T.D., Pinedo, H.M. Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts. Rev.Oncol;6(3); (2004)

605. Van der Hoeven, J.J.M., Krak, N.C., Hoekstra, O.S., Comans, E.F.I., Boom, R.P.A., Van Geldere, D., Meijer, S., Van der Wall, E., Buter, J., Pinedo, H.M., Teule, G.J.J., Lammertsma, A.A. FDG Pet in staging of locally advanced breast cancer. J Clin Oncol Aprl 1:22(7):1253-9 (2004)

606. Van der Vliet, H. J.J., Molling J.W., Von Blomberg M.E., Nishi, N., Kölgen, W., Van den Eertwehg A.J.M., Pinedo, H.M., Giaccone, G., Scheper, R.J. The immunoregulatory role of CD1d-restricted natural killer T cells in desease.Clin Immunology 112 ; 8-23.(2004)

83

607. Van Hensbergen, Y., Broxterman, H.J., Rana, S., Van Diest, P.J., Duyndam, M.C.A., Hoekman, K., Pinedo, H.M., Boven, E. Reduced growth, increased vascular area and reduced response to cisplatin in CHD13-overexpressing human ovarian cancer xenografts. Clin.Cancer.Res. 11, feb. 1: 1180-1187 (2004)

608. Van Riel, J.M.G.H., Van Groeningen, C.J., De Greve, J., Gruia, G., Pinedo, H.M., Giaccone, G. Continuous infusion of hepatic arterial irinotecan in pretreated patients colorectal cancer metastatic to the liver. Ann Oncol. Jan;15 (1):59-63 (2004)

609. Witlox, A.M., Van Beusechem, V.W., Molenaar, B., Bras, H., Schaap, G.R., Alemany, R., Curiel, D.T., Pinedo, H.M., Wuisman, P.I., Gerritsen, W.R. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin Cancer Res. 1:10(1pt1):61-7 (2004)

2005610. Codacci-Pisanelli, G., Pinedo, H.M., Lankelma, J., Van Groeningen, C.J., Van Kuilenburg, A.B.<

Van Gennip, A.H., Peters, G.J. Pharmacokinetics of bolus 5-fluorouracil:relationship between dose,plasma concentrations, area-under0the0curve and toxicity. J Chemother.Jun;17(3):315-20 (2005)

611. Haanen,J.B. Baars, A., Gomez, R., Weder, P., Smits, M., De Gruijl, T.D., Von Blomberg, B.M., Bloemena, E., Scheper, R.J., Van Ham, S.M., Pinedo, H.M., Van den Eertwegh, A.J. Melanoma-specitif tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother. Apr 55(4):451-458(2006)

612. Hansma, A.H.G., Broxterman, H.J., Van der Horst, I., Yuana, Y., Boven, E., Giaccone, G., Pinedo, H.M., Hoekman, K. Recombinant human endostatin administered as a 28-day contnious intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann of Oncology. Oct 16(10):1695-1701 (2005)

613. Kuenen, B.C., Giaccone, G., Ruijter, R., Kok, A., Schalkwijk, C., Hoekman, K., Pinedo, H.M. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res, Sept 1;11 (17):6240-6246 (2005)

614. Middelburg, R., De Haas. R., Dekker, H., Kerkhoven, R.M., Pohlmann, P.R., Fuentes-Alburo, A., Mohar, A., Pinedo, H.M., Lankelma, J. Induction of p53 Up-Regulated Modulator of Apoptosis Messenger RNA by Chemotherapeutic Treatment of Locally Advanced Breast Cancer.Clin.Cancer.Res Mar 1:1863-1869 (2005)

615. Oosterhoff, D., Pinedo, HM., Witlox, MA., Carette, JE., Gerritsen, WR., Van Beusechem, VW. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther. Jun;12(12)1011-2018 (2005)

616. Oosterhoff, D., Overmeer, R.M., de Graaf, M., vander Meulen, I.H., Giaccone, G., Van Beusechem, V.W., Haisma, H.J., Pinedo, H.M., Gerritsen, W.R. Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroid to CPT-11. Br J Cancer. Mar 14; 92(5):882-887 (2005)

617. Uyl-de Groot, C.A., Vermorken, J.B., Hanna M.G. Jr., Verboom,P. Groot, M.T., Bonsel G.J., Pinedo, H.M., Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective of medical and economic benefits. Vaccine. 2005 March 18;23 (17-18):2379-87.

2006618.Boddart M.S., Gerritsen W.G., Pinedo, H.M., On our way to targeted therapy for cachexia in

cancer? Curr Opin Oncol. Jul;18(4):335-40 (206)619. De Bruin, M., Temmink, O.H., Hoekman, K., Pinedo, H.M., Peters, G.J., Role of Platelet derived

endothelial cell growth factor / thymidine phosphorylase in health and disease. Cancer Therapy, in press.

620. Comijn E.C., Weaver D., Willey J.C., Voorn D., Van der Vijgh W.J., Pinedo, H.M., Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel og gemcitabine and cisplatin-sensitive or –resistant human ovariun cancer cell lines. Int J Oncol. Jan;28(1):237-44 (2006)

621. Fontijn D, Duyndam M.C., van Berkel M.P., Yuana Y., Shapiro L.H., Pinedo H.M., Broxterman H.J., Boven E., CD13/Aminopeptidase N overexpression by basic fibroblast growth factors mediates enhanced invasiveness of 1F6 human melanoma cells. Br J Cancer, June 5;94(11):1627-1636 (2006)

622. De Gruijl T.D., Sombroek C.C., Lougheed S.M., Oosterhoff D., Buter J., van den Eertwegh A.J.M., Scheper R.J., Pinedo H.M., A postmigrational switch among skin-derived dentric cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance, Journ of Immunol, June 15;176(2): 7237-7242 (2006)

623. Fluitsma D.M., Van den Eertwegh A.J., Pinedo H.M., Scheper R.J., De Gruijl T.D., A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+)

84

Langerhans cell precursor. J Leukoc Biol. 2007 Dec;80(6):1337-44. Epub 2006 sep 7.

85

624. Hanna M.G., Hoover H.C. Jr, Pinedo H.M., Finer M., Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological pharmacodynamics. Hum Vaccin Jul-Aug;2(4):185-91 (2006)

625. Kroep, J.R., Smit, E., Van der Born, K., Giaccone, G., Beijnen, J.H., Rosing, H., Van Groeningen, C.J., Van der Vijgh, W.J.F., Postmus, P.E., Pindeo, H.M., Peters, G.J., Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol, Oct;58(4):509-516 (2006)

626. Peters, G.J., van Moorsel C.J., Lakerveld, B., Smid, K., Noordhuis, P., Comijn, E.C., Weaver, D., Willey, J.C., Voorn, D., Van der Vijgh W.J., Pinedo, H.M., Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cis-platin-sensitive or resistant human ovarian cancer cell lines. Int. J.Oncol.Jan ;28(1):237-244 (2006).

627. Smorenburg,C.H., Peters,G.J.,van Groeningen, C.J., Noordhuis, P.,Smid, K.,van Riel, A.M., Dercksen,W. Pinedo,H.M., Giaccone,G. Phase ll study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol Jan;17(1):35-42 (2006)

628. Santegoedts S.J.A.M., Masterson A.J., Van der Sluis P.C., Lougheed S.M., Fluitsma D.M., Van den Eertwegh A.J.M., Pinedo H.M., Scheper R.J., De Gruijl T.D., A CD34+ human cell line model of myeloid dendritic cell differentiation : evidence for a CD14+CD11b+ Langergans cell precursor. J Leukoc Biol, Dec ;80(6) :1337-44 (2006)

2007629. Giovannetti E., Backus H.H.J, Wouters D., Ferreira C.G., Houten van V.M.M., Brakenhoff R.H.,

Poupon M-F, Azzarello A., Pinedo H.M., Peters G.J. Changes in the status of p53 affect drug sensitivity tothymidylate synthase (TS) inhibitors by altering TS levels, Br J Cancer 2007 Mar 12;96(5):769-75

630. Duyndam M.C., Van Berkel M.P., Dorsman J.C., Rockx D.A., Pinedo H.M., Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor 1 activity in human ovarian cancer cells. Biochem Pharmacol. 2007 apr 6;

631. Eekhoff E.M., Pinedo H.M., Lips P., Osteoporosis in patients under treatment for cancer and possibilities for prevention and treatment, Ned Tijdschr Geneeskd.2007 Jun 23;151(25):1388-93

632. Fontijn D., Duyndam M.C., Belien J.A., Gallegoz Ruiz M.I., Pinedo H.M., Boven E. The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis. Melanoma Res. 2007 Jun; 17(3):155-68

633. Fontij D, Adema A.D., Bhakat K.K., Pinedo H.M., Peters G.J., O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells, Mol Cancer Ther. 2007 Oct;6(10):2807-15

634. Mauritz R., Van Groeningen C.J., Smid K., Jansen G., Pinedo H.M., Peters G.J. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. Int J Cancer. 2007 Jun 15;120(12):2609-12

635. Verheul H.M. Pinedo H.M., Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007 Jun;7(6):475-85

2008636. De Gruijl T.D., Eertwegh A.J.M., Pinedo H.M., Scheper R.J., Whole-cell cancer vaccination :from

autologous to allogeneic tumor-and dendritic cell-based vaccines, Clinical Immunology and Immunotherapy (in

press (2008)637. Mauritz R.,Peters G.J., Kathmann I., Teshale H. Noordhuis P., Comijn E.M., Pinedo H.M., Janse G. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in Murine leukaemia cells in virtro and in vivo. Cancer Chemoptherapy and Pharmacology.2008 ;62(6) ;937- 948.638 Park G-Ho, Hwang T., Leu T., Sze D., Kim J.S., Kwon H.. Oh S.Y., Yoon J., Hong S., Moon A., Speth K., Park C., Ahn Y., Daneshmand M., Rhee B.G., Pinedo H.M., Bell J.C., Kirn D.H., Use of a Targeted Oncolytic poxvirus JX-594, in patients with refractory primary or metastatic liver cancer : A phase I trial. The Lancet Oncology.2008 ;9(6) : 533-542.639. Emmering J., Krak N.C., Van der Hoeven J.J.M., Spreeuwenberg M.D., Twisk J.W.R., Meijer S.,

86

Pinedo H.M., Hoekstra O.S. Annals of Oncology.2008 ;19(9) :1573-1577.

2009640. Mauritz R., Giovannetti E., Beumer I.J., Smid K.,van Groeningen C.J., Pinedo H.M.,Peters G.J. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. Clincal Colorecctal Cancer, 2009 :8(3) : 146-154.

2010641. Pavlidis N., Gatzmeier W., Popescu R., Stahel R., Pinedo H.M., Cavalli F., Costa A., The Masterclass of the European School of Oncology : The ‘key educational event’of the school. European Journal of Cancer. 2010 ;46(12) :2159-2165.

2011642. Johnston P.G., Pinedo H.M., The high Tide of cancer research in Europe. Oncologist.2011 ;16(5) :539-542.643. Bosch J.W.,Carvalho B., FijnemanJ.A., Jimenez C.R., Pinedo H.M., Van Engeland M., Meijer G.A. Molecular tests for colorectal cancer screening.Clinicalcolorectal Cancer. 2001 ;10(1) :8-23.

2012

644. Meunier F., Lawler., Pinedo H.M. Commentary : Fifty years of the European organisation for research and treatment of cancer (EORTC)- making the difference for the European Oncology Community. Oncologist.2012 ;17(6) :e6-e7.645. Le Chevalier T., Johnston P.G., Conte P., Pinedo H.M. European perspectives : A dialogue with The European oncology community.Oncologist. 2012 ;17(4) :1-2.646. De Weger V.A., Turksma A.W., Voorham Q.J.M., Euler Z., Bril H., Van den eertwegh A.J., Bloemena E., Pinedo H.M., Vermorken J.B., Van Tinteren H., Meijer G.A., Hooijberg E. Clinical effects of adjuvant active specific immunotherapy differ between patients with Microsatellite-stable and micorsatellite-instable colon cancer. Clinical Cancer Research.2012 ;18(3) :882-889647. Van den Eertwegh A.J.M., Versluis J., Van den Berg H.P., Santegoets S.J.A.M., Van Moorselaar J.A., Van der Sluis T.M., Gall H.E., Harding T.C., Jooss K., Lowy I., Pinedo H.M., Scheper R.J., Stam A.G.J., Von Blomberg M.E., De Gruijl T.D., Hege K., Sacks N., Gerritsen W.R. Combined Immunotherapy with granulocity-macrophage colony-stimulatingfactor-transduced allogeneic Prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer : A phase 1 dose –escalation trial. The Lancet Oncology.2012 ;13(5) :509-517.

2013648. Lindenberg J.J., Oosterhoff D., SombroekC.C., Lougheed S.M., Hooijberg, Stam A.G.M., Santegoets S.J.A.M., Tijssen H.J., Buter J., Pinedo H.M., Van den Eertwegh A.J.M., Scheper R.J., Koenen H.J.P.M. Van de Ven R., De Gruijl T.D. IL-10 Conditioning of Human Skin Affects the Distribution Of Migratory Dendritic Cell Subsets and Functional R Cell Differentiation. PLoSONE. 2013 ;8(7).

2014649. Lawler M., Le ChevalierT., MurphyJr. M.J., Banks I., Conte P., De Lorenzo F., Meunier F., Pinedo H.M., Selby P., Armand J-P., Farvacid M., Barzach M., Bergh J., Bode G., Cameron D.A. De Braud F., de Gramont A., Diehl V., Diler S., Erdem S., Fitzpatrick J.M, Geissler J., Hollywoodz D., Højgaard L., Horgan d., Jassem J., Johnson P.W., Kapitein P., Kellyv J., Kloezen S., La Vecchia C., Löwenberg B., Oliver K., Sullivan r., Tabernero J., van de Velde C.J., Wilking N., Wilson R., Zielinski C., zur Hausen H., Johnston P.G. A catalyst for change : The european cancer patient’s

87

bill Of rights. Oncologist, 2014 ;19(3) :217-224.650. Lawler M., Le Chevalier,T., Banks I., Conte P., De Lorenzo F., Meunier F., Pinedo H.M., Selby P MurphyJr. M.J., Johnston P.G. A Bill of Rights for patients with cancer in Europe. The Lancet Oncology.2014 ;15(3) :258-260.

2015651. The 42nd David A. Karnofsky memorial award lecture : Understanding Journal of Clinical Oncology.2015 ;33(5) :510-517.

Prof. Dr. Herbert (Bob) Pinedo is Professor of Medical Oncology at the Free University of Amsterdam (VUMC). He was Chief of the VUMC Department of Oncology from 1979 to 2005. He was past president and chair of the board of VU Cancer Center Amsterdam (VUMC) from 2003 to 2005 and he served as vice-chair of the Netherlands Organization for Health Research and Development from 2004 to 2009. During his career he served 25 years on the Board of the Dutch Cancer Society. Currently he is consultant to the board of the VU Medical Center

Since 2008 he is visiting Professor at Johns Hopkins University and the Technical University of Twente. Since 2009 he chairs the Prevention Foundation of Curacao.

He served on the boards and committees of many European and American organizations. He founded the New Drug Development Office -Oncology, which coordinates early clinical trials with anticancer agents internationally. He was the first president of the Federation of European Cancer Societies and a president of the European Society of Medical Oncology (ESMO). He has served on several committees of the American Association of Cancer Research and the American Society of Clinical Oncology and on numerous scientific advisory boards of cancer institutes as well as companies, including Iconic Therapeutics and Bristol Myers Squibb (Europe). He is a consultant to Spectrum Pharmaceuticals, and a past director of OSI Pharmaceuticals, Inc.

The scientific journal Annals of Oncology was founded during his Presidency of the ESMO. While he is one of the founding members of the prestigious American Journal The Oncologist. He served on editorial boards for numerous scientific journals, including Clinical Cancer Research and Journal of Clinical Oncology. He has authored more than 700 peer-reviewed international publications and more than 120 chapters, invited papers and proceedings.

Dr. Pinedo’s career is a benchmark of original, top quality, translational cancer research in which he has consistently combined leading-edge basic science with clinical excellence. He is noted as a clinical investigator who takes new concepts to early clinical trials. He has made seminal observations in cancer biology and treatment-related mechanisms of drug action and resistance in the patient. In 2006 The Society of Translational Oncology established the Pinedo award for clinical patient care. He is still practicing medical oncology.

He has many international awards including the prestigious Josef Steiner Award (1995), the Spinoza Award (1997) and Cino del Duca (1999). He is a member of the Royal Netherlands Academy of Arts and Sciences and has been decorated by Her Royal Majesty Queen Beatrix of the Netherlands with the prestigious Knight in the Order of the Netherlands Lion and Commander in the Order of Orange-Nassau.

88

Date post:	12-Apr-2017
Category:	Documents
Upload:	bob-pinedo
View:	146 times
Download:	8 times

CV Dr. Pinedo

Documents